Bringing two worlds closer together : addressing methodological challenges in the economic evaluation of public health programs by Alayli-Goebbels, A.F.G.
  
 
Bringing two worlds closer together : addressing
methodological challenges in the economic evaluation
of public health programs
Citation for published version (APA):
Alayli-Goebbels, A. F. G. (2013). Bringing two worlds closer together : addressing methodological
challenges in the economic evaluation of public health programs. Maastricht: Datawyse / Universitaire
Pers Maastricht.
Document status and date:
Published: 01/01/2013
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
 
 
 
Bringing two worlds closer together 
Addressing methodological challenges in the economic  
evaluation of public health programs 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Layout: Tiny Wouters 
Cover design: Omar Alayli 
Printed by: Datawyse | Universitaire Pers Maastricht 
ISBN: 978 94 6159 278 1 
 
© Adrienne Alayli-Goebbels, Maastricht 2013 
No part of this book may be reproduced or transmitted in any form or by any means, 
without prior permission in writing by the author, or when appropriate, by the publishers of 
the publications.  
 
The research in this dissertation was mainly funded by a Toptalent grant of the Netherlands 
Organisation for Scientific Research (NWO), project number 0.21.001.034. Additional 
financial support was provided by the School of Public Health and Primary Care (Caphri). 
The study described in Chapter 3 was funded by ROCHE Netherlands BV. 
 
Financial support for printing this dissertation was kindly provided provided by the Health 
Technology Assessment Program of the School for Public Health and Primary Care (Caphri), 
Maastricht University.  
 
 
Bringing two worlds closer together 
Addressing methodological challenges in the economic  
evaluation of public health programs 
 
 
 
Proefschrift 
 
 
 
 
Ter verkrijging van de graad van doctor 
aan de Universiteit Maastricht,  
op gezag van de Rector Magnificus, Prof. dr. L. L. G. Soete,  
volgens het besluit van het College van Decanen,  
in het openbaar te verdedigen  
op dinsdag 10 december 2013 om 16.00 uur 
 
 
door 
 
 
 
Adrienne Alayli-Goebbels 
UNIVERSITAIRE
PERS MAASTRICHT
P
M
 
Promotores 
 
Prof. dr. J. L. Severens (Erasmus Universiteit Rotterdam) 
Prof. dr. N. K. de Vries 
 
 
Copromotor 
 
Dr. A. A. J. H. Ament 
 
 
Beoordelingscommissie 
 
Prof. dr. D. Ruwaard (voorzitter) 
Prof. dr. C. D. Dirksen 
Prof. dr. M. W. van Tulder (Vrije Universiteit Amsterdam) 
Prof. dr. H. de Vries 
Dr. G. A. de Wit (Universitair Medisch Centrum Utrecht) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents 
Chapter 1  Introduction  7 
 
Chapter 2  A review of economic evaluations of behavior change interventions:  27 
 setting an agenda for research methods and practice 
 
Chapter 3 Estimating the implicit value of statistical life based on public  55 
 interventions implemented in the Netherlands 
 
Chapter 4  Exploring non-health outcomes of health promotion: the  69 
 perspective of participants in a lifestyle behavior change intervention 
 
Chapter 5  Consumer preferences for health and non-health outcomes of health  91 
 promotion: results from a discrete choice experiment 
 
Chapter 6 Consumer willingness to invest money and time for benefits of lifestyle  113 
 behavior change: an application of the contingent valuation method 
 
Chapter 7  General discussion 133 
 
 Summary 155 
 
 Acknowledgements 161 
 
 Curriculum Vitae 167 
 
 List of publications and presentations 171 
  
 
  
 
 
 
CHAPTER 1 
 
 
 
Introduction 
 
 Ch
ap
te
r 
1 
 
8 
  
  Introduction 
 
Ch
ap
te
r 
1 
 
9 
This dissertation focuses on methodological challenges in the economic evaluation of 
public health programs. Chapter 1 provides a general background on the topic and 
outlines the objectives and methods of this research.  
What is public health? 
Public Health has been defined as the science and art of preventing disease, prolonging 
life and promoting health, through organized efforts of society.1 The methods and 
practice of public health are in continuous development, adapting to the prevailing and 
evolving health risks and problems. The changing focus of Public Health from its origins 
to the Modern or New Public Health has been described in terms of six eras.2 
 
 
 
 
 
 
Figure 1.1 Six generations of Public Health (based on Awofeso)2 
 
 
In the first era (antiquity to the 1830s), public health was characterized mainly by health 
protection. It was an integral part of societies’ social structures and consisted of 
enforced regulation of behavior through religious and cultural rules as well as quarantine 
measures. Typical measures included hand washing rules, theologically sanctioned 
quarantine of leprosy sufferers and societal responses to the Black Death plague (e.g. 
isolating plague victims, tracing and incarcerating their contacts as well as restrictions on 
travelling and shipping).2,3 The discovery of highly developed sewer and water supply 
systems built by civilizations in antiquity is also worth noting, as it documents early 
public health engineering efforts.4  
In the second era (1840s to 1870) public health was primarily concerned with miasma 
control. Miasma, originally meaning stain or pollution of sin, which offended the gods, 
was considered a poisonous vapor or mist filled with particles from decomposed matter 
that caused disease.5 Measures included centralized activities to tackle unsanitary 
environmental conditions (e.g. provision of clean water) and legislation regarding 
sewage and waste disposal.2,4 
The next era (1880s-1930), referred to as the contagion control era, was characterized 
by an improved understanding of the pathogenesis of infectious diseases, like cholera. 
This drew the attention somewhat away from the sanitary problems of water supply, 
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street cleaning, housing and living conditions of the poor, and opened the door for new 
ways to control infectious diseases, such as the development of vaccines against 
diphtheria and cholera. Another significant public health achievement in this era included 
the development of methods to measure bacteria in air, water and milk.2,4 
The preventive medicine era (1940s to 1960s) was an extension of the contagion control 
era in that it continued to improve scientific understanding of the pathogenesis of 
infectious diseases, including the role of nutrient deficiencies and disease vectors. Public 
health became more disease-oriented during this era focusing on prevention and cure of 
infectious diseases among the ill and high-risk groups, such as pregnant women, factory 
workers, school children and the elderly.2 Due to growing successes in infectious disease 
control, life expectancy increased considerably and chronic diseases became the new 
frontier of public health in the last half of the 20th century.6 New challenges involved 
tobacco-related diseases, unhealthy diet, physical activity, lack of access to preventive 
care, injuries, violence, as well as sexual and substance abuse behaviors.4,7 
In response to these challenges, the primary care era (1970s -1980s) took a largely 
preventive approach. The WHO Alma Ata Declaration in 1978 formalized the key 
elements and goals of this approach, including (a) primary health care as backbone of 
the public health strategy, with an emphasis on health promotion and disease prevention 
strategies (b) global cooperation and piece as important aspects of primary health care, 
(c) adaptation of health services to countries and communities, (d) the recognition that 
healthcare reflects broader social and economic development, (e) the achievement of 
equity in health status and (d) involvement of all sectors in the promotion of health.2 
Modern public health (1990 – present) is referred to as the health promotion era. It can 
be regarded as a continuation of the primary care era: several of its core principles 
remain relevant today, including the emphasis on multi-sector collaboration, achieving 
health equity and attention for the impact of social and economic conditions.2,6 Due to a 
modified definition of health and recognition of the need to increase opportunities for 
people to make healthy choices the scope of public health has been broadened during 
the health promotion era.2,6 As documented by WHO’s 1986 Ottawa Charter for Health 
Promotion, modern public health is based on a positive health concept, perceiving health 
as a resource for everyday life and not the objective of living. Consequently, modern 
public health programs go beyond disease control towards improving quality of life and 
wellbeing.6 Actions take place in five key areas (i.e. building healthy public policy, 
creating supportive environments, strengthening of community action, developing 
personal skills and reorienting health services) and consist of three core activities (i.e. 
health education, prevention and protection).  
Modern public health activities incorporate components of previous eras, which have 
been further developed or reframed. To give an example, quarantine practices from the 
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health protection era and vaccination methods from the contagion era continue to be a 
part of the modern public health. The original quarantine practices have been replaced 
however by more targeted, humane and less stigmatizing measures, and contemporary 
vaccination programs use social marketing and persuasion techniques rather than legal 
enforcement to achieve necessary vaccination coverage.2 
Modern public health programs are challenging for evaluation, because they often 
address multiple factors, consist of multiple strategies and take place on multiple 
analytical levels. Table 1.1 provides an overview of the different factors and analytical 
levels that may be targeted by modern public health programs alongside with several 
example interventions.  
 
Table 1.1 Analytical levels targeted by modern public health interventions 
Level Factors addressed  Interventions 
Intrapersonal  Characteristics of the 
individual, such as 
knowledge, attitudes, 
behavior, self-concept and 
skills. Includes the 
developmental history of 
the individual.  
Aim to change individuals and may include 
educational programs, mass media, support groups, 
organizational incentives or peer counselling. 
Example: Training adolescents to resist peer pressure 
related to smoking. 
Interpersonal  Interpersonal processes 
and primary groups, such 
as formal and informal 
social network and social 
support systems (e.g. 
family, work group and 
friendship networks). 
Aim to change social influences on individuals by 
addressing social norms and social groups to which 
individuals belong.  
Example: Changing norms about drug use within 
existing networks or creating alternative networks. 
Institutional  Social institutions with 
organizational 
characteristics and both 
formal and informal rules 
as well as regulations for 
operation.  
Directed at creating an organizational culture and 
structures supportive of health issues and healthy 
behavior. Organizational context may also be used 
for the diffusion of health promotion programs. 
Example: Changing food offerings in cafeterias or 
implementing stress reduction interventions that 
improve worker supervisor relationships.  
Community  Relationships among 
organizations, institutions 
and informal networks 
within defined boundaries. 
Seek to increase coordination among community 
agencies to improve delivery of services, encourage 
coalition building to influence community awareness 
and local health policies, and to improve access to 
community political and power structures.  
Example: Strategies to include representation from 
disadvantaged populations on community boards.  
Public policy  Local, state and national 
laws and policies.  
Include regulatory policies, procedures and laws to 
promote and protect health of the community, as 
well as the establishment of health promotion centres 
in universities and health promotion offices/agencies 
in federal and state government. 
Example: Restrictions on alcohol sales, increased 
taxes on alcohol and cigarettes.  
(based on Mc Leroy)8 
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Evidence-informed decision-making on public 
health 
Due to innovation and research, interventions with the potential to improve public health 
are continuously introduced and further developed. However, not every innovation leads 
to improved population wellbeing and not all effective interventions can be implemented 
due to limited public resources.9 Therefore, it is important to distribute resources wisely, 
considering available evidence.  
Health Technology Assessment (HTA) encourages evidence-informed decision-making by 
building a bridge between scientific research and policy-making.10 It has been defined as 
’’a multidisciplinary process that summarizes information about the medical, social, 
economic and ethical issues related to the use of a health technology in a systematic, 
transparent, unbiased, robust manner’’.11 
The term ‘technology’ in HTA is defined very broadly, comprising actual technologies, 
like medical devices or diagnostic tests, but also organizational changes, rehabilitation, 
prevention and health promotion programs. Although countries differ regarding the 
structure of HTA agencies and specific HTA procedures, the general elements of the HTA 
process are quite similar across countries.12  
The HTA process may be regarded as a continuous and interdependent flow of twelve 
activities.13 It begins with the (1) assessment of health needs of a population and the (2) 
prioritization of health needs to concentrate on. Then (3) technologies are identified that 
could be used or are in use to treat, prevent or manage the priority health needs. From 
the available technologies (4) a selection is made of technologies to be further assessed. 
This decision may be based on preliminary literature review and/or consultation with 
experts. In the next step (5) external specialists/researchers are identified and asked to 
participate in the assessment of the selected technologies. In consultation with the 
external specialists the (6) assessment objectives and target audience for the technology 
are defined. Then (7) specific research questions are formulated, defining the clinical, 
social and economic impacts of the technology that will be assessed. These questions 
guide the actual assessment of the technology, which consists of the (8) identification 
and collection of relevant evidence, (9) the analysis and synthesis of the evidence, (10) 
preparing a draft report for assessment by internal and external reviewers, and (11) 
writing and editing the final HTA report. The report is then (12) disseminated to the 
appropriate people who make decisions regarding the use of the technology. When a 
technology is implemented in practice, the assessment process does not finish. It is 
recommended that the performance of the technology is regularly examined and if 
necessary, the technology may re-enter the assessment process.14 
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Although a broad number of aspects of health technologies are regarded relevant to 
consider during the technology assessment process (e.g. effectiveness, cost-
effectiveness, psychological, social and ethical issues, organizational and professional 
implications),12 in practice the systematic assessment of technologies, is often limited to 
a few aspects (i.e. efficacy, safety, and cost-effectiveness).15,16 This appears for instance 
from the Measurement Interactive Loop, also referred to as Technology Assessment 
Iterative Loop, which is frequently used as a framework to guide the technology 
assessment process (see Figure 1.2).17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Measurement Iterative Loop 
 
 
The framework links evaluation questions defined during the technology assessment 
process with research methods that can be used to answer the questions. It describes a 
sequence of scientific methods that may used to inform decisions about health 
technologies starting from methods to quantify the burden of illness and identify likely 
causes, through methods for evaluating community effectiveness and efficiency of 
6
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interventions, and back again to methods determining whether disease burden has been 
reduced by the technology. After a technology has been identified, the framework 
suggests performing scientific assessment of two major pieces of evidence: (1) 
community effectiveness, which incorporates information about efficacy, safety (e.g. side 
effects), screening and diagnostic accuracy, coverage, as well as compliance; and (2) 
efficiency, which integrates evidence on efficacy or community effectiveness with 
evidence on costs.17 Systematic methods for considering social, ethical, cultural or 
organizational aspects of the technology are not described by the framework. The 
authors only mention briefly that such aspects should be assessed to determine the 
feasibility of implementing the technology, when synthesizing information in step five.17 
Methods to consider such broader societal impacts are not well developed and rely more 
on qualitative rather than quantitative information.18 For this reason several countries, 
including The Netherlands, divide the technology assessment process into two distinct 
phases.19,20 The first phase, referred to as ‘assessment phase’, focuses on ‘hard’ 
quantitative measures, such as burden of disease and costs per Quality Adjusted Life 
Year (QALY) gained.19 Based on these measures recommendations are made for 
decision-making, which are reassessed in the second phase, referred to as ‘appraisal 
phase’. In contrast to the research-based assessment phase, the appraisal phase relies 
on social value judgments. The information considered in the appraisal phase is more 
qualitative and collected in a less systematic manner than the information considered 
during the assessment phase. It relates to issues, such as social justice and 
solidarity.19,21 The National Institute for Health and Care Excellence, which is responsible 
for conducting technology assessments and appraisals in the United Kingdom, notes that 
in practice the dividing line between the appraisal and assessment phase is not always 
very clear.22  
Economic evaluation 
Cost-effectiveness evidence can be a useful tool for decisions about health technologies 
because it can provide clear policy guidance as to which investments provide the largest 
health gain for a given budget. Cost-effectiveness or efficiency of health technologies 
can be assessed by means of economic evaluation studies. The methods used in 
economic evaluation studies and their application to public health are the primary focus 
of this research. An economic evaluation is a comparative analysis of alternative courses 
of action or interventions in terms of both their costs and consequences.23 It can take 
five different forms, referred to as cost-effectiveness analysis (CEA), cost-utility analysis 
(CUA), cost-benefit analysis (CBA), cost-consequence analysis (CBA) and cost-
minimization analysis (CMA). The identification and measurement of costs is similar 
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across all forms of economic evaluation. The difference lies in the nature of the 
consequences being considered and the way consequences are measured.23  
In CEA consequences are measured in terms of a single, common unit of effect that may 
differ in size between the alternatives. Results of a CEA are expressed in terms of the 
cost per unit of effect, such as for instance the cost per life-year gained, cost per 
infection averted, cost per disability day avoided or cost per person who quits smoking.23 
CUAs also compare alternatives in terms of their cost per unit of effect. The unit of effect 
in CUA is a single measure accounting for both changes in life expectancy and quality of 
life. The most frequently used measure is the QALY. It is calculated by multiplying a 
person’s life expectancy with a weight for the health-related quality of life (HRQOL) 
experienced in that period. The HRQOL weight is a number between 0 and 1, which 
represents a value ascribed to a specific health state relative to full health (weight = 1) 
and death (weight = 0). This weight is mostly derived by means of generic preference 
based instruments, such as the EQ-5D, which describe health states in terms of different 
HRQOL dimensions that can take several levels. The health state descriptions are usually 
derived from patients or program participants, while the corresponding weight or value 
is derived from a general population sample.24 The advantage of CUAs compared to 
CEAs, is that they go beyond specific intervention outcomes and allow for a comparison 
of a broad number of health programs.  
CBAs use an even broader measure of effect than CUAs. They express program 
consequences in monetary terms. As monetary values can in principle be attached to all 
types of consequences, there is no need to restrict the analysis to health outcomes only. 
Expressing program consequences in monetary terms also has the advantage that it 
allows for a direct comparison of program costs and consequences. Hence, the analyst 
can assess whether the program is worthwhile (i.e. net monetary benefit >0). Despite 
these advantages, CBA is not used very much in the health sector, because attaching a 
monetary value to health and life is not a straightforward operation. There are several 
methods available for monetary valuation, such as the human capital approach and 
revealed and stated preference methods, but these are controversial and sometimes 
even regarded as unethical.23 
Analysts who seek to consider various types of outcomes, but do not want to attach a 
monetary value to them or present them in one aggregate measure (like a QALY or a 
cost-effectiveness ratio) can use a CCA approach. In CCA relevant costs and 
consequences of alternatives are presented separately, for example in a tabular format. 
This has the advantage that the policy maker can consider components of special 
interest separately and decide about their relative importance.23-25 A weakness of this 
approach is however, that there is no clear decision rule. It is for example difficult to 
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determine the overall impact of the program when some outcomes improve and others 
get worse.26,27 
CMA can be used in situations, where previous research suggests that consequences of 
two or more programs are broadly equivalent. The analysis is then reduced to a 
comparison of costs of the alternatives. It has been argued that this form of economic 
evaluation is only justifiable when the alternatives under comparison are nearly identical, 
which is for example the case when comparing drugs in the same pharmacological 
class.23 CMA is unlikely to be useful for the comparison of public health programs, 
because these programs are targeted to specific contexts and populations, and thus 
seldom identical.  
The five forms of economic evaluation described here can be designed in two major 
ways: they can be either trial- or model-based. Trial-based studies involve the collection 
of new primary data alongside a randomized controlled trial, a pragmatic trial or another 
study design used to examine program effectiveness. Trial-based designs provide 
specific data on the level of intervention participants, which is attractive for both data-
analysis and internal validity.23 Model-based studies use mathematical relationships to 
define possible consequences resulting from alternative options being evaluated. They 
make use of secondary data, which are synthesized from different sources. This allows 
for instance to compare more alternatives and subsamples than what is feasible in a 
trial. Models can also be used to extrapolate costs and consequences of an alternative 
over time, for example by linking an intermediate measure of effect (e.g. reduction in 
cholesterol) to long-term health outcomes.28 Hence, model and trial-based studies can 
be regarded as complementary rather than mutually exclusive and may be combined in 
one study. 
Methodological standards for economic 
evaluation 
To enhance the credibility and usefulness of economic evaluation studies for decision-
making the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) and the Society of Medical Decision Making (SMDM) have established good 
practice guidelines for designing, conducting and reporting both trial- and model based 
economic evaluation studies.29,30 A number of key methodological standards addressed 
in these guidelines are discussed in the following chapters and therefore briefly outlined 
below.  
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Study endpoints 
It is recommended to directly measure program consequences in either QALYs or 
monetary terms and to avoid intermediate outcome measures, such as for instance 
percentage LDL cholesterol reduction. However, the stronger the relationship between 
intermediate outcomes and long-term disease outcomes, the more it is justified to rely 
on intermediate endpoints.29 
Time horizon 
The time horizon of an economic evaluation should be sufficiently long to capture all 
health effects and costs relevant to the decision problem. Ideally this includes lifetime 
costs and consequences of the alternatives under evaluation.29,30 
Appropriate trial design 
Generally pragmatic effectiveness trials are regarded the best vehicle for economic 
evaluation studies.29 The study design of these trials is equal to that of randomized 
controlled trials (RCTs), but the study protocol is somewhat relaxed to allow providers of 
the health program and patients or participants to behave as they would under real 
world (i.e. routine practice) circumstances.31 However, pragmatic effectiveness trials are 
usually not feasible in an early stage of the development process, before the health 
program or drug has been approved for marketing. Therefore, RCT studies assessing 
effectiveness under ideal circumstances (i.e. efficacy) may also be acceptable for use in 
economic evaluation.29 
Discounting 
Economists generally assume that individuals and society have a positive rate of time 
preference. This means that they prefer to experience additional benefits today rather 
than in the future. For costs it is assumed that people prefer to incur costs later rather 
than sooner. To account for time preference in economic evaluation it is recommended 
to apply discounting, a method to adjust costs and consequences incurred in the future 
to their present value, using a common real discount rate.23,29 
Summary measures  
For a meaningful comparison of costs and consequences between alternatives, it is 
recommended to report a measure, which summarizes the additional value of one 
alternative compared to another. For this incremental comparison, three types of 
summary measures may be used: ratio measures, difference measures or probability 
measures.  
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Ratio measures are obtained by dividing the incremental costs by the incremental benefit 
of one alternative compared to another alternative. An incremental cost-effectiveness 
ratio (ICER) can take the form of an additional cost per QALY or an additional cost for 
any other unit of effect (e.g. averting one case of HIV infection).29 
The net monetary benefit (NMB) of a program is a commonly used difference measure. 
It can be calculated when a monetary value has been attached to program outcomes. 
According to this approach a program is cost-effective when the ICER is lower than the 
maximum willingness to pay (WTP) for a QALY or other unit of effect employed in the 
ICER. A positive NMB (>0) suggests that the incremental benefits of the program exceed 
its costs, which is for example the case when the WTP for a QALY gained by a new 
program is higher than the incremental costs per QALY. NMB measures can be used 
when willingness to pay is estimated within a cost-benefit framework using for example 
revealed or stated preference methods.23,29 
Cost-effectiveness acceptability curves are a frequently used probability measure. They 
characterize the likelihood that a program is more cost-effective than an alternative, 
given different possible WTP values. WTP is varied, because WTP for a QALY or another 
unit of effect is considered an arbitrary societal value.23,29 
Sensitivity analyses  
Results of economic evaluation are subject to uncertainty from a number or sources. 
Parameter estimates, such as unit costs, event probabilities and the discount rate are a 
key source of uncertainty. It is therefore recommended to use sensitivity analysis to 
assess the impact of parameter uncertainty on incremental cost-effectiveness results.29 
Sensitivity analyses can be either deterministic (where values are varied using point 
estimates) or probabilistic (where values are varied using probability distributions). It is 
often appropriate to use both types of sensitivity analyses within a single economic 
evaluation study.23,30 
Costs and resource use  
The measurement of costs and resource use has to be consistent with the time horizon 
and the perspective of the study. If the study is conducted from a societal perspective 
the costs considered should also reflect social opportunity costs.29 
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Applying economic evaluation methods to public 
health  
The vast majority of economic evaluation studies focus on biomedical health 
interventions, such as pharmaceuticals, medical devices and surgical procedures, but 
applications of economic evaluations to public health programs are increasing.32-34 This is 
especially the case for clinical preventive programs, such as screening and vaccination, 
and for programs directed at lifestyle behavior changes. Economic evaluations of public 
health programs addressing wider environmental and socio-economic determinants of 
health, such as poverty and unemployment, are still very rare.32,33 
The relative lack of economic evaluation evidence in public health can be attributed to 
three major factors. First, there are very limited resources available for evaluating public 
health interventions.33,35,36 There is little opportunity to generate profit from public 
health programs. Therefore, these studies are generally not funded by large 
multinational companies, as is often the case for economic evaluations of clinical or 
pharmaceutical interventions. Consequently, these studies have to rely on limited 
funding from government, charitable organizations and private foundations.33,37 
Second, systematic decision-making mechanisms for priority setting in public health are 
not well developed in most countries.36,37 Consequently, there are usually no clear 
requirements for the use of economic evaluation evidence in decision-making on public 
health programs, unlike the requirements that are in place for pharmaceuticals. For 
instance, the Health Care Insurance Board (College voor Zorgverzekeringen), which 
provides advice to the Dutch government regarding reimbursement of pharmaceuticals 
by the social health insurance scheme, has published guidelines for economic evaluation 
studies that need to be followed by companies, requesting reimbursement of 
pharmaceuticals.38 In the Netherlands and most other countries such guidelines do not 
exist for public health programs.  
Third, modern public health programs pose a number of challenges to evaluation 
methods, which are described in more detail in the next paragraph. 
Methodological challenges for economic 
evaluation of public health programs  
Based on the scientific literature we identified seven methodological challenges for the 
economic evaluation of public health programs. First, they tend to have a long time 
horizon. The health impacts of behavior changes and changes to broader environmental 
or economic conditions take so long to accrue, that they are usually not measured within 
effectiveness trials. Although extension of follow-up periods is theoretically possible, it is 
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very expensive and often not feasible in practice. Hence, alternatives to actual 
measurement are needed, such as mathematical modeling, which may be used to 
translate intermediate outcomes (e.g. behavior changes) to final outcomes (e.g. changes 
to life expectancy or quality of life).33,39 
Second, modern public health programs do not only focus on improving health. They 
also aim to impact on broader domains of wellbeing6. A typical objective is for instance 
empowerment of individuals. This may include increasing their self-esteem, health 
literacy, communication and problem solving skills.1,40,41 Changes to these outcomes are 
not captured by standard measures of health outcomes, such as QALYs. Intended 
broader outcomes are however not well-defined and theoretically underpinned outcome 
measures for use in economic evaluation are currently lacking.42 
Third, public health programs address determinants of health and wellbeing on multiple 
operational levels. At the individual level, educational interventions are for example 
implemented to promote healthy lifestyle choices and enhance people’s life skills. At the 
community level, interventions may be directed at developing systems to strengthen 
public participation in health matters,43 and interventions at the societal level may 
address social, economic and environmental determinants of wellbeing by means of 
fiscal measures (e.g. alcohol tax), legislation (e.g. smoke free work place legislation) or 
organizational changes (e.g. changing food offerings in schools).8,44,45 As a consequence 
of this multi-level approach, outcomes may also be produced on multiple levels.46 
Outcome measurement in economic evaluation studies however tends to focus only on 
individual level outcomes.47 
Fourth, reducing health inequities is an important objective of public health programs, 
while economic evaluation studies usually do not account for equity outcomes.48 They 
are based on a utilitarian framework and seek to compare which of the programs under 
evaluation achieves the highest degree of overall utility or health benefit. For example, 
for each Euro invested, evaluators compare which program achieves the largest number 
of QALYs possible, regardless of whom the QALYs accrue to.48 
Fifth, the most preferred forms of effectiveness evidence for use in economic evaluations 
are (pragmatic) RCTs and meta-analyses of RCTs. The evidence base in the field of 
public health does not always fit into this framework, because RCT designs are often not 
an appropriate and feasible option.35 Randomization into different experimental 
conditions may not possible due to practical reasons (e.g. in case of policy or structural 
interventions) or ethical reasons (e.g. in studies of the effects of environmental tobacco 
smoke)49 and when evaluating mass-media interventions it is difficult to use an 
appropriate control group, because people cannot be excluded from participation. 
Another problem is that public health interventions are not standardized, but often 
tailored to local contexts. Hence, effects may not be transferable to other settings. RCT 
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designs are not sufficient to examine interaction with local context and transferability of 
effectiveness findings to other contexts.50 
Sixth, public health interventions often require multi-sector collaboration.37,51 For 
example an intervention to create bicycle paths to stimulate more physical activity 
requires collaboration between the sectors health, transport and spatial planning. As a 
result multiple societal sectors contribute financial and other resources to public health 
programs.51,52 It is currently unclear what kind of non-health sector resources these 
exactly are and how to consider these within economic evaluation.34,53 
Finally, multi-sector collaboration also creates the need for decision-makers to compare 
possible investments in the area of public health with investments in other areas. The 
methods to compare efficiency of public health interventions with efficiency of 
interventions in for example transport and the environmental sector are however not 
well developed, and it is unclear which measures to use in the comparison. Economic 
evaluation studies in public health have mainly adopted cost-effectiveness and cost-
utility analysis frameworks. These frameworks are not used in other societal sectors, 
which hampers comparability. A potential way to increase comparability across sectors 
would be to use a cost-benefit analysis framework. But, there is still uncertainty about 
feasibility and validity of methods, which can be used to assign monetary values to 
intervention outcomes (e.g. contingent valuation).54,55  
Objectives and scope  
This research had two objectives. First, to provide a general overview of the 
methodological quality of economic evaluations of public health programs and the 
progress that has been made regarding the seven challenges for evaluation described 
above. Second, to contribute to potential solutions to overcome the challenges 
associated with comparing efficiency across multiple societal sectors and the impacts 
public health programs may have on broader domains of wellbeing at the individual 
level. With respect to public health, this research focuses primarily on lifestyle behavior 
change interventions (LBCIs), which constitute a key attention area of modern public 
health/health promotion and an area of public health where a relative large number of 
economic evaluation studies are available. Additionally, progress is likely to occur in this 
area because some methodological challenges may be overcome more easily for LBCIs 
than for other public health programs. For example due to increasing availability of 
epidemiological data, which allow for translation of behavior changes into long-term 
health outcomes.56  
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Outline  
In Chapter 2 a systematic literature review provides insights into how economic 
evaluation studies of lifestyle behavior change interventions addressed methodological 
challenges for evaluation and their methodological quality. Chapter 3 describes a study 
exploring the possibility to use the Value of Statistical Life as a common parameter of 
efficiency in a multi-sector comparison of life saving public health interventions and life 
saving interventions implemented in three other societal sectors in the Netherlands.  
Chapter 4 reports on a qualitative study conducted among participants of a lifestyle 
intervention trial to identify experienced broader outcomes of public health that are not 
captured by typical measures of health outcome used in economic evaluation. For 
consideration of such broader outcomes in decision-making, it is crucial to understand 
their importance to society. This question is addressed in Chapter 5, which describes the 
results of a discrete choice experiment, examining the relative importance of health 
outcomes usually considered within economic evaluations and broader non-health 
outcomes that were identified by the qualitative research described in Chapter 4. 
Chapter 6 illustrates an application of contingent valuation to value both health and 
broader outcomes of public health in monetary terms. Questions regarding the feasibility 
and validity of the method to derive willingness to pay from an individual consumer 
perspective are also addressed.  
In Chapter 7 the research findings presented in the previous chapters are discussed with 
respect to their implications for practice, policy making and future research.  
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Abstract 
Objective 
To review methodological quality of economic evaluations of lifestyle behavior change 
interventions (LBCIs) and to examine how they address methodological challenges for 
public health economic evaluation identified in the literature. 
 
Methods 
Pubmed and the NHS economic evaluation database were searched for published studies 
in six key areas for behavior change: smoking, physical activity, dietary behavior, 
(illegal) drug use, alcohol use and sexual behavior. From included studies (n=142), we 
extracted data on general study characteristics, characteristics of the LBCIs, 
methodological quality and handling of methodological challenges. 
 
Results 
Economic evaluation evidence for LBCIs showed a number of weaknesses: methods, 
study design and characteristics of evaluated interventions were not well reported; 
methodological quality showed several shortcomings; and progress with addressing 
methodological challenges remained limited. 
 
Conclusion 
Based on the findings of this review we propose an agenda for improving future 
evidence to support decision-making. Recommendations for practice include improving 
reporting of essential study details and increasing adherence with good practice 
standards. Recommendations for research methods focus on mapping out complex 
causal pathways for modeling, developing measures to capture broader domains of 
wellbeing and community outcomes, testing methods for considering equity, identifying 
relevant non-health sector costs, and advancing methods for evidence synthesis. 
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Introduction 
Lifestyle behavior is responsible for a large part of the disease burden to society. 
Therefore, interventions to change lifestyle behaviors, such as smoking, physical activity, 
diet and alcohol use, are increasingly developed.1 As public resources are limited, policy-
makers should give priority to lifestyle behavior change interventions (LBCIs) that 
produce the largest benefit per dollar invested. Economic evaluation studies can assist in 
this process by providing insights into the relative costs and benefits of interventions.2 
Such studies become increasingly available for LBCIs,3,4 but their methodological quality 
has been questioned5 and there is increasing recognition that methods, which have been 
developed to evaluate bio-medical health interventions, need amendments to deal with 
the challenges posed by public health interventions, such as LBCIs.6-8 
Six key challenges have been identified in the literature. Four of these concern the 
measurement of intervention outcomes: (i) as health benefits of LBCIs take a long time 
to accrue, lengthy follow up periods are needed or intermediate outcomes need to be 
translated to final outcomes (e.g. survival); (ii) LBCIs may produce a broad number of 
outcomes, which are not fully captured by standard measures of health outcome, such 
as Quality Adjusted Life Years (QALYs);8,9 (iii) LBCIs may have consequences for people, 
who are not directly targeted by the intervention or the community at large.7,10 Outcome 
measurement in economic evaluation, however, tends to focus on individual intervention 
participants only; (iv) many LBCIs are designed to achieve more health equity, but 
methods to account for equity outcomes in economic evaluation are not well 
developed.11,12 
The identification and measurement of costs create a fifth challenge. LBCIs take place in 
a wide range of settings and often produce costs outside the health sector. How to deal 
with non-health sector costs in economic evaluations is still unclear.7,13 Finally, there is 
discussion about the study design for evaluating effectiveness. Most economic evaluation 
guidelines indicate a preference for randomized controlled trials (RCTs), which are not 
always feasible in the context of LBCIs.7,12-14 
The aim of this research was 2-fold: (i) to examine the general methodological quality of 
economic evaluations of LBCIs and (ii) to examine how they addressed the six 
challenges for public health economic evaluation. 
Methods 
A systematic literature review was conducted focusing on six key areas for behavior 
change: smoking, physical activity, dietary behavior, (illegal) drug use, alcohol use and 
sexual behavior. Relevant references (n=5798) were identified through PubMed and the 
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NHS Economic Evaluation Database (see Supplementary data, Appendix 2.1 for the 
search strategy). From these we selected 142 for inclusion in this study (see Figure 2.1 
for the selection strategy and Supplementary data, Appendix 2.2 for full references). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Study selection procedure 
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Data extraction and analysis 
Included studies were divided between six reviewers (A.G., S.E., D.A., A.A., J.T. and 
J.S.). One reviewer assessed each study using a data extraction form, piloted by the 
research team, on 20 randomly selected articles. Data were extracted on general study 
characteristics, characteristics of the LBCIs evaluated, methodological quality and 
handling of methodological challenges. Methodological quality was examined using the 
10 main questions of a checklist for assessing economic evaluations developed by 
Drummond et al.2 (see Table 2.2). Due to ongoing discussion about the types of costs 
and consequences to be considered in public health economic evaluations, we further 
specified question 4 and focused only on program costs, survival and health-related 
quality of life outcomes. Question 10 was discarded, because examples and instructions 
regarding this question did not provide specific criteria for assessment.  
To assess handling of the six methodological challenges, we extracted data about study 
design and time horizon. Outcome measures used were identified and classified into the 
following categories: (i) intermediate outcomes, such as behavior changes (e.g. smoking 
cessation) or biomedical health indicators (e.g. body mass index); (ii) health outcomes, 
measured in terms of morbidity or disease occurrence (e.g. HIV infections prevented); 
(iii) final outcomes, including survival; health-related quality of life (HRQOL) and general 
quality of life (GQOL) or wellbeing; and (iv) equity outcomes (i.e. the impact of the 
intervention on distribution of health and wellbeing across socio-economic groups). 
Outcome measures were also classified according to measurement level (i.e. intervention 
participants, people not directly targeted or the community/society as a whole). Finally, 
we examined cost types included (i.e. program costs, health sector costs and non-health 
sector costs) and study designs used to determine intervention effectiveness. To reach 
consensus about questions arising during the data extraction and analysis process, 
regular meetings were held. 
Results 
General study characteristics of the economic evaluation studies and LBCIs evaluated are 
displayed in Table 2.1. 
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Table 2.1 Study characteristics of the economic evaluations (ntotal=142) 
Study characteristic   n (%) 
1981-1990  7 (4.9) 
1991-2000  43 (30.3) 
Year of publication  
2001-2009  92 (64.8) 
US  84 (59.2) 
UK   10 (7.0) 
Australia   10 (7.0) 
Sweden   5 (3.5) 
Netherlands  5 (3.5) 
Country of study 
Other   28 (19.8) 
Smoking   36 (25.4) 
Physical activity  17 (11.9) 
Diet  18 (12.7) 
Sexual behavior  19 (13.4) 
Alcohol abuse   11 (7.7) 
Illegal drug use  1 (0.7) 
Behavior area  
Several behavior areas   40 (28.2) 
Universal  24 (16.9) 
Selective   36 (25.4) 
Indicated   54 (38.0) 
Care related  18 (12.7) 
Combination of prevention levels  6 (4.2) 
Prevention level  
Not described  4 (2.8) 
Cost-effectiveness analysis  68 (47.9) 
Cost-utility analysis  15 (10.6) 
Cost-benefit analysis  8 (5.6) 
Cost-consequence analysis  12 (8.5) 
Cost-minimization analysis  4 (2.8) 
Type of economic evaluation 
Multiple types combined  35 (24.6) 
Doing nothing  49 (34.5) 
Usual care/standard intervention  29 (20.4) 
Pharmacotherapy  11 (7.7) 
Comparators used  
Other   56 (39.4) 
Study design  Trial   58 (40.9) 
 Modeling  56 (39.4) 
 Combination  23 (16.2) 
 Not described  5 (3.5) 
Time horizon ≤2 years  53 (37.3) 
 ≤5 years  8 (5.6) 
 ≤10 years  8 (5.6) 
 >10 years  12 (8.5) 
 Lifetime   30 (21.1) 
 Not described  31 (21.8) 
Effectiveness data derived from RCT  80 (56.3) 
 Quasi experiment  18 (12.7) 
 Other  27 (19.0) 
 Not described   17 (12.0) 
Costs included Intervention costs  133 (93.7) 
 Health-care costs   90 (63.4) 
 Costs in other societal sectors  11 (7.7) 
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Methodological quality  
Table 2.2 displays several methodological shortcomings. Only two thirds of the economic 
evaluations reported a well-defined research question. The perspective of the analysis 
was for example only explicitly stated by 57% of the studies (n=81). Less than half of 
the studies described the alternatives under evaluation in sufficient detail and specific 
behavior change techniques could only be determined for 11 studies (7.7%). Relevant 
costs and consequences were identified by only 41% (n=58) of the studies, despite the 
fact that we restricted ourselves to considering program costs, survival and HRQOL 
outcomes. Measurement and valuation of costs and consequences were rated as 
accurate in more than two-thirds of the studies. From studies with a time horizon 
exceeding 1 year (n=89) only 78.7% (n=70) used discounting to adjust for differential 
timing of costs and consequences. Incremental analysis was conducted by less than two-
thirds of the studies (59.8%). Studies performing sensitivity analyses (n=98, 69%) to 
account for uncertainty in estimated parameters usually did this consistently for both 
costs and consequences (n=73, 74.5%). But in less than half of the cases (n=43, 
43.9%) authors gave justifications for the value ranges or distributions used. Likewise, 
relatively few studies performed sensitivity analyses on the discount rate (n=41, 41.8%). 
Economic evaluations scored better regarding program effectiveness, which was either 
established beforehand or examined simultaneously with the economic evaluation by 
93% of the studies (n=132). Methodological quality of more recently published studies 
(2001-09) was comparable with the total sample.  
 
Table 2.2 Methodological quality scores 
n (%)  Checklist questions  
Yes No Can’t tell 
1. Was a well-defined question posed in an 
answerable form? 
92 (64.8) 50 (35.2) - 
2. Was a comprehensive description of competing 
alternatives given? 
63 (44.4) 79 (55.6) - 
3. Was the effectiveness of the programs or services 
established? 
132 (93.0) 4 (2.8) 6 (4.2) 
4. Were all the important and relevant costs and 
consequences for each alternative identified? 
58 (40.8) 83 (58.5) 1 (0.7) 
5. Were costs and consequences measured accurately 
in appropriate physical units? 
107 (75.4) 17 (12.0) 18 (12.7) 
6. Were costs and consequences valued credibly? 97 (68.3) 17 (12.0) 28 (19.7) 
7. Were costs and consequences adjusted for 
differential timing? 
77 (54.2) 59 (41.6) 6 (4.2) 
8. Was an incremental analysis of costs and 
consequences of alternatives performed? 
85 (59.8) 39 (27.5) 18 (12.7) 
9. Was allowance made for uncertainty in the 
estimates of costs and consequences?  
98 (69.0) 44 (31.0) - 
10.  Did the presentation and discussion of results 
include all issues of concern to users of the 
economic evaluation? 
- - - 
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Handling of challenges  
Design and time horizon of economic evaluations 
Model-based studies (n=56) were equally represented as trial-based (n=58) studies and 
23 studies (16.2%) used a combination of both approaches (Table 2.1). Five studies did 
not describe study design. Trial-based studies generally had a follow-up of two years or 
less (n=48). Only six studies had longer follow-up periods (up to 5 years). This is long 
for a trial, but insufficient to assess long-term health consequences of LBCIs. Modeling is 
a useful approach to extrapolate study findings beyond the trial period. From the 79 
studies with a modeling component, only 38% (n=30) calculated lifetime intervention 
consequences, as recommended by good practice guidelines.15 
Scope of outcomes considered  
Outcomes incorporated in the studies are summarized in Table 2.3. Two studies (1.4%) 
did not specify outcome measures. More than one-third of the studies (n=52, 36.6%) 
only incorporated intermediate outcome measures. Fourteen studies (9.9%) 
incorporated health outcomes, but no final outcomes, and 74 studies (52.1%) 
incorporated final outcomes. Survival (48.6%) and HRQOL (36.6%) were the most 
common final outcome measures and often used simultaneously (33.8%), for example 
when authors calculated QALYs. Only two studies (1.4%) used measures of GQOL or 
wellbeing. Johannesson et al.16 applied contingent valuation (CV) to value changes in 
subjective wellbeing and Quist Paulsen et al.17 used a measure of life satisfaction in 
sensitivity analyses to examine whether cost-effectiveness results alter when adjusted 
for quality of life. 
Measures of behavior change (n=60, 42.3%), such as the number of people who quit 
smoking or the number of drinks per day, were the most common intermediate outcome 
measures. Biomedical health indicators (e.g. reductions in weight, blood pressure or 
cholesterol) were incorporated by 33 studies (23.2%). Twelve (8.5%) studies 
incorporated other intermediate measures (e.g. increased health knowledge,18 improved 
daily stress management, increased problem solving ability and self-efficacy,19 unwanted 
pregnancies prevented,20,21 increased endurance levels,22 intervention recall,23 reduced 
sick leave,24,25 hospital admissions26 and outpatient visits26,27). 
None of the studies examined the impact of LBCIs on equity outcomes or explored 
whether cost-effectiveness varied for different socio-economic groups.  
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Table 2.3 Outcomes of LBCIs incorporated in economic evaluations by measurement level 
(ntotal=142) 
 Intermediate outcomes 
n (%) 
Health 
outcomes 
n (%) 
Final outcomes 
n (%) 
 
Measurement 
level (n) 
Behavior Biomedical 
health 
indicators 
Other Any  Survival HRQOL General 
QOL/ 
wellbeing 
Any 
Targeted 
individuals  
(n=140) 
 
60 
(42.3) 
33 
(23.2) 
11 
(7.7) 
84 
(59.2) 
41 
(28.9) 
69 
(48.6) 
52 
(36.6) 
2 
(1.4) 
74 
(52.1) 
Not directly 
targeted  
individuals 
(n=12) 
 
0 
(0.0) 
1 
(0.7) 
0 
(0.0) 
1 
(0.7) 
5 
(3.5) 
7 
(4.9) 
6 
(4.2) 
0 
(0) 
7 
(4.9) 
Community/ 
society  
(n=1) 
 
0 
(0.0) 
0 
(0.0) 
1 
(0.7) 
1 
(0.7) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
Total  
(n=140) 
60 
(42.3) 
33 
(23.2) 
12 
(8.5) 
86 
(60.6) 
42 
(29.6) 
69 
(48.6) 
52 
(36.6) 
2 
(1.4) 
74 
(52.1) 
Notes: The total number of studies incorporating outcomes at any of the measurement levels is lower than the 
total number of studies, because two studies did not specify outcome measures. Some studies considered the 
same outcome on more than one measurement level. Therefore, numbers in columns do not always add up. 
 
Twelve studies (8.5%) incorporated outcomes for not directly targeted individuals. Most 
of these (n=10) evaluated interventions addressing sexual behaviors.21,28-36 They 
incorporated either health outcomes (i.e. HIV and other STD infections averted) or final 
outcomes (i.e. life years and QALYs gained) among sexual partners of targeted 
individuals. Two studies evaluated interventions in other behavior change areas. One 
evaluated a nutrition education intervention and accounted for education spillovers and 
external benefits to people in the environment of targeted individuals.37 The other study 
evaluated a prenatal health education program and described how the program affected 
children’s birth weight of participating mothers.38 
Community level outcomes were only incorporated by one study evaluating an 
intervention for problem drinkers.39 The authors ascribed a monetary value to reduced 
quality of life caused by crimes and accidents based on jury compensations paid for pain 
and suffering caused by physical injuries and fear.  
Nineteen studies (13.4%) identified potentially relevant outcomes of LBCIs not 
incorporated in the economic evaluation due to a lack of adequate methods or limited 
scope of the research. These mostly concerned outcomes for individuals not directly 
targeted (i.e. health outcomes, survival, behavior changes and other intermediates, such 
as empowerment of staff delivering the intervention) and outcomes for intervention 
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participants not captured by standard measures of health outcome (e.g. changes in 
quality of life due to withdrawal symptoms or psychological wellbeing resulting from 
physical activity). Few studies (n=5) identified community level outcomes, such as a 
better sense of community, increased community support and the emergence of a black 
market due to changes in smoking legislation.  
Costs included 
Table 2.1 shows that the majority of studies included direct program costs (n=133, 
93.7%), health-care costs (n=90, 63.4%) or both (n=84, 59.2%). Eleven studies (7.7%) 
included costs in other societal sectors,20,39-48 such as costs of motor-vehicle accidents, 
violent crimes, incarceration, personal injury, property damage, fire destruction, law 
enforcement (e.g. roadside breath testing and handling legal challenges in court) and 
costs to industry, commerce and the voluntary sector. Detailed descriptions of 
identification, measurement and valuation of these costs were not provided. Out of 
pocket payments and time investments for behavior changes by participants were 
accounted for by 11.3% (n=16) and 20.4% (n=29) of the studies, respectively.  
Study designs to determine effectiveness of LBCIs 
Table 2.1 shows that effectiveness data were mostly derived from RCTs (n=80, 56.3%). 
This included single RCTs (n=62) and meta-analyses of RCTs (n=18). Eighteen studies 
(12.7%) derived effectiveness data from quasi-experiments, which provide an alternative 
design to the RCT, when randomization is not possible (e.g. in community-based 
interventions). In some cases it may even be difficult to use an appropriate control 
group, because people cannot be excluded from participation in the intervention. Two 
studies evaluating mass media interventions to encourage smoking cessation therefore 
used historical data as comparator, which were collected among the same 
population.49,50 Other sources of effectiveness data were expert opinion, systematic 
literature research (not further specified), hypothetical data or combinations of the study 
designs above.  
Discussion 
Main finding of this study 
Economic evaluations of LBCIs identified in this study (n=142) are characterized by a 
number of weaknesses. Methods, study design, and characteristics of LBCIs are not 
always reported in sufficient detail to assess relevance and quality of the evidence. 
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Methodological quality showed several areas for improvement and methodological 
challenges still need to be addressed. 
What is already known on this topic 
The Wanless reports in the UK pointed out that cost-effectiveness evidence to support 
decision-making about LBCIs is scarce and that applying economic evaluation methods 
to complex public health interventions, such as LBCIs, is difficult.51,52 Influenced by these 
reports, the National Institute for Health and Care Excellence (NICE) was one of the first 
organizations worldwide to introduce a systematic and transparent approach to 
producing guidance for evidence-informed decision-making about public health 
interventions, including LBCIs.53 Kelly et al.6 described methodological challenges 
emerging during the first years of developing this guidance. Several other researchers 
also identified methodological challenges7-9,12,54,55 and a systematic review by Weatherly 
et al.7 showed that few empirical studies tackled these in practice. 
What this study adds 
This study provides a further exploration of the progress made with addressing 
methodological challenges in the area of behavior change. It adds to the work of 
Weatherly et al.7 by (i) considering economic evaluation studies published before 2000 
and after 2005, and (ii) by examining their methodological quality. 
Based on our findings several priority areas for improving future evidence were 
identified.  
 
(i) Essential study details should be better reported. Quality assessment checklists, 
such as Drummond et al.2, Evers et al.56 and Philips et al.57 can provide guidance 
on reporting of methodological aspects of the study. Davidson et al.58 can be used 
to identify intervention characteristics essential to report, while Abraham and 
Michie59 can assist in describing behavior change techniques.  
(ii) To increase compliance with methodological standards, such as performing an 
incremental analysis, sensitivity analyses and the use of discounting, we suggest 
that evaluators use good practice guidelines (e.g. Ramsey et al, 200515, Caro et 
al., 201260) when planning and designing new studies. 
(iii)  Long-term costs and outcomes should be incorporated more often. This requires 
availability of (better) data and more use of mathematical models adopting a 
lifetime horizon. To improve availability of data for modeling, future research 
should map out social diffusion effects of LBCIs, as well as relationships between 
final and intermediate outcomes, in particular for intermediates other than 
behavior changes and bio-medical health indicators.61,62 Alternatives to Markov 
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models may be needed to model some of these relationships (e.g. interactions 
between individuals).63,64 More use of long-term modeling may also be 
encouraged through building modeling skills and reducing costs by using models 
in multiple applications.65 
(iv) Measures of final outcome need to be developed that allow for incorporation and 
valuation of broader domains of wellbeing relevant for LBCIs. Such measures are 
currently not available, but first steps to develop instruments are on their way. 
For example Lorgelly et al.66 explored the possibility to develop an outcome 
measure based on Sen’s capability approach. Willingness to pay is an alternative 
measure for capturing broader domains of wellbeing.8,54 One study in this review 
applied contingent valuation (CV) to value broader outcomes in willingness to 
pay, but did not specify which aspects of wellbeing were valued.16 More 
experiences with CV are needed to examine feasibility and validity of the method 
for evaluating LBCIs. 
(v) Incorporating outcomes for individuals who are not directly targeted is relevant in 
all behavior change areas examined. Progress was, however, mainly limited to 
studies evaluating interventions directed at sexual behaviors. These studies can 
give direction to methods development in other areas (e.g. to consider health 
impacts of smoking cessation for people exposed to second-hand smoke).67,68 
(vi) Future research should focus on developing measures of community level change 
for use within economic evaluation. Hawe, Shiell and Gold55,69 propose to build 
these on system-based approaches to evaluation increasingly used in public 
health, which describe complex relationships between process and long-term 
outcomes on multiple levels (e.g. individual, family, institutions, neighborhood 
and policy level) using logic models and examine intervention impacts by means 
of a combination of qualitative and quantitative methods.70,71 
(vii) Reducing health inequities is an important public health objective and therefore 
relevant to consider in decision-making. Future research should test systematic 
methods to consider equity outcomes both directly within economic evaluation 
and alongside economic evaluation results. Suggested methods for use within 
economic evaluation, include for example reviewing background information on 
equity, presenting cost-effectiveness for equity-relevant subgroups and 
systematic assessment of expected distributional effects of implementing 
interventions under evaluation.11,72 The equity effectiveness loop framework can 
help identify equity evidence relevant to consider in decision-making and the 
Equity Methods Group of the Cochrane collaboration is a good source for finding 
such evidence.73 
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(viii) It is important that future studies consider relevant non-health sector costs. To 
increase consistency in the costs considered, research should compile an overview 
of broader costs in each behavior change area and develop guidance on how to 
identify, measure and value these. 
(ix) RCTs designs ensure the highest degree of internal validity and are an important 
source of efficacy evidence. They are however not always feasible or ethical. In 
these situations natural experiments can be a useful alternative.74,75 RCTs also 
provide limited insights into intervention processes, contextual factors, participant 
experiences and implementation fidelity.14,76 Hence, augmenting RCTs with 
another study component (e.g. a discrete choice experiment, qualitative study or 
observational study) may be helpful.76,77 Methods to synthesize diverse forms of 
evidence for decision-making, such as cost-consequence analysis, multi-criteria 
decision analysis or logic frameworks should be further developed and tested.14,78 
 
Finally, to support decision-making using limited evidence, we suggest that evaluators 
clearly identify costs and outcomes not considered in the study and their expected 
impact on cost-effectiveness. 
Limitations 
This review only included full economic evaluations. Hence, it is possible that studies 
with very low quality (e.g. simple pre-post designs) were excluded and that 
methodological quality has even been overestimated. Our search strategy was limited to 
studies included by PubMed and the NHS economic evaluation database before April 
2009. Therefore, we cannot preclude the possibility that we have missed relevant studies 
and that our conclusions do not apply to the most recent years. 
Conclusion 
Weak evidence on cost-effectiveness currently hampers priority setting between LBCIs. 
Our study identified a number of steps to improve future evidence, but decisions about 
allocation of public resources to LBCIs still need to be taken using available evidence. 
The methods NICE applies to make best use of existing evidence (e.g. adapting existing 
models from other decision contexts) can provide directions to policy makers in other 
countries.79 
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Appendix 2.1 Search strategies 
To retrieve economic evaluation studies, we developed separate search strategies for 
PubMed and the NHS Economic Evaluation Database (EED). Records in the NHS EED are 
based on rigorous weekly searches in four other databases: Medline, EMBASE, 
PsychINFO and CINAHL. Our search strategy consisted of MeSH terms and free text 
covering the topics economic evaluation, public health and the six behavior change 
areas. Search terms for economic evaluation and the choice of the two databases were 
based on recommendations for retrieving economic evaluation studies1,2. Search terms 
for public health were based on those used in previous reviews of public health 
interventions3,4 and search terms for the six behavior change areas were developed in 
consultation with experts in each area. Combining these search terms, resulted in the 
following two search strategies. 
 
PubMed  
("drug use"[Title/Abstract] OR "Substance Abuse, Intravenous"[Mesh] OR "Opioid-Related 
Disorders"[Mesh] OR "Marijuana Abuse"[Mesh] OR "Amphetamine-Related Disorders"[Mesh] OR 
"Cocaine-Related Disorders"[Mesh] OR "Needle Sharing"[Mesh] OR "needle 
sharing"[Title/Abstract] OR "drug addiction"[Title/Abstract]) ("Alcohol-Induced Disorders"[Mesh] 
OR "alcohol drinking"[MeSH Terms] OR “alcohol” [Title/Abstract]) OR ("acquired 
immunodeficiency syndrome"[Title/Abstract] OR "aids"[Title/Abstract] OR "Hiv Infections"[MeSH] 
OR "Hiv"[MeSH] OR "hiv"[Title/Abstract] OR "Hiv Seropositivity"[MeSH] OR "Condoms"[MeSH] OR 
condom [Title/Abstract] OR "Sexual Behavior"[MeSH Terms] OR "sexual behavior"[Title/Abstract] 
OR "sexual behaviour"[Title/Abstract] OR "Safe sex"[Title/Abstract] OR "Safer sex"[Title/Abstract] 
OR "Sexually Transmitted Diseases"[MeSH] OR "sexually transmitted"[Title/Abstract]) OR 
("Smoking"[MeSH] OR "Tobacco use cessation"[MeSH] OR "Tobacco Use Disorder"[MeSH] OR 
"tobacco use cessation"[Title/Abstract] OR "smoking cessation"[Title/Abstract]) OR 
(“Locomotion"[MeSH] OR "Exercise"[MeSH] OR "Physical Fitness"[MeSH Terms] OR "Exercise 
Movement Techniques"[MeSH] OR “motor activity“[Title/Abstract] OR “workout“[Title/Abstract] 
OR “motion”[ Title/Abstract] OR “training”[Title/Abstract] OR “physical activity” [Title/Abstract] OR 
"motor activity"[Title/Abstract]) OR ("feeding behavior"[MeSH] OR "Nutrition Assessment"[MeSH] 
OR "Nutritional Support"[MeSH] OR "Nutrition Therapy"[MeSH] OR "Diet"[MeSH] OR "Bottle 
Feeding"[MeSH] OR "Breast Feeding"[MeSH] OR "Eating"[MeSH] OR "Nutritional 
Requirements"[MeSH] OR "Nutritional Status"[MeSH] OR “nutritional support”[Title/Abstract] OR 
“five a day” [Title/Abstract] OR “weight control”[Title/Abstract] OR “nutrition”[Title/Abstract])  
AND  
("Life Style"[Mesh] OR "Health Behavior"[Mesh] OR "Public Health Practice"[Mesh] OR "Preventive 
Health Services"[Mesh] OR "Prevention and Control"[Subheading] OR "Harm Reduction"[Mesh] OR 
"Risk Reduction Behavior"[Mesh]) 
AND 
("Costs and Cost Analysis"[MeSH] OR "cost analysis"[Title/Abstract] OR "cost 
utility"[Title/Abstract] OR "cost effectiveness"[Title/Abstract] OR "Quality-Adjusted Life 
Year"[Title/Abstract] OR "Quality-Adjusted Life Years"[MeSH] OR "QALY"[Title/Abstract] OR 
"Economic analysis"[Title/Abstract] OR "cost-consequence"[Title/Abstract] OR "Cost 
minimization"[Title/Abstract] OR "Cost minimisation"[All Fields] OR "Economic 
evaluation"[Title/Abstract] OR "Cost benefit"[Title/Abstract] OR “Economic” [Title]) 
Limits 
Language: English’ and ‘Species: humans’ 
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"drug use" [Any field] OR "Substance Abuse, Intravenous"[Mesh] OR "Opioid-Related 
Disorders"[Mesh] OR "Marijuana Abuse"[Mesh] OR "Amphetamine-Related Disorders"[Mesh] OR 
"Cocaine-Related Disorders"[Mesh] OR "Needle Sharing"[Mesh] OR "needle sharing" [Any field] 
OR "drug addiction" [Any field] OR "Alcohol-Induced Disorders"[Mesh] OR "alcohol 
drinking"[MeSH] OR alcohol drinking [Any field] OR alcohol consumption [Any Field] OR "Acquired 
Immunodeficiency Syndrome"[MeSH] OR "acquired  AND immunodeficiency AND syndrome" [Any 
field] OR "aids" [Any Field] OR "Hiv Infections"[MeSH] OR "hiv"[MeSH] OR "hiv" [Any field] OR 
“hiv seropositivity"[MeSH]" OR Condoms"[MeSH] OR “condom” [Any Field] OR "Sexual 
Behavior"[MeSH Terms] OR "sexual AND behavior" [Any Field] OR "sexual AND behaviour" OR 
"Safe sex" [Any Field] OR "Safer sex" [Any Field] OR "Sexually Transmitted Diseases"[MeSH] OR 
"sexually AND transmitted" [Any Field] OR "Smoking"[MeSH] OR "Tobacco use cessation"[MeSH] 
OR "Tobacco Use Disorder"[MeSH] OR "tobacco use cessation"[Any Field] OR "smoking 
cessation"[Any Field] OR “Locomotion"[MeSH] OR "Exercise"[MeSH] OR "Physical Fitness"[MeSH] 
OR "Exercise Movement Techniques"[MeSH] OR “motor activity“[Any Field] OR “workout“[Any 
Field] OR “motion”[Any Field] OR “training”[Title/Abstract] OR “physical activity” [Any Field] OR 
"motor activity"[Any Field] OR "Feeding Behavior"[MeSH] OR "Nutrition Assessment"[MeSH] OR 
"Nutritional Support"[MeSH] OR "Nutrition Therapy"[MeSH] OR "Diet"[MeSH] OR "Bottle 
Feeding"[MeSH] OR "Breast feeding"[MeSH] OR "Eating"[MeSH] OR "Nutritional 
Requirements"[MeSH] OR "Nutritional Status"[MeSH] OR “Nutritional Support”[Any Field] OR “five 
a day” [Any Field] OR “weight control”[Any Field] OR “nutrition”[Any Field] 
AND  
"Life Style"[Mesh] OR "Health Behavior"[Mesh] OR "Public Health Practice"[Mesh] OR "Preventive 
Health Services"[Mesh] OR “prevention and control” [Any Field] "Harm Reduction"[Mesh] OR "Risk 
Reduction Behavior"[Mesh].  
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Abstract 
Objective 
In the Netherlands allocation decisions have not yet been explicitly based on the Value 
of Statistical Life. However, when policy makers decide whether or not to implement life 
saving interventions this trade-off is made implicitly. This study aimed to gain insights 
into this trade-off, hereafter referred to as Implicit Value of Statistical Life (IVSL), by 
means of a retrospective investment analysis of life saving interventions implemented in 
the Netherlands. 
 
Methods 
A literature search was conducted to find life saving intervention cases meeting the 
requirements for IVSL calculation. A final sample of ten cases was included in the study 
concerning interventions implemented in different societal sectors. For each case, an 
IVSL estimate was calculated according to a uniform method.  
 
Results 
IVSL estimates derived from the intervention cases differed considerably and ranged 
from €1 to almost € 11 million. Differences were most extreme when comparing IVSL 
estimates concerning interventions implemented in different societal sectors. However, 
IVSL estimates also varied greatly between interventions in the same sector and even 
within the same interventions when critical assumptions were altered.  
 
Conclusion 
Our findings suggest that there are great imbalances between societal investments for 
preventing a statistical death. This highlights the need for further deliberation about how 
to improve transparency of policy decisions. An approach ex ante determining the Value 
of Statistical Life by means of empirical methods and based on societal preferences 
might circumvent the problems associated with the IVSL and needs further exploration. 
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Introduction 
Human life is the most valuable good we have and protecting it has high priority. The 
belief has even been expressed that costs should not play a role in saving human lives.1 
In different societal sectors, such as health care, transport, consumer safety and the 
environment, regular efforts are made to develop interventions reducing mortality risk. 
However, because public resources are limited implementing all of these interventions is 
impossible and choices have to be made between competing intervention options.  
In the healthcare sector decisions about the allocation of scarce resources are 
increasingly based on economic evaluations.2 In these evaluations, efficiency is often 
expressed in terms of costs per quality-adjusted life-year (QALY). The QALY integrates 
life expectancy and health-related quality of life in a single outcome measure.3 It can be 
used to compare different types of healthcare interventions, including screening, 
diagnosis, treatment, monitoring or a combination of these and as such contributes to 
allocative efficiency. Due to these advantages, in the Netherlands guidelines were 
formulated that explicitly recommend the application of the QALY in economic 
evaluations of pharmaceuticals that come into consideration for reimbursement.4 
For interventions directed at mortality risk reduction, the economic literature suggests 
the Value of Statistical Life (VSL) as a common measure of efficiency. The VSL refers to 
the value that an individual or society would be willing to pay to avoid a statistical death 
(i.e. the risk of an anonymous premature death). It is a measure of the marginal rate of 
substitution of wealth for risk of death, due to a specific cause.5-7 Empirically, it can be 
determined by dividing an individual’s willingness to pay (WTP) for a change in initial 
mortality risk, by the change in risk. WTP estimates can be determined by means of 
revealed or stated preference techniques.8 Revealed preference techniques draw on 
actual market behaviour, whereas stated preference techniques are survey-based 
approaches.9 Both methods result in individual WTP estimates that can be aggregated to 
determine a societal VSL.  
As the VSL can be used to evaluate all kinds of mortality risk reducing interventions, it 
may assist policy makers in their assessment of competing intervention options across 
societal sectors. Hence, the VSL has the potential to support allocation decisions on a 
more central level, similar to the role the QALY plays for allocation decisions in the 
healthcare sector. However, to our knowledge policy decisions in the Netherlands have 
not been explicitly based on VSL estimates. Instead, the trade-off between wealth and 
mortality risk is made implicitly when policy makers decide whether or not to implement 
certain life saving interventions.10-11 These policy decisions give the best available 
indication of societal willingness to pay for reductions in mortality risk. As there is no 
scientific evidence regarding this Implicit Value of Statistical Life (IVSL), the present 
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study had the objective to gain insights into its magnitude based on life saving 
interventions implemented in different societal sectors in the Netherlands. 
Methods 
For the purpose of this study, the IVSL was defined as the monetary value society 
commits to preventing one statistical death as revealed by public life saving 
interventions that have already been implemented. According to this definition, the IVSL 
can be calculated by dividing the total investment made for an intervention by the total 
number of lives saved by that intervention, where the number of lives saved equals the 
difference between the expected number of deaths before and after the intervention. 
This method has previously been referred to as Cost per Life saved.9 
To allow for the calculation of IVSL estimates based on implementation decisions of the 
Dutch government, we defined the following selection criteria for life saving 
interventions to be included in this study. First, the interventions concern a measure or 
strategy reducing the probability of premature death among a specified target 
population. Secondly, the decision to implement the interventions has been taken by the 
Dutch central government, whereas the implementation itself and the costs may also be 
the responsibility of private parties. Finally, the literature reports estimates of the 
investment made and the number of lives saved by the intervention or provides 
sufficient information to allow for a belated calculation of these estimates.  
To find suitable cases of life saving interventions, the authors initially reviewed 
interventions implemented or planned for implementation in the Netherlands that 
play(ed) a central role in the public debate of governmental policy and met the above 
selection criteria. Literature regarding economic evaluations conducted with respect to 
these interventions was searched using governmental and related websites. 
Furthermore, we contacted experts in different sectors of public policy working in 
ministries and research institutes that operate on behalf of the Dutch government. They 
were asked whether they were aware of policy documents regarding these particular 
interventions and other life saving interventions that might meet the inclusion criteria.  
The majority of the reports and policy documents collected by this method initially did 
not meet the selection criteria. In several cases, however, additional information could 
be obtained from original authors and literature regarding the projected investment, the 
expected number of lives saved and the implementation status of the interventions. This 
process resulted in a final sample of 10 life saving intervention cases included in the 
study.  
For each of these cases, first the investment made and the number of lives saved were 
determined. In case that these estimates were reported directly, the original calculations 
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were reconstructed in order to gain insights into the comparability of estimates across 
the intervention cases. Subsequently, the IVSL was calculated according to the above 
described definition. With respect to the calculations, the following choices were made. 
To make IVSL estimates comparable across cases, annual estimates were transferred to 
total estimates. Furthermore, when uncertainty was reported around the estimates of 
the investment and/or number of lives saved (e.g. in terms of sensitivity analyses or 
minimum and maximum estimates), an IVSL was calculated for each of the possible 
values of the estimates. 
Results 
First, the intervention cases analyzed in this study are described according to the 
societal sector in which they were implemented and with particular emphasis on how the 
investment and number of lives saved were estimated. Subsequently, the IVSL estimates 
derived from these cases are discussed. 
Water control: Measures to reduce mortality risk from flooding 
In 2003 the Dutch Ministry of Transport, Public Works and Water Management 
commissioned the Netherlands Environment Assessment Agency (MNP) to evaluate the 
previous governmental policy of managing flooding risk.12 In the framework of this 
evaluation the cost-effectiveness of two water control measures was assessed aiming to 
improve the Dutch populations’ protection against flooding risk: (i) the water barriers 
built in the southwestern part of the Netherlands after the flooding disaster in 1953 and 
(ii) the water barriers built in Central Holland based on the recommendations of the so-
called “Delta Commission” made in 1960.12 The MNP report did not explicitly mention the 
perspective from which the economic analyses were performed, but as it concerned an 
evaluation of governmental policy, it is assumed that a public payer perspective was 
used. 
For both interventions the investment and number of life saved estimates were directly 
reported. However the calculations underlying these estimates could not be 
reconstructed, due to unpublished literature and/ or inaccessible data. From the 
descriptions in the MNP report the following information could only be derived. In the 
Central Holland case the investment estimate was only based on the investment directly 
associated with the water control measures, whereas in the South West Netherlands 
case the investment estimate represents the investment associated with the water 
control measures, minus additional economic benefits due to the further development of 
the Vlissingen harbor area. Furthermore, the number of lives saved estimate in the 
South West Netherlands case was based on the number of fatalities caused by the 
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flooding disaster in 1953. For the Central Holland case we were not able to retrieve the 
literature sources providing the estimated number of lives saved. Both, the investment 
and number of live saved estimates, were reported on an annual basis assuming an 
interest rate of 4 percent and administration costs of 1 percent.  
Consumer safety: Measures to reduce mortality risk from contamination of 
pharmaceutical products  
In 1996, patients with a new variant of Creutzfeldt Jakob disease (CJD) representing a 
bovine-to-human transmission of BSE (bovine spongiform encephalopathy) were for the 
first time discovered. Because there is no cure available for this disease, the Dutch 
government took a series of measures to protect consumers from contracting it. These 
included tracking down and slaughtering diseased cattle, banning the import of cattle 
from Great Britain and testing cattle older than 30 months for BSE.13 In addition, 
changes in regulations were made to reduce the transmission risk of the disease by 
pharmaceutical products containing animal derivates. To adhere to these new 
regulations, pharmaceutical companies had to change production processes, conduct 
additional analyses and use other raw materials. The costs and benefits of these 
measures were recently estimated for the companies SynCo Bio Partners, Sobel, Sanquin 
and Centocor using data from interviews with company representatives and additional 
literature.13 
The investment estimates reported consist of structural and once only costs made by the 
companies in an 8-year period and include both costs made to comply with the 
legislation and voluntary costs made to reduce the transmission risk.13 The number of 
lives saved were estimated based on a hypothetical population at risk for contracting the 
disease of 1 billion and on an estimated initial mortality risk, that was calculated as 
cumulative risk of the separate protection moments (i.e. each time patients take the 
pharmaceutical product under consideration). 
Transport sector: Measures to reduce mortality risk from road accidents  
Every year, a considerable number of people get injured or die in road accidents due to 
the limited field of view truck drivers have when turning right. In response to this 
problem, the Dutch government introduced a legal obligation to equip trucks with field of 
view improving systems (i.e. blind spot mirror or camera) in 2003. Shortly after this 
legislation was implemented, Langeveld & Schoon (2004)14 conducted an economic 
evaluation of this measure from a societal perspective. The investment estimate they 
report includes the costs made by the government for law making and educational 
campaigns and the costs made by truck owners for equipping their vehicles with field of 
view improving systems. The number of lives saved estimate used in the report was 
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derived from previous research.15 It was calculated using accident statistics and was 
based on two main assumptions: (i) the differences between the number of casualties 
caused by trucks turning right and trucks turning left can be accounted for by the blind 
spot; and (ii) field of view improving systems have a 40% lower effectiveness than direct 
view. Both the investment and the number of lives saved concerned an 8-year period 
and were discounted to present value using a 4 percent discount rate.  
Health care: Measures to reduce mortality risk from pandemic influenza  
Based on WHO recommendations the Dutch Ministry of Health, Welfare, and Sports 
developed an Influenza Pandemic Preparedness Plan with the objective to minimize the 
effects of a possible influenza pandemic on population and society. In the framework of 
this plan, the National Institute for Public Health and the Environment (RIVM) assessed 
the impact of different intervention measures on health services in terms of resources 
needed and health consequences, including mortality.16 The intervention measures 
concerned two possible scenarios: (i) the situation in which an influenza vaccine is 
available at the beginning of the pandemic and (ii) the situation in which such a vaccine 
is not available. For the latter case two intervention options were assessed. First, 
pneumococcal vaccination of groups at risk for influenza to prevent the complications 
associated with influenza, and second a therapeutic strategy administering 
neuraminidase inhibitors (i.e. antiviral agents) to people with influenza-like symptoms. 
Prophylactically administering neuraminidase inhibitors was another intervention option 
examined, but this was not included in this study as it did not meet our selection criteria. 
To date, the Netherlands have not been confronted with an influenza pandemic. 
However, the Dutch government has already invested in influenza vaccines (4 million 
units), pneumococcal vaccine (1 million units), and antiviral agents (5 million cures) to 
ensure rapid action in case a pandemic outbreak occurs.16,17 
The investment associated with the alternative intervention options was not reported by 
the RIVM, but it could be calculated due to the detailed description provided of the 
resources needed for the different intervention options. Given that only health care 
resources were described in the report, we conducted the analysis from a health care 
perspective. The investment estimate includes drug costs, pharmacy prescription fees 
and the costs of GP visits for the number of patients that is expected to receive the 
interventions.18-21 The numbers of lives saved were estimated using a mathematical 
model synthesising data from various literature sources, including GP registries and 
Statistics Netherlands. The model was based on several assumptions regarding age 
dependency of attack rates, the spreading time of influenza and the conversion of death 
rates in the normal epidemic to the pandemic situation and was validated by an expert 
panel. Due to the uncertainty regarding the extent of a possible pandemic, the estimates 
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of the investment and the number of lives saved were reported for the situation in which 
the pandemic hits 30 percent and 50 percent of the population. Given the lack of 
knowledge regarding the efficacy of neuraminidase inhibitors when used for therapeutic 
purposes, the investment made and the number of lives saved was also calculated for 
different degrees of efficacy (25 percent and 75 percent). 
 
Table 3.1 IVSL Estimates and Input Parameters for the IVSL Calculation 
IVSL (€) 
Case (per sector) 
Investment 
(* € 1000) 
Lives Saved 
(N) Min 
Point 
estimate 
Max 
Water control 
     
Central Holland 300 000 100-5 440 55 147  3 000 000 
South West Netherlands 700 000 64 - 10 937 500 - 
      
Consumer safety      
SynCo Bio Partners 50 28 908 - 2 - 
Sobel 113 200 11 095 - 10 203 - 
Sanquin 191 000 192 719 815 - 1 - 
Centocor 36 000 73 000 - 493 - 
      
Transport       
Field of view improving systems 13 610 12 - 1 134 167 - 
      
Health care/Public Health      
Influenza vaccination      
pandemic hits 30%  69 825 2 251 - 31 020 - 
pandemic hits 50% 69 825 3 752 - 18 610 - 
Neuraminidase inhibitors      
pandemic hits 30%; efficacy 25% 294 690 1 010 - 291 772 - 
pandemic hits 50%; efficacy 25% 501 600 1 600 - 313 500 - 
pandemic hits 30%, efficacy 75% 294 690 3 030 - 97 257 - 
pandemic hits 50%, efficacy 75% 501 600 5 000 - 100 320 - 
Pneumococcal vaccination      
pandemic hits 30% 63 884.4 137 - 466 309 - 
pandemic hits 50% 63 884.4 230 - 277 758 - 
Notes: All estimates presented in this table were rounded to absolute numbers. 
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Discussion 
This study aimed to provide insights into the magnitude of the Implicit Value of 
Statistical Life (IVSL) by means of 10 cases of life saving interventions implemented in 
different societal sectors in the Netherlands. Our findings show that IVSL estimates differ 
considerably between the intervention cases and range from €1 to almost € 11 million 
per statistical death prevented. This indicates that society’s investments for mortality risk 
reductions vary extremely. However, one can question whether the IVSL estimates in 
this study give a good indication of which of life saving interventions represent a better 
investment than others in terms of efficiency. The IVSL estimates derived in this study 
have the advantage that they were calculated according to a uniform method and 
express the efficiency of different types of interventions in the same terms. Ideally, such 
a common efficiency parameter allows for a comparison of different types of 
interventions. However, the differences existing between crucial input parameters for the 
IVSL calculation (i.e. the investment and number of lives saved estimates) hamper valid 
comparison of the interventions in this study. The differences have several reasons.  
First, the investment and number of lives saved estimates derived from the intervention 
cases were determined using different perspectives. In the pharmaceutical sector cases 
the perspective of individual companies was applied, while in the other intervention 
cases a health care, societal or public payer perspective was used. As a result the types 
of costs included in the investment estimate and the population at risk used to estimate 
the number of lives saved are not comparable across cases.  
Second, discounting is not applied consistently. In the transport sector case discounting 
is used to adjust future monetary and health effects for their differential timing. In all 
other cases discounting was not applied or not reported. Due to the preventive nature of 
the interventions in this study, benefits are generally produced in the future, while costs 
are generated immediately. Therefore, the choice whether or not to use discounting and 
the choice for the method of discounting can have profound effect on the cost-
effectiveness of these interventions.22, 23 Although there is still ongoing discussion 
regarding whether or not to discount the benefits of preventive interventions, the 
methods used should at least be consistent in order to allow for a comparison.24 
Third, additional economic benefits produced by the interventions are not consistently 
included in the investment estimate. As part of the water control measures in South 
West Netherlands, the Vlissingen harbor area was further developed. The additional 
economic benefits resulting from these measures were subtracted from the total 
investment made for the intervention. In the remaining intervention cases, benefits 
other than mortality risk reduction were either not accounted for or this was not 
reported. 
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Finally, the investment and number of lives saved estimates vary in the accurateness by 
which they were estimated. This is due to differences in the quality and scope of the 
economic evaluations performed in relation to the intervention cases. The estimates 
derived from the consumer safety cases are for instance based on a short explorative 
study, whereas the estimates derived from the health care sector cases are based on a 
decent and comprehensive analysis. The estimates in the transport sector case appear to 
be based on a rather global estimation and for the water control cases we could not 
reconstruct how estimates were calculated. These accuracy differences may for instance 
explain why IVSL estimates derived from the consumer safety cases are so low 
compared to IVSL estimates of other cases. The mortality risks in the consumer safety 
cases were largely based on ad hoc estimates made by company managers. As people 
generally have difficulties appraising small risks,25 it is possible that this approach has 
resulted in an overestimation of the initial mortality risk and the risk reductions achieved 
by the intervention and hence in biased IVSL estimates.  
Given the potential bias introduced by studies with a rather limited scope and suboptimal 
research methods, it would have been advisable to use the quality of the data as an 
additional selection criterion for the cases included in this study. However, as the 
availability of intervention cases meeting the requirements for the IVSL calculation was 
limited, we chose not to use the quality of the data as a separate selection criterion.  
In addition to the limited comparability of IVSL estimates, there are also some 
conceptual problems inherent to the IVSL. The IVSL is based on investment decisions 
that have often been taken by policy makers in an ad hoc manner. As a result the trade-
off between wealth and mortality risk may be a highly imperfect process not adequately 
reflecting policy preferences.11 
Furthermore, the IVSL only gives an indication of the lower bound of society’s 
willingness to pay for a statistical death prevented. It reveals the amount society has 
paid in the past, while it would be more relevant to know what society would be willing 
to pay as a maximum.  
A third problem of the IVSL is related to the fact that it has to be determined 
retrospectively based on secondary data sources. Hence, data about the decision 
contexts of the wealth-risk trade-offs is not readily available, which limits the opportunity 
to systematically examine possible determinants of IVSL estimates. Meta-analyses of 
empirical VSL studies, suggest that VSL estimates are influenced by a variety of factors, 
including characteristics of the sample (e.g. income), characteristics of the affected 
population at risk (e.g. life expectancy and average mortality risk) and context-specific 
factors (e.g. country of origin, year of publication or “unionization” in labour market 
studies).26, 27 Insights into these factors and their relationship with the VSL are important 
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as they contribute to our understanding of the variations found between VSL estimates 
from different studies.  
Forth, it may be argued that the IVSL concept does not reflect preferences of society, 
but rather the revealed preferences of policy makers themselves, which is in contrast to 
the widely shared opinion among economists that the monetary value of safety in public 
sector cost-benefit analyses should reflect the preferences of those affected by the 
measure.9 
Finally, the IVSL assumes that decisions to implement life saving interventions are solely 
based on the trade-off between wealth and mortality risk. However, this trade-off is only 
one of the many factors that may be considered by decision-makers. Additional factors 
taken into account include for instance the broader benefits the intervention has for 
society, the potential unrest or panic that may be reduced by the intervention, and the 
consideration that we can be better safe than sorry, which is referred to as the 
precautionary principle.28,29 Moreover, policy decisions are not only based on a rational 
weighing of arguments, but often represent a political compromise. Decision-makers 
have to argue with different stakeholders and have to sell their decisions in the light of 
being re-elected.30 Hence, the IVSL does not provide an adequate reflection of the 
complex reality of decision-making. 
Conclusion 
This study has demonstrated that an IVSL derived by means of an ex post investment 
analysis is not an adequate means to compare the efficiency of different life saving 
interventions. This is due to the incomparability of input data for the IVSL calculation 
when these are derived from secondary data sources, but primarily, due to conceptual 
problems inherent to the IVSL. Despite the limitations of this approach, the IVSL 
estimates derived in this research suggest that there are great imbalances between 
society’s investments for avoiding a statistical death. At this moment we lack information 
about the possible reasons of these imbalances. This highlights the need for further 
deliberation about how policy decisions can be made more transparent. A decision-
making approach explicitly and ex ante taking the VSL into account could be a step 
forward. When determined by means of empirical methods and based on societal 
preferences, the VSL might circumvent the problems associated with the implicit VSL 
approach and might provide a useful decision aid for policy-makers. Further research 
efforts are needed to examine applications of this method in the practice setting. 
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Abstract 
Objective 
To provide insights into health promotion outcomes that are not captured by 
conventional measures of health outcome used in economic evaluation studies, such as 
EQ-5D based QALYs.  
 
Methods 
Twelve semi-structured interviews and five focus group discussions were conducted with 
participants of a randomized controlled trial (n=52) evaluating the effectiveness of a 
theory-based lifestyle intervention in Dutch adults at risk for diabetes mellitus and/or 
cardiovascular disease. Transcripts were analysed by two independent researchers using 
a thematic analysis approach.  
 
Results 
In total we identified twelve non-health outcome themes that were important from the 
participant perspective. Four of these were reported as direct outcomes of the lifestyle 
intervention and eight were reported as consequences of lifestyle behavior change. Our 
findings also suggest that lifestyle behavior change may have spillover effects to other 
people in the participants’ direct environment.  
 
Conclusion 
This study provides evidence that in the context of lifestyle behavior change EQ-5D 
based QALYs capture health promotion outcomes only partially. More insights are 
needed into non-health outcomes and spillover effects produced by health promotion in 
other contexts and how participants and society value these. Methods to account for 
these outcomes within an economic evaluation framework need to be developed and 
tested.  
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Introduction 
Health promotion (HP) interventions are increasingly regarded as a way to tackle the 
growing global burden of chronic diseases.1-3 The need to invest in HP interventions is 
also recognized at the policy level, which is demonstrated by a wide range of HP policies 
implemented by governments and international organisations, worldwide.4 Economic 
evaluation studies provide a comparative analysis of costs and consequences of 
alternative intervention options and can support decisions about which interventions to 
include in such policies.5 To date, economic evaluation studies are hardly used for 
decision making about HP.6 First, because in most countries there are no systematic 
procedures for considering economic evaluation evidence in HP decision-making7 and 
second, because economic evaluation evidence is scarce for HP interventions.8 Even 
when economic evaluation studies are available, the adequacy of the evidence they 
provide is questionable. There is growing recognition that the methods, which have been 
developed to evaluate clinical health interventions (e.g. drugs, medical procedures and 
devices), do not adequately deal with challenges posed by complex HP interventions.9-11 
The broad number of outcomes HP interventions intend to produce constitutes one of 
the key challenges.9,10 A common objective of HP is, for instance, to improve individuals’ 
ability to make informed decisions and control their personal life. To achieve such 
empowerment, individuals have to undergo a personal development process which may 
include consciousness raising and the acquisition of problem solving skills.12-14 Changes 
to such broader outcomes are usually not captured by economic evaluation studies, 
which tend to focus on health outcomes only. Health outcomes are increasingly 
measured using a cost-utility framework and expressed in Quality Adjusted Life Years 
(QALYs).15-17 QALYs are a measure of a person’s (expected) length of life weighted by 
the health-related quality of life (HRQOL) experienced over that period.5 The HRQOL 
weight is mostly derived using generic preference based instruments (such as the EQ-
5D). The use of such off the shelf instruments for evaluating HP interventions is 
problematic, because they neglect relevant broader outcomes of HP, which may lead to 
suboptimal allocation of public resources.10,18 Intended broader outcomes of health 
promotion are, however, not well-defined and theoretically underpinned outcome 
measures for use in evaluation studies not readily available.12,19-22 More insights are 
needed into the types and nature of non-health outcomes of HP to advance the 
discussion about adequate ways to consider these within an economic evaluation 
framework in a healthcare decision-making context. The present research aimed to 
identify non-health outcomes from the perspective of participants in a lifestyle behavior 
change (LBC) intervention. 
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Methods 
A combination of semi-structured interviews (SIs) and focus group discussions (FGDs) 
was used, because previous research suggests that this type of triangulation of 
qualitative methods may enhance understanding of the phenomenon studied (here: non-
health outcomes).23,24 SIs give respondents the opportunity to elaborate on their 
experiences more in detail and share information they find too personal to discuss in a 
group, while FGDs provide a greater breadth of perspectives.25,26 
Study population and recruitment procedure 
Respondents were recruited from participants in the Hoorn Prevention Study (HPS), a 
randomized controlled trial evaluating the effectiveness of a theory-based lifestyle 
intervention in adults with an increased risk for type 2 diabetes mellitus (T2DM) and/or 
cardiovascular disease (CVD).27 The intervention was directed at improving motivation 
and self-empowerment of individuals to make sustainable changes in their lifestyle 
behaviors. Participants received a median of 2 face-to-face counselling sessions 
(interquartile range: 1-3) and a median of 2.3 follow up sessions by phone (interquartile 
range: 1-3). The sessions were provided by trained practice nurses using evidence-
based counseling techniques (i.e. motivational interviewing and problem solving 
treatment).27,28 Participants in the intervention group (n=314) could choose to focus on 
smoking cessation, physical activity, diet or a combination of these lifestyle behaviors. 
The control group (n=308) received written information about their risk to develop 
T2DM and CVD and existing brochures containing information about how to stop 
smoking and about health guidelines regarding physical activity and diet.27 For this 
qualitative study we recruited intervention group participants only, because familiarity 
with the HP intervention was regarded as crucial in order to talk about intervention 
consequences based on personal experiences.29  
Respondents for SIs were recruited in January and February 2009, one year after 
commencement of the HPS. Participants, who had a research visit for physical 
measurements of the HPS scheduled during this period (n=20), were contacted by 
phone. They were asked whether they were willing to give an interview after the 
research visit. This resulted in a final sample of 13 participants (see Figure 4.1).  
Two of these were a couple and interviewed together. So, 12 SIs were held in total. To 
maximise diversity in perspectives and experiences all intervention group members still 
participating in the HPS in March 2009 (n=282, 90%) were invited for FGDs. The 
invitation was send by mail and included a response form (n=282). In case this form 
was not returned within two weeks, participants were contacted by phone. This resulted 
in a sample of 40 participants (see Figure 4.1). Five FGDs (with 6 to 12 participants) 
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were held in March and April 2009. Background characteristics of both SI and FGD 
participants are presented in Table 4.1 and were measured at baseline of the HPS 
(between December 2007 and April 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Recruitment procedures 
Recruitment procedure SIs
Telephone invitation to intervention group
members with scheduled research visits
(n=20) 
Unable to attend scheduled visit
(n=3)
Refused to give interview
(n=2)
Agreed to give interview 
(n=15)
Not interviewed
(n=2)
1 called in sick
1 did not attend
Interviewed
(n=13)
Did not return response form
(n=103)
Written invitation to intervention group
members still included in the HPS
(n=282) 
Willing to participate
(n=32)
Refused to participate
(n=147)
Contacted by phone
(n=65)
Not reached
(n=33)
Refused to participate
(n=44)
Willing to participate
(n=21)
FGD scheduled
(n=44)
Returned response form
(n=179)
Dropped out of HPS 
(n=5)
Recruitment procedure FGDs
Not interviewed
(n=4)
3 called to cancel
1 did not attend
Interviewed
(n=40)
Scheduling not possible
(n=9)
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Table 4.1 Characteristics of study participants (n=52) 
Variables N (%) 
Type of interview FGD 12 (23.1) 
 SI 39 (75.0) 
 Both 1 (1.9) 
Gender Male 22 (42.3) 
Age 30–35 years 5 (9.6) 5 (9.6) 
 36–40 years 13 (25.0) 13 (25.0) 
 41–45 years 12 (23.1) 12 (23.1) 
 46–50 years 21 (40.4) 21 (40.4) 
 >50 years 1 (1.9) 1 (1.9) 
Education level Primary education 1 (1.9) 
 Secondary education 36 (69.2) 
 Higher education  13 (25.0) 
Income (gross per month) <€ 2500 14 (26.9) 
 € 2500–3000 11 (21.1) 
 > € 3000 12 (23.1) 
 Prefer not to tell 8 (15.4) 
Work status Having paid work 44 (84.6) 
 Working full-time (≥36 h/week) 21 (40.4) 
 Working part-time  21 (40.4) 
Country of birth The Netherlands  49 (94.2) 
Living arrangement Living alone 4 (7.7) 
 Living with partner  6 (11.5) 
 Living with partner and child(ren)  39 (75.0) 
 Other arrangement 1 (1.9) 
Smoking status Non-smoker 25 (48.1) 
 Smoker  8 (15.4) 
 Former smoker  17 (32.7) 
Having any problems on EQ5D dimensions Mobility  7 (13.5) 
 Self care  1 (1.9) 
 Usual activities  5 (9.6) 
 Pain/discomfort  24 (46.1) 
 Anxiety/depression 10 (19.2) 
EQ5D visual analogue scale score Mean (SD) 76.21 (10.94) 76.21 (10.94) 
Notes: Percentages do not always add up to 100, because there were missing values for several 
items: education level (n=2), income (n=7), having paid work (n=2), working full- or part-time 
(n=10), country of birth (n=2), living arrangements (n=2), smoking status (n=2), and all EQ5-D 
dimensions (n=2). 
 
The interview process 
SIs and FGDs both commenced with a general introduction about the purpose, 
procedure and confidentiality of the interviews. SIs proceeded with a broad opening 
question (You are participating in the Hoorn Prevention Study. Can you tell me how you 
experience this?). Respondents were then asked how they experienced the counseling 
sessions and to describe any consequences the counseling had for them. We also asked 
specifically whether respondents had made changes to any of the three lifestyle 
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behaviors due to the counseling and if so, which consequences these had for them. In 
case respondents did not change lifestyle behavior due to the intervention, we asked 
them whether they could describe experiences with changing the three lifestyle 
behaviors of interest in other situations (e.g. self-accomplished changes in absence of an 
intervention, such as becoming a member in a gym and exercising regularly). We asked 
about these experiences, because the RCT study was still ongoing when this qualitative 
research was conducted and intervention effectiveness was unclear. So, in case that the 
intervention was not effective in changing behavior, participants’ previous experiences 
with LBC could nevertheless provide useful insights into non-health outcomes of LBC. 
Probing questions were used to encourage participants to elaborate on their views and 
experiences (e.g. Can you explain what you mean by feeling good?). The interviewer 
used a topic guide to ensure that all relevant issues were covered. For FGDs the same 
topic guide was used as for SIs, but topics were introduced in a different way using 
techniques to encourage interaction and equal participation of respondents.30 A 
whiteboard was used to gather different ideas put forward by respondents. Post its were 
used on which respondents could first list items individually and then share them with 
the group. All interviews were conducted by the same interviewer (AG), a health 
economics researcher with a background in public health. SIs lasted between 30 and 60 
minutes and FGDs between 1.5 and 2 hours. Participants’ travel and parking costs were 
reimbursed. Additionally, SI participants received a breakfast and FGD participants 
received refreshments and a USB stick. Ethical approval for the study was obtained from 
the VU University Medical Centre Research Ethics Committee. 
Data processing and analysis  
All SIs and FGDs were audio-taped, transcribed and entered into QSR Nvivo 8.0. Each 
transcript was analyzed by two researchers (AG and JL or AA or JS) using thematic 
analysis.31 Text fragments were identified referring to any outcomes participants 
experienced as a consequence of the counseling or LBC. From these we selected 
fragments referring to non-health outcomes. Non-health outcomes were defined as all 
outcomes not incorporated in EQ-5D based QALYs. Consequently, text fragments 
referring to changes in life expectancy and outcomes covered by the five HRQOL 
dimensions of the EQ-5D instrument (i.e. mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression) were excluded from further analyses.32 From 
the included text fragments non-health outcome themes were identified. Regular 
meetings were held to compare identified themes and reach consensus about coding. 
Based on the final coding a tree structure was developed in Nvivo. The non-health 
outcome themes were indicated as tree nodes and divided into nodes referring to 
themes of non-health outcomes experienced as a consequence of the counseling and 
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themes of non-health outcomes experienced as a consequence of LBC. This distinction 
was made, because the outcomes were not necessarily experienced simultaneously. 
Respondents may have participated in the counseling intervention and experienced 
consequences of the counseling without acting upon it by performing lifestyle changes, 
while other respondents may have performed behavior changes independent of 
participating in the intervention (see Box 4.1 for a more detailed description of the 
impact of the counseling on LBC). All coded text fragments in the transcripts were linked 
to the tree nodes allowing to analyze all interview data simultaneously. These final 
analyses were conducted by the first author and consisted of three steps: (1) identifying 
key non-health outcome themes across all interviews (2) determining relevance of non-
health outcomes of LBC for each of the lifestyle behaviors of interest and (3) selecting 
citations to support key themes. Results of the analyses were presented to the project 
team to check whether they gave a good representation of the data. 
 
Box 4.1 The impact of the counselling on lifestyle behavior change 
Participants in the SIs and FGDs had mixed experiences with and views about the counseling 
intervention. Several respondents clearly indicated that the counseling encouraged them to 
change their lifestyle behaviors. The changes they reported concerned for example smoking 
cessation, using the bike more frequently instead of the car, eating more regularly and having 
breakfast, drinking less alcohol, using healthier fats for cooking and using low fat sandwich 
fillings.  
 
“Well, I stopped smoking because of this [the counseling]. Well, I managed this and now it is 
also a matter of physical activity. It goes alright, but it could be more. I just need to do this 
better.” (Woman, FGD 3) 
 
Such changes in lifestyle behaviors induced by the counseling were reported by 3 of the 13 
respondents in the SIs and were discussed by respondents in all 5 FGDs. Other respondents 
found the counseling useful, but they did not change their lifestyle behaviors.  
 
“I don’t change my life because of it [the counseling]. Well, but it reminds you that you should 
watch out a little bit, that you have to live healthy.” (Woman, SI 3)  
 
And a third group of respondents did not appreciate counseling sessions at all.  
 
“Well, I have my experience. I had a conversation and it was nothing new actually. And then I 
stopped immediately in fact. It was a conversation and it was not worthwhile in my situation.” 
(Man, FGD 3) 
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Results 
In total we identified 12 themes of non-health outcomes, which are not incorporated in 
EQ-5D based QALYs (see Figure 4.2). The identified non-health outcome themes were 
identical across SIs and FGDs and therefore presented together.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Non-health outcomes identified that are not incorporated in EQ-5D-based QALYs 
 Notes: *Outcomes were relevant for: Physical activity (P), diet (D) and smoking 
cessation (S). 
 
Lifestyle behaviour changeCounseling 
Individuals 
Outcomes included in EQ-5D based QALYs
•Life expectancy
•HRQOL dimensions of EQ-5D 
−Mobility
−Self-care
−Usual activities
−Pain/discomfort
−Anxiety/depression
Non-health outcomes
•Awareness
•Motivation for LBC
•Goals for LBC
•Confirmation and 
acknowledgement  
Non-health outcomes
•Body satisfaction (PDS)*
•Stress reduction & relaxation (PS)
•Endurance (P)
•Social interaction (PS)
•Feeling of control (PD)
•Overcoming addiction (S)
•Feeling fresh & clean (S)
•Effort (PDS)
participate in
may have other experiences with
may lead to
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Non‐health outcomes of the counseling  
Four of the identified themes concerned outcomes reported as consequence of the 
counseling. 
Awareness  
One of the most frequently discussed benefits of the counseling was increased 
awareness of health risks respondents are facing and awareness that these can be 
reduced by means of LBC.  
 
“Otherwise it just goes by, because it doesn’t bother you, you are feeling well (…) you 
have to wait until you have health complaints and then you are actually too late, so I 
think for me this is very positive in particular that you are now very aware of what you 
can do.” (Man, FGD 2)  
 
The conversations with the counselor also raised awareness of respondent’s own 
unhealthy behavior patters and pitfalls they encounter while trying to change their 
lifestyle.  
 
“Well, I become more aware of it (…) what I struggle with, every time. Because I want 
to change my lifestyle, but I don’t manage to.” (Woman, FGD 1) 
 
Awareness of their own behavior patterns helped respondents also to see new 
possibilities for LBC. 
 
“Well, what it brings is that you are more actively aware of physical activity, with the 
patterns that you have (…). When I look at myself then that is the gain. Like you can 
simply take the stairs in stead of the lift.” (Man, FGD 3) 
Motivation for LBC 
Many respondents felt that the counseling sessions increased their motivation for LBC. 
Some already had the intention to perform lifestyle changes before participating in the 
counseling, but did not find the motivation to actually do so.  
 
“I did nothing [sport] anymore, and then [when participating in the HPS], I started 
again. I just needed this kick, you know.” (Man, FGD 4). 
  
The counseling sessions provided the opportunity to discuss progress with LBC on a 
regular basis. This motivated respondents to continue with lifestyle changes. Some 
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respondents were only externally motivated, however. They felt the need to justify 
failure to progress with lifestyle changes otherwise.  
 
“When I know that I have to go to such a person to have a conversation, I don’t do it 
(…) I can’t do it, because next week the scales have to go down. If I put a cookie into 
my mouth, it’s not going to work.“ (Woman, FGD 4) 
 
Therefore, when the counseling finished not all participants were able to maintain 
motivation for LBC.  
 
“When this moment of control is not there anymore, yes then it [motivation] is likely to 
abate. I really need a little bit of control.” (Woman, FGD 3)  
 
A possible way to improve the potential of the counseling to increase participants’ 
motivation for LBC was also discussed. Several respondents had the expectation that the 
results of the physical measurements conducted during the HPS (i.e. anthropometric 
measurements, blood pressure and blood tests) would be addressed during the 
counseling. They were disappointed that this was not the case and some pointed out 
that they perceive this as a lost opportunity for monitoring the impact of their lifestyle 
changes. Incorporating regular monitoring of the impact of LBC on physical indicators of 
health risks was suggested as a way to improve the counseling and to increase 
motivation for LBC.  
 
“When I go exercising what does this actually mean for what changes for me? What 
about the blood values, what about the cholesterol? Because I think that this could be 
the gain, the extra gain. (…) it could certainly improve, could be very motivating, 
because you see that your cholesterol goes down or you see that your cholesterol goes 
up. Then you can say what happens to you.” (Man, FGD 3) 
Goals for LBC  
The counseling sessions also helped respondents to set more concrete and realistic goals 
for LBC. Together with the counselor they broke intended lifestyle changes down into 
smaller steps that can be implemented more easily. Respondents described for instance 
that as a first step to LBC they started to rearrange their daily life schedules to create 
rest and time for themselves.  
 
“You simply make a choice now, like, I do this and that. Before that, I wanted 
everything, I wanted everything and I did nothing (…). Now it is simply structure, 
bringing structure into your whole life”. (Woman, FGD 4) 
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Confirmation and acknowledgement 
SIs and FGDs revealed that participants appreciated the positive feedback they received 
during the counseling sessions regarding lifestyle changes they made. It gave them 
confirmation and acknowledgement of their achievements. As answer to the question 
how the counselling has helped her, one respondent said:  
 
“Well, in the sense that you feel supported, not only that, but also that you have actually 
achieved something, that it is acknowledged again. That it is good.” (Woman, SI 11)    
Non‐health outcomes of LBC 
From the identified non-health outcomes of LBC (n=8), two were reported only for LBCs 
in other situations (i.e. ‘feeling fresh and clean’ and ‘overcoming addiction’). All other 
non-health outcomes themes were concordant for both LBCs performed during the 
intervention and LBCs in other situations and therefore described together. Most non-
health outcomes (n=6) were relevant for one or two of the behaviors of interest (see 
Figure 4.2). Only two non-health outcome themes (i.e. ‘body satisfaction’ and ‘effort’) 
were relevant for all three lifestyle behaviors. 
Body satisfaction 
Many respondents experienced a change in their body shape as consequence of LBC. 
Most of them reported that increased physical activity levels and/or changes in dietary 
behavior lead to a slimmer body. This resulted in greater body satisfaction, which 
respondents described as finding themselves more attractive and being less ashamed 
about their body. Several respondents also mentioned to be happy that they are able to 
wear a smaller clothing size, which was associated with the possibility to find prettier 
clothes.  
 
“I am so happy with this [weight loss], that I think for myself I do not want to go back 
to that [82.5 kg]. So, I want to keep these 74 [kilos]. (…) I find my body acceptable 
with 74 kilo’s. And of course it can always be better, it can always be more beautiful, but 
I can do what I want and I feel happy with this.” (Woman, SI 7) 
 
Some respondents reported that they gained body weight due to LBC. They became less 
satisfied with their body. This happened mostly to people who stopped smoking and 
then started eating more unhealthy snacks, but also to a woman who went to a fitness 
centre. She explained that she stopped going, because she was unhappy with extra 
weight she had gained.  
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“I go to looking dapper in your clothes [name of a training program]. That’s what I 
want, too. (…) Then you go there [fitness centre] and you get a whole program of what 
you have to do. I say to this man, this is not going well, the scales are only going up. 
(…) He says you don’t loose weight, but you get muscles (…). I left and never went 
back.” (Woman, FGD 4)   
 
The body satisfaction aspect was not equally important to respondents. Some found 
outer appearance very important, whereas others considered it less important and 
attached more value to health risk reduction.  
“I sometimes look into the mirror and see love handles developing and so forth, that you 
think: but I actually absolutely don’t want this. But then you rather push this aside, too 
easily. For me it was only that I said ok, I apparently have a health risk that I thought 
oh dear.“ (Man, FGD 4)   
Stress reduction and relaxation 
According to several respondents increased physical activity levels contributed to stress 
reduction and relaxation. They described this as being able to clear their mind and 
feeling calmer. Some respondents also explained that through relaxation they gained 
new mental strength to deal with life challenges.  
 
“When you have stress, things, I also notice it when I had a busy day at work. Then I 
enjoy these 25 minutes on the bike. Because I know when I come home it starts with 
‘mum, mum, mum’ and then the other ‘mum, mum, mum’. Listening stereo and 
answering in stereo. Well, then it is pleasant that your mind is clear” (Woman, SI 7)   
 
Relaxation was also identified as a non-health outcome theme in relation to smoking 
cessation. One female respondent reported that smoking has always been a way for her 
to relax and that she experiences less moments of relaxation since she quit smoking.  
 
“Then [when you don’t smoke] you simply continue. And this is a moment, a fag really is 
a little moment for yourself.” (Woman, SI 10)  
Endurance  
Improved endurance was commonly reported as a positive consequence of increased 
physical activity. Respondents explained that regular physical activity made them feel 
stronger, fitter and more energetic. Some respondents described the improvement in 
endurance also as the experience that physical activity became gradually easier and less 
tiresome.  
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“I feel simply less tired, now. Yes, because of the fitness [training]. So, if you have a big 
job in the garden or so, then you are broken after a day of hard work in the garden. But 
now I don’t have this anymore.“ (Man, SI 8)  
Social interaction  
Several respondents described that they enjoyed being physically active, because it 
provided them with an opportunity for social interaction. In this context respondents also 
mentioned the value of feeling part of a team, which they experienced when engaging in 
team sport, such as volleyball.   
 
“When you go exercising, you also go there partly for fun. I mean you get some 
enjoyment out of it. (…) So that you say I get a pleasant evening and social contact and 
such things and that is an enrichment of your life.” (Man, FGD 1) 
 
The benefit of social interaction was also mentioned with respect to smoking cessation. 
Despite the overall benefit derived from cessation, two respondents noted that they had 
fewer or less pleasant interactions with other people since they stopped smoking.  
 
“When you stop smoking you miss all internal communication. All that happens in the 
hospital, all departments, such as his relationship ended and he got married. Smokers 
come really everywhere, I really missed the gossip.” (Woman, FGD 3) 
Feeling of control  
The FGDs and SIs revealed that due to their experiences with LBC respondents learned 
that achievements, such as weight loss or increased endurance are a result of their own 
efforts to change behavior. This gave them a feeling of control over their lifestyle 
choices.  
 
“This [loosing weight] is pleasant, yes. That’s why I also think that I can simply manage 
to get rid of it [weight gained again].You see?” (Woman, SI 4)  
Overcoming addiction  
Respondents who stopped smoking reported that they were happy to have overcome 
tobacco addiction. They described this as not having a constant urge for a cigarette 
anymore, which enabled them to focus better on work or other activities. 
 
“Now, after 8.5 years [of cessation] I can only say yes I simply don’t have this urge 
anymore and everything (…) and I simply hope that I never do it [smoking] again.”   
(Woman, FGD 2) 
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Feeling fresh and clean 
Another benefit of smoking cessation experienced by respondents was that they felt 
fresher and cleaner. A woman who stopped smoking recently mentioned that she liked 
the idea that her lungs will get completely clean again. But generally this theme 
concerned getting rid of tobacco odor in respondents’ clothes, hair, skin and house.  
 
“No, I find it good for now [that I stopped smoking]. It [the odor] stays in your hair and 
in your skin. I just didn’t want it anymore.” (Woman, SI 10) 
Effort  
A negative consequence of LBC many respondents mentioned was the effort associated 
with it. For example respondents found it hard to get up early in the morning and go out 
into the cold in order to exercise. With respect to changing dietary patterns, some 
respondents described that they had to resist the temptation of buying fast food or 
ready-made meals. Others reported that they had to make an effort to prepare separate 
meals for other family members, who were not willing to adapt to the new diet. Denying 
yourself sweet or fat snacks was also a commonly reported topic.  
 
“I hope that I loose another thirteen kilos, but I find it difficult. Yes, because you really 
have to abstain from things.” (Woman, FGD 1)  
 
Respondents who quit smoking also described that they had to make an effort, first to 
overcome withdrawal symptoms and subsequently to handle the risk of relapse.   
 
“It’s so easy for me to start [smoking] again (….). I never have it that I think, yuck the 
first cigarette. Yes, I just instantly like the taste again. So, it will always remain a 
weakness for me.” (Woman, SI 10)  
Differentiating between non‐health and health outcomes 
The research team agreed that the above described non-health outcome themes 
concern distinct aspects of wellbeing not covered by EQ5D-based QALYs. The dividing 
line between the non-health and health outcomes was however not always clear-cut. To 
provide transparency about outcomes excluded from further analysis, some examples of 
text fragments referring to health outcomes are presented in Box 4.2. 
Spillover effects  
As the lifestyle intervention evaluated in the HPS was directed at individuals, this 
research focused on identifying non-health outcomes experienced by individual 
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participants of the intervention. The FGDs and SIs suggested, however, that LBC of 
individual participants also had spillover effects on the broader social and family 
environment. Respondents described for example that becoming more physically active 
encouraged LBC in their partners and colleagues.   
 
“My partner went to this gym together with me and also at work my colleagues see that 
I am pretty active and that stimulates them, too (…) I see everybody walking more and 
using the stairs more.” (Man, FGD 3)  
 
The impact of changing grocery habits and cooking patters on dietary behavior of other 
household members was also frequently discussed.  
 
“(…) and we do the groceries. Then I simply don’t buy it [unhealthy snacks]. Things that 
are not in the house are not going to be eaten.“ (Woman, FGD 2)  
 
 
Box 4.2 Examples of text fragments referring to health outcomes 
Several respondents mentioned increased life expectancy as an expected benefit of LBC.  
 
“I also think now I should not become any bigger, because I would like to see my children grow 
old, and I simply know, heart failure is in our family. My father had one with 50, my 
grandmother with 45 and her brothers and sisters, too, all around the same age. So, I believe: 
yes, I should, hmm well yes, when you have a lot of overweight you have a risk to get 
something like this, a heart attack. “(Woman, FGD 1). 
 
Respondents also indicated that losing weight reduced difficulties they had while being 
physically active. This outcome was coded as pertaining to mobility dimension of the EQ5D.  
 
“It all goes a bit slower (…) a bit more difficult, you know. I still did it, because I am doing 
sports already for years, but I was quite fat of course (…) you see, when I lift one leg now, I lift 
six kilos instead of 10 kilos, you understand? (...) the lighter you become, the easier it gets, of 
course.” (Woman, SI 5) 
 
In many interviews respondents mentioned the physical measurements that were conducted 
during the HPS. They had hoped that the results of these tests were used in the counseling 
sessions. Although this was not the case, respondents still benefitted from the test results, 
because they provided them with information on their personal health risk and reduced anxiety. 
Text fragments referring to anxiety reduction were coded as pertaining to the 
anxiety/depression dimension of the EQ5D. 
  
“Then you know your blood pressure is good, your blood sugar is good, you name it. If it is 
good, then it is a confirmation that it goes fine (…) than you know in any case how you perform 
physically. Personally, that calms me down.” (Man, SI 9) 
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Discussion 
This research explored non-health outcomes produced by HP that are not captured by 
EQ5D-based QALYs. By means of SIs and FGDs we identified in total 12 non-health 
outcome themes from the perspective of participants in a LBC intervention directed at 
changing smoking, physical activity and dietary behaviors. As the existing evidence 
regarding non-health outcomes of HP is very limited, most of the identified themes have 
to our knowledge not previously been described in the health economics literature. Only 
three of the identified themes confirmed earlier research findings. Increased ‘social 
interaction’ was previously reported as a non-health outcome of HP by Borghi and Jan.33 
They found that participants in a community based HP intervention directed at maternal 
and newborn health in Nepal were willing to pay for the opportunity of social interaction 
the intervention provided. A study by Weimer et al.34 provides support for the non-health 
outcome theme ‘overcoming addiction’. Their findings show that current smokers in the 
US were willing to pay for a smoking cessation intervention that eliminates addiction. 
The non-health outcome theme ‘feeling of control’ (in our study: over lifestyle choices) 
previously received attention in the context of social care. A discrete choice experiment 
by Ryan et al.35 showed that older people attach importance to the outcome ‘control 
over daily life’. The concordance between non-health outcomes identified in this study 
and non-health outcomes identified in other research, suggests that the identified non-
health outcomes may also be relevant for both other HP interventions and healthcare 
interventions. Our analyses comparing the relevance of non-health outcome themes of 
LBC for each of the lifestyle behaviors of interest indicate, that the non-health outcomes 
that were experienced differed according to the type of the LBC made by respondents. 
For example the non-health outcome theme ‘overcoming addiction’ and ‘endurance’ were 
only relevant for respondents who changed smoking behavior and physical activity, 
respectively. So, whether a non-health outcome is relevant for a specific HP intervention 
may depend on the intervention focus (e.g. changing smoking behavior vs. encouraging 
safe sexual practices). More research is needed to explore non-health outcomes 
produced by other HP interventions, in other settings and among other populations to 
provide an overview of the range of non-health outcomes relevant for consideration 
within an economic evaluation framework and to categorize outcomes according to their 
relevance for different types of HP interventions.  
The combination of SIs and FGDs was useful in providing different insights into non-
health outcomes experienced by participants. SIs were more likely than FGDs to provide 
information about sensitive topics, such as body satisfaction, while FGDs generated more 
information about similar and contrasting views and experiences. 
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The results of this research suggest that HP can also produce spillover effects to others 
in participants’ social environment. This finding confirms previous research showing that 
HP and other health care interventions have spillover effects to family members.36-38 
Future research should provide more insights into the nature and value of such spillover 
effects. 
Several limitations of this study are worth mentioning. First, our study population was a 
selected sample. Ethical approval to conduct this research was obtained when the HPS 
had already commenced and only provided under the condition that participants, who 
had dropped out of the study, were not approached again. Findings may therefore not 
apply to dropouts. A dropout analysis suggests, however, that there were no significant 
differences in baseline variables (i.e. lifestyle behaviors and risk of type 2 diabetes 
mellitus or cardiovascular disease) between participants who completed the study and 
those who dropped out.28 Second, the distinction between health and non-health 
outcomes made in this study is not decisive. Non-health outcomes were defined as all 
outcomes not captured by EQ5D-based QALYs. The EQ5D is one of the most frequently 
used HRQOL measures32,39 and represents current economic evaluation practice. 
However, health outcomes could also be defined by means of a different generic 
preference-based instrument (e.g. SF-6D, 15D or AQOL), which may result in shifting 
boundaries between non-health and health outcomes. We currently lack clear definitions 
distinguishing between health and non-health outcomes. Such definitions need to be 
developed to guide future research aiming to identify relevant outcomes for use in 
decision-making. Third, this study focused on non-health outcomes representing actual 
consequences for individual participants of a HP intervention. Outcomes derived from 
intervention characteristics (e.g. duration or location) or provider characteristics (e.g. 
attitude, occupation), which are also referred to as non-health (or process) outcomes, 
were not considered. Previous research examining preferences towards such outcomes 
suggests that these are also important to participants of HP interventions.40-42 Fourth, 
we did not address relative importance of the identified non-health outcomes compared 
to each other and to health outcomes captured by EQ5D-based QALYs (i.e. changes in 
life expectancy and outcomes covered by the HRQOL dimensions of the EQ5D 
instrument), which have also been mentioned by respondents. Future research should 
provide insights into relative importance by means of discrete choice modelling or 
ranking exercises to enable attachment of weights to different outcomes that are 
considered in decision-making.35 Non-health outcomes may be accounted for in decision-
making in various ways. They could be incorporated directly within economic evaluation 
studies or considered separately in the appraisal phase of decision-making process. For 
direct incorporation several approaches are possible. New generic preference-based 
measures for constructing QALYs could be developed including HRQOL dimensions 
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relevant for HP or using capabilities.9,10 Contingent valuation may be used for monetary 
valuation of both health and non-health outcomes within cost-benefit analysis. And a 
third alternative is to describe all outcomes in separate units using cost-consequence 
analysis.43 Each of the approaches provides a useful source of information for decision- 
makers and requires further development and testing. 
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Abstract 
Objective 
Health promotion (HP) interventions have outcomes that go beyond health. Such 
broader non-health outcomes are usually neglected in economic evaluation studies. To 
allow for their consideration, insights are needed into the types of non-health outcomes 
that HP interventions produce and their relative importance compared to health 
outcomes. This study explored consumer preferences for health and non-health 
outcomes of HP in the context of lifestyle behavior change. 
 
Methods 
A discrete choice experiment was conducted among participants in a lifestyle 
intervention (n=132) and controls (n=141). Respondents made 16 binary choices 
between situations that can be experienced after lifestyle behavior change. The 
situations were described by 10 attributes: future health state value, start point of future 
health state, life expectancy, clothing size above ideal, days with sufficient relaxation, 
endurance, experienced control over lifestyle choices, lifestyle improvement of partner 
and/or children, monetary cost per month and time cost per week.  
 
Results 
With the exception of time cost per week and start point of future health state, all 
attributes significantly determined consumer choices. Thus, both health and non-health 
outcomes affected consumer choice. Marginal rates of substitution between the price 
attribute and the other attributes revealed that the attributes endurance, days with 
sufficient relaxation and future health state value had the largest impact on consumer 
choices. The life expectancy attribute had a relatively low impact and for increases of 
less than 3 years respondents were not willing to trade. 
 
Conclusion 
Health outcomes and non-health outcomes of lifestyle behavior change were both 
important to consumers in this study. Decision-makers should respond to consumer 
preferences and consider non-health outcomes when deciding about health promotion 
interventions.  
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Introduction 
Health promotion (HP) interventions aim to improve health and wellbeing through a 
process of enabling individuals and communities to increase control over their health.1 A 
large variety of activities take place under the name of HP, including mass-media 
campaigns to increase awareness of the dangers of smoking and drink-driving, school-
based comprehensive health education programs, fluoridation of water, introducing seat-
belt legislation and community development projects to enable disadvantaged mothers 
to strengthen their parenting skills.2 Modern HP interventions are increasingly complex, 
multi-factorial interventions, which take place on various levels (e.g. individual, policy 
and physical environment) and have multiple outcomes.3,4 This complexity poses a 
number of methodological challenges to economic evaluation studies.5-7 One of the key 
challenges is that outcome measures commonly used in economic evaluation studies do 
not capture all outcomes health promotion interventions aim to achieve. Outcome 
measurement in economic evaluation studies focuses on individual health outcomes, 
which are increasingly measured using Quality Adjusted Life Years (QALYs).8,9 QALYs 
measure the improvement in life expectancy obtained through a specific intervention 
adjusted for the health-related quality of life (HRQOL) experienced in that period.10,11 
While improving life expectancy and HRQOL is clearly an important goal of HP, it is not 
the only goal. Empowerment of individuals and communities is also a central objective of 
HP.2 This may involve for instance consciousness raising, increased self-esteem and 
participation in a group to experience mutual support or engage in collective political 
action. Life skills, such as health literacy, problem solving and communication skills, 
stress management and skills to cope with emotions12-14 can also be acquired during the 
empowerment process.12-14 Neglecting changes to such broader non-health outcomes in 
economic evaluation studies leads to incomplete information about the relative value of 
HP interventions and may hamper efficient allocation of public resources to such 
interventions.  
To improve evidence for future decision-making relevant non-health outcomes of HP 
should also be examined. For an adequate consideration of non-health outcomes, insight 
is needed into a) the range and types of broader outcomes relevant to include in 
economic evaluation studies, and b) the relative importance of health and non-health 
outcomes of HP programs.6,15 The latter is crucial to determine the relative weight that 
should be given to the different outcomes in economic evaluation studies. Previous 
research identified several non-health outcomes that are important to participants of HP 
and other stakeholders,15,16 but the available evidence is scarce and relates to HP 
interventions in the field of women’s health only. Studies examining relative consumer 
preferences towards non-health outcomes of HP interventions are also scarce17,18 and 
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have so far focused on non-health outcomes reflecting the design or process of the 
intervention (e.g. travel time, extent of physician involvement, intensity of the 
intervention and group vs. individual focus). Evidence on consumer or societal 
preferences towards non-health outcomes representing actual consequences of HP 
interventions is currently lacking.  
The present study contributes to the evidence by assessing consumer preferences 
towards health outcomes and non-health outcomes experienced as a consequence of a 
lifestyle behavior change intervention. 
Methods 
A discrete choice experiment (DCE) was conducted among participants of the Hoorn 
Prevention Study (HPS). The HPS is a randomized controlled trial evaluating the 
effectiveness of a HP intervention aiming to change lifestyle behaviors (i.e. physical 
activity, smoking and dietary behaviors) in adults with an increased risk for developing 
type 2 diabetes and/or cardiovascular disease.19 DCE surveys are increasingly used in 
health economics to elicit preferences towards health interventions, policies and 
services.20,21 The methods involved in DCEs are well-described in the literature20-23 and 
usually consist of five steps: 1) establishing the attributes and levels to be included in 
the experiment; 2) selecting the experimental design; 3) developing the questionnaire 
and actual choice tasks presented to respondents; 4) data collection; and 5) analysis of 
the discrete choice data. 
Establishing attributes and levels 
DCEs in health care have used as many as 12 attributes.22 In the present study the DCE 
consisted of 10 attributes (Table 5.1). Three attributes represented health outcomes 
measured within the QALY framework (i.e. life expectancy, future health state and 
timing of future health state) and reflect current economic evaluation practice. The life 
expectancy attribute was based on the current average life expectancy in the 
Netherlands at birth.24 It was varied by a maximum of three years, because research 
evidence suggest that a healthier lifestyle can increase life expectancy within this 
range.25 Life expectancy was used as an attribute instead of risk of premature death, 
because research evidence shows that people have difficulties in understanding risk 
information.26 The future health state attribute was based on the EQ-5D instrument, a 
widely applied generic preference based measure of health,27,28 which is used to obtain 
the health-related quality of life (HRQOL) weight for calculating QALYs based on 
5 dimensions of health (i.e. mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression).28 The attribute was defined in terms of four HRQOL weights 
  Consumer preferences for health and non-health outcomes 
 
Ch
ap
te
r 
5 
 
95
representing four of 243 possible EQ-5D health states. First, we selected four HRQOL 
weights that seemed plausible given the sample’s EQ-5D scores at baseline of the HPS. 
Then we identified the corresponding EQ-5D health states using Dutch population Time 
Trade Off value sets.29 These states were presented in the DCE together with the 
HRQOL weights. Given that consumers of health promotion were essentially healthy at 
the time of participation in the intervention, they would not experience an improvement 
in their HRQOL immediately. The benefit of health promotion rather lies in preventing 
deterioration of their future health state. To account for the long time horizon required 
to achieve changes in HRQOL we included a third attribute representing different start 
points of the future health state.  
Due to a lack of literature on non-health outcomes of lifestyle behavior change, non-
health outcome attributes were derived from semi-structured interviews (n=12) and 
focus group discussions (n=5) with HPS intervention group members (n=52). 
Respondents were asked to describe any consequences they experienced from lifestyle 
behavior changes they made as a result of participating in the HP intervention. Reported 
consequences included both health outcomes (captured by EQ-5D based QALYs) and 
broader non-health outcomes. From the reported non-health outcomes, four attributes 
were selected for inclusion in the experiment based on their relevance for the total 
sample. The four non-health outcome attributes included body satisfaction, relaxation, 
endurance and experienced control over lifestyle choices. In the interviews a higher 
body satisfaction was frequently associated with the ability to wear a smaller clothing 
size. As clothing size can be quantified more easily than body satisfaction, we used 
clothing size as a proxy attribute for body satisfaction. To allow for the subjective 
dimension of body satisfaction, clothing size was further specified according to the 
degree of deviation from the respondent’s ideal size from the respondent’s perspective. 
The degree of relaxation was quantified as varying number of days per week during 
which people experience sufficient relaxation. We did not find useful existing measures 
to express the attributes endurance and experienced control over lifestyle choices in 
quantitative terms. Therefore, qualitative levels were used to describe these attributes 
ranging from poor to very good for endurance and from little to much for experienced 
control over lifestyle choices.  
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Given that many participants in the interviews and focus group discussions described 
spillover effects of their own lifestyle changes to lifestyle behaviors of their partners and 
children, we also included an attribute representing these spillover effects. Finally, two 
attributes were included to reflect the monetary and time costs associated with lifestyle 
behavior change. The monetary cost attribute was based on willingness to pay for 
effective lifestyle change interventions reported during interviews and focus group 
discussions, as well as market prices for gym subscriptions. The time cost attribute had 
levels ranging from 0-6 hours per week, which we considered as a realistic maximum 
time investment. For each attribute, except for lifestyle improvement of partner/children, 
we defined four levels to create sufficient variation in the attribute levels to produce 
meaningful choices.21  
Experimental design  
Using a full factorial design, containing all possible combinations (49 x 21) of attribute 
levels for the selected attributes was not feasible. Hence, a fractional factorial design 
was created following design principles of Street and Burgess (2007).30 An orthogonal 
main effects starting design was selected from a design catalogue.31 The starting design 
had level balance and consisted of 32 rows and nine attributes, of which eight had four 
levels and one had eight levels. The eight-level attribute was collapsed into a two level 
attribute. An additional four-level attribute was created by adding a new column to the 
design. The design was then repeated three times, so that each of the four levels of the 
new attribute occurred together with all attribute level combinations of the starting 
design. This resulted in a design with 128 rows. Expanding the design in this way 
allowed us to estimate two-factor interactions between the new attribute (here: future 
health state value) and all other attributes.  
 
Based on this design choice sets with two options were generated using design software 
developed by Burgess (2007).32 Generators were used to create the second option by 
shifting the attribute levels of the starting design a specified number of levels.30 One set 
of shift generators was required to estimate main effects and a second to estimate the 
2-factor interactions of interest. This resulted in a final design with 256 choice sets. The 
D-efficiency of the constructed 256 choice sets for estimating main effects was 87.9%. 
The D-efficiency of the design for estimating main effects plus specified two – factor 
interactions could not be calculated. All main and interaction effects, however, were 
orthogonal (i.e. the levels of each attribute varied independently of each other and of 
their 2-way interactions) and could be estimated.30 The design was blocked into 
16 versions to achieve a number of choice tasks (n=16) respondents can handle without 
problems.33-35  
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Questionnaire and choice tasks 
To increase flexibility in the presentation of the choice tasks an online questionnaire was 
used.36 This allowed for instance the use of hyperlinks, which could be used by 
respondents to look up EQ-5D health state descriptions (i.e. definitions of the levels of 
the attribute future health state value) throughout the experiment. Online administration 
of the survey also facilitated the use of a flexible random allocation procedure to ensure 
equal representation of the 16 versions among respondents. The questionnaire 
commenced with a number of background questions. Then the choice task was 
introduced. Each respondent was asked to make 16 forced choices involving two 
unlabeled alternatives (see Table 5.2). A generic context was used to be concordant with 
the generic approach to outcome evaluation in EQ-5D based QALYs. The alternatives 
were presented as potential situations that may be experienced after lifestyle change 
and characterized by different consequences (i.e. the attributes and levels). Respondents 
were asked to imagine themselves in these situations and to choose the situation they 
preferred most.  
A forced choice approach was used in this exploratory study to encourage respondents 
to make trade-offs between the attributes of interest and ensure that they cannot 
choose the opt-out option to avoid making difficult choices.37 This approach was also in 
line with our objective to study preferences for outcomes experienced given that lifestyle 
behavior changes have taken place. Respondents were instructed to assume that they 
have to spend the money and time continuously for the rest of their lives and that they 
could not spend this time and money for other purposes anymore. It was emphasized 
that all consequences of lifestyle change would be experienced immediately, except for 
future health state, which would be experienced only after some years indicated by the 
attribute start point of future health state. To neutralize the potential impact of attribute 
ordering on the relative importance of attributes, which has been suggested by previous 
research,38 the ordering of health and non-health attributes was varied across the 
different versions of the experiment. The monetary and time cost attributes were always 
presented last, because this is regarded the most realistic place for a cost attribute in 
DCEs.38  
After completion of the choice tasks respondents were asked how difficult they perceived 
the choice task on a 5-point scale ranging from very easy to very difficult. Respondents 
were also asked to indicate any other consequences of lifestyle change not being 
included in the choice task, which they considered while making the choices. The final 
questionnaire, which is available upon request from the authors, was piloted (n=7) to 
assess understandability and possible ambiguity in interpretations. This led to minor 
adaptations of survey layout, and wording of questions and instructions. 
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Table 5.2 Example choice task 
 Situation A Situation B 
Future health state: start point and value in 2 years → 0.8 in 5 years → 0.7 
Life expectancy  I become 81 years I become 80 years 
Clothing size  ½ size above my ideal 1 size above my ideal 
Sufficient relaxation 2-3 days per week 0-1 days per week 
Endurance good modest 
Experienced control over lifestyle choices some little 
Lifestyle improvement potential 
partner/children no yes 
I spend on lifestyle change:    
 Time  6 hours per week 4 hours per week 
 Money €50 per month €25 per month 
Which situation do you prefer?  □ □ 
 
Data collection and participants  
Respondents were recruited from participants of the HPS. The HPS started in February 
2008 and included men and women aged between 30 and 50 years living in the semi-
rural region of West-Friesland in the Netherlands. Study participants had an increased 
risk for type 2 diabetes and/or cardiovascular disease. They were selected by means of a 
two-step screening procedure, which is described in more detail elsewhere.19 
Participants included in the study were randomly assigned to an intervention and control 
group. The intervention group received a theory-based cognitive behavioral program 
delivered by trained practice nurses applying counseling techniques of motivational 
interviewing and problem solving treatment. The control group received written 
information about their risk of developing type 2 diabetes and cardiovascular disease, 
and existing brochures containing guideline recommendations for a healthy diet and 
physical activity as well as advice on smoking cessation.19  
 
Invitations for participation in the present study were mailed to all participants still 
included in the HPS cohort in June 2010 (n=515). In this sample, intervention (49.3%) 
and control group were equally distributed (50.7%). Participants with known e-mail 
addresses (n=499) also received an invitation by e-mail including a direct link to the 
survey. Participants who did not complete the survey nor indicated that they did not 
wish to participate received a reminder after one week and in case of non-response a 
second reminder after two weeks. Ethical approval for this research was granted by the 
VU University Medical Centre Research Ethics Committee.  
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Data analyses  
The discrete choice data were analyzed using Nlogit Version 4. The effect of changes in 
attribute levels on consumer preferences was initially estimated by means of a 
multinomial logit (MNL) model. Using this model we tested for hypothesized interactions 
between attributes (see Table 5.1) and interactions between attributes and intervention 
experience, socio-demographics and attribute ordering. To account for the panel nature 
of the data and allow for possible preference heterogeneity across respondents a 
random parameter logit (RPL) model was estimated.22 First, the RPL model was 
estimated with the constant term as only random parameter. This is a common way of 
capturing heterogeneity in repeated measures or panel data39 and provides a test for 
left-to-right bias (i.e. the tendency to consistently choose either the first or second 
alternative in the choice task). Since respondents differed regarding their free time and 
available income, it is likely that their preferences for investing time and money for 
lifestyle change differ as well. So, an RPL model including additional random parameters 
for the attributes time and money was also estimated. Finally, we estimated an RPL 
model including additional random parameters for the attribute clothing size above ideal, 
because respondents disagreed most on the importance of this attribute during 
qualitative interviews and focus groups.  
For all three models the estimation was conducted using 2000 Halton draws. The 
random parameter of the constant was drawn from a normal distribution. All other 
random parameters were drawn from a constrained triangular distribution. Following 
recommendations in the literature effects coding was applied for categorical 
attributes.23,40,41 Linear coding was used for the attributes time per week [(0 hours=0), 
(2 hours=2), (4 hours=4), (6 hours=6)] and money per month spend on lifestyle change 
[(€0=0), (€25=0.25), (€50=0.5), (€100=1)]. To investigate the relative impact of each 
attribute on the utility respondents derived from the alternatives, we calculated 
willingness to pay (WTP) estimates based on marginal rates of substitution (MRS) 
between the cost attribute and all other attributes.42 Confidence intervals for WTP values 
were derived using the Delta method.43 
Results 
In total 273 respondents (53%) completed the DCE survey. The majority had performed 
all 16 choice tasks (n=264). Nine respondents did not fully complete the choice tasks, 
leading to 42 missing observations. The 16 different versions of the survey were spread 
fairly evenly across respondents. Most versions (n=14) were completed by 13 to 20 
respondents and two versions were completed by 23 and 24 respondents, respectively. 
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A summary of respondent background characteristics is presented in Table 5.3. As can 
be seen from this table, responders were similar to non-responders.  
 
Table 5.3 Background characteristics of responders and non-responders 
N (valid %) 
Characteristic Responders (n=273) Non-responders (n= 242) 
Intervention experience   
 yes  132 (48.4)  122 (50.4) 
Gender    
 female  163 (59.7)  132 (55.0) 
Age    
 30-39  33 (12.1)  33 (13.6) 
 40-49  140 (51.3)  145 (60.0) 
 50-59  100 (36.6)  64 (26.4) 
Household income (net/month)   
 low (€1100)  13 (4.8)  - 
 middle (€3500)  79 (28.9)  - 
 high (3500)  135 (49.5)  - 
 do not want to tell  46 (16.8)  - 
Work situation   
 having paid work  233 (85.4)  211 (88.3) 
Living circumstances    
 Living alone   17 (6.2)  14 (5.9) 
 Living with partner   36 (13.2)  24 (10.1) 
 Living with child(ren)  13 (4.8)  12 (5.0) 
 Living with partner and child(ren)  207 (75.8)  188 (79.0) 
EQ5D health state utility (mean; SD)  0.89 (0.137)  0.92 (0.132) 
Notes: Background characteristics of non-responders were derived from questionnaire data 
collected at baseline of the HPS. Several items of the HPS questionnaire differed from items used in 
the present study. Hence, income data were not comparable.  
 
Table 5.4 provides a comparison of model fit across the alternative models that were 
estimated. The Likelihood ratio (LR) test shows that the MNL model including 
parameters for the attributes has significantly more explanatory power than the constant 
only model. This indicates that the attributes contribute to the capability of the model to 
predict choices of respondents. The RPL model with the constant term as only random 
parameter in turn performed significantly better than the MNL model, demonstrating the 
presence of preference heterogeneity. Even when adjusting for the loss of degrees of 
freedom that occurs when a model is expanded, the RPL model performed best. This 
appears from reductions in the Akaike information criterion (AIC) and Bayesian 
information criterion (BIC)44 (see Table 5.4).  
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Specifying additional random parameters did not significantly improve the model fit. 
Hence, the RPL model with the constant term as only random parameter was used to 
estimate the effect of the attributes on consumer choices. We only present results of the 
main effects RPL model here, as most of the tested interaction terms were non-
significant and including significant interactions did not improve the model.  
 
Table 5.4 Goodness-of-fit statistics for alternative models 
Summary statistics PseudoR2  Log-likelihood χ2 LL ratio-test (df) AIC BIC 
RPL clothing size above ideal 0.169 -2490.799 1.24 (3) 1.16 1.20 
RPL time and money 0.170 -2489.131 5.16 (2) 1.16 1.20 
RPL constant  0.169 -2491.71 74.14 (1)* 1.16 1.20 
MNL 0.157 -2528.78 939,49 (24)* 1.18 1.22 
Constant only - -2998.53 - 1.39 1.39 
Notes: The constant only MNL model was used as null model for Pseudo R2; χ 2 LL ratio-test 
statistic is presented for comparisons with the next less sophisticated model; *exceeds critical value 
for =0.05. 
 
 
The health outcome attributes future health state and life expectancy significantly 
determined consumer choices in the expected direction (Table 5.5). Furthermore, all 
non-health outcomes attributes (i.e. clothing size above ideal, days with sufficient 
relaxation, endurance and experienced control over lifestyle choices), spillover effects to 
partner/children as well as the monetary cost attribute had a significant impact on 
consumer choices. Two attributes were found to be non-significant. These were start 
point of the future health state and time per week required for lifestyle behavior change. 
Estimates of willingness to pay (WTP) for changes in attribute levels obtained from MRS 
are displayed in Table 5.5. They show that the endurance attribute had the largest 
impact on utility respondents derived from alternative post lifestyle change situations. 
For an improvement from ‘poor’ to ‘very good’ endurance respondents were willing to 
trade €298.94 per month and for an improvement from poor to modest endurance 
respondents were willing to trade €159.75 per month. The attribute days with sufficient 
relaxation had the second largest impact on utility, with respondents being willing to 
trade €117.98 per month for an increase from 0-1 to 6-7 days with sufficient relaxation 
per week. The attribute future health state value is on third place with respondents 
being willing to trade €110.85 per month for an improvement of the future health state 
value from 0.5 to 1.0. WTP for changes in life expectancy was relatively low. 
Respondents were willing to pay €31.98 per month for an increase in life expectancy 
from 80 to 83 years. For smaller increases in life expectancy respondents were not 
willing to trade.  
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Validity of the findings 
The majority of respondents (97%) filled in the DCE survey completely. However many 
respondents perceived the choice tasks as difficult or very difficult (59.1%), which raises 
the question whether respondents gave valid answers. Theoretical validity was tested by 
examining signs and significance levels of parameter estimates. With the exception of 
the attribute start point of future health state and time per week all attributes 
significantly determined choices (see Table 5.5). Generally, attributes in the estimated 
utility function behaved in line with a priori expectations (see hypothesized direction of 
preferences in Table 5.1). There was only one exception. We found that a reduction in 
clothing size to zero sizes above ideal was somewhat less preferred than a reduction to 
half a size above ideal.  
Interactions between respondents’ income and the two cost attributes also provided 
support for the validity of our findings. As could be expected, a higher income was 
associated with a less negative preference for an increase in money respondents had to 
spend per month on lifestyle behavior change (β=0.423, t=3.173). As the time cost 
attribute itself, the interaction between income and time spent on lifestyle change per 
week was non-significant (β=0.003, t=0.140). Tested interactions between trial arm and 
attributes (data not shown) did not provide clear evidence for differences in preferences 
between members of the intervention and control group of the HPS. Tested interactions 
between the ordering variable and the attributes (data not shown) indicated that 
attribute ordering did not systematically affect the relative importance of the attributes.  
The constant term was not significant, which suggests that, on average, respondents 
considered the attributes described in the choice task and did not simply choose the 
same alternative repeatedly. In concordance with this finding, qualitative data from open 
questions suggest that only three respondents did not trade between all attributes. One 
of them did not trade in order to simplify the choice task, but the other two respondents 
behaved rationally. They only considered attributes they found personally relevant. So, 
their choices reflect actual preferences. Qualitative data also suggest that only few 
respondents considered additional attributes not included in the experiment. These were 
personal attainability on the long term (n=1), the possibility to have a comfortable way 
of life without the need to consider all sorts of things (n=1), current health state (n=2) 
and more specific outcomes for respondents‘ partner and/or children (n=3). In line with 
recommendations in the literature we did not remove respondents from the analyses 
based on their decision strategies.45 
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Table 5.5 Results from the main effects RPL model 
WTP (in € per month) Attribute  Coefficient 
 
SE 
 Mean CI 
Random parameters:     
Constant 
SD 
 0.000 
 0.578 † 
0.050 
0.055 
- - 
Non-random parameters:    
Future health state value    
 0.5 (referent) - - - - 
 0.7  -0.042 0.056  45.54 * 9.96 – 81.12 
 0.8  0.029 0.056  59.82 † 17.98 – 101.65 
 1.0  0.283 † 0.056  110.85 † 67.98 – 153.71 
Start point of future health state    
 in 2 years (referent) - - - - 
 in 5 years  0.008 0.040  16.77   -8.39 – 41.94 
 in 10 years  0.064 0.040  27.92    -1.15 – 56.98 
 in 20 years  0.003 0.041  15.63   -10.54 – 41.80 
Life expectancy    
 80 years (referent) - - - - 
 81 years  0.006 0.043  13.85 -11.82 – 39.52 
 82 years  -0.039 0.040  4.86 -23.09 – 32.81 
 83 years  0.096 * 0.041  31.98 *    6.28 – 57.68 
Clothing size above ideal     
 2 sizes (referent) - - - - 
 1 size  0.017 0.042  56.67 † 29.20 – 84.13 
 ½ size  0.130 † 0.041  79.29 †   44.04 – 114.53 
 0 sizes  0.118 † 0.039  77.01 †   46.05 – 107.97 
 Days with sufficient relaxation      
 0-1 per week (referent) - - - - 
 2-3 per week  -0.059 0.040  53.68 † 26.63 – 80.73 
 4-5 per week  0.125 † 0.041  90.61 †   55.11 – 126.11 
 6-7 per week   0.261 † 0.041  117.98 †   82.05 – 153.91 
Endurance       
 poor (referent) - - - - 
 modest  -0.130 † 0.040  159.75 † 114.04 – 205.46 
 good   0.491 † 0.039  284.26 † 211.12 – 357.39 
 very good  0.564 † 0.041  298.94 † 223.55 – 374.32 
Experienced control over  
lifestyle choices 
    
 little (referent) - - - - 
 some  -0.021 0.039  22.86 -1.91 – 47.63 
 moderate  0.009 0.044  28.88 -3.02 – 60.78 
 much  0.146 † 0.041  56.22 † 28.07 – 84.37 
Lifestyle improvement of potential 
partner/children 
     
 no (referent)  - -  - 
 yes  0.181 † 0.018  72.75 †   50.48 – 95.03 
Time per week  0.004 0.010  0.85 -3.22 – 4.91 
Money per month  -0.498 † 0.063 - - 
*p<0.05, †p<0.01 
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Discussion 
The present DCE study provides evidence that, in the context of lifestyle behavior 
change, consumers of health promotion are concerned with a broader number of 
benefits than health benefits only. In addition to the health outcome attributes life 
expectancy and future health state value, the following non-health outcome attributes 
significantly influenced consumer choices: clothing size above ideal, the number of days 
with sufficient relaxation, endurance and the degree of experienced control over lifestyle 
choices. Lifestyle changes that occur in consumer’s partners and/or children were also 
found to significantly influence consumer choices. This is concordant with earlier 
research by Basu & Melzer (2005),46 suggesting that spillover effects to family members 
affect patient preferences. Additional qualitative data provided by respondents in the 
present study suggest that consumers value spillover effects because they provide both 
health and non-health effects to their loved ones. But more targeted research is needed 
to unravel why individual consumers value spillover effects. 
Overall, we found that health and non-health improvements in health promotion 
outcomes both influenced consumer choices. Marginal rates of substitution between the 
price attribute and other attributes revealed that consumers’ WTP for non-health 
outcomes and spillover effects was in a similar range as WTP for health outcomes. This 
finding suggests that consumers attach value to outcomes that are not captured by 
economic evaluation studies using EQ-5D based QALYs as outcome measure. It also has 
important implications for HP practice. Since consumers attach value to non-health 
outcomes, emphasizing non-health benefits in HP interventions may increase uptake and 
motivation for behavior change. 
Respondents were willing to pay most for improvements in endurance, second most for 
an increase in days with sufficient relaxation and third most for improvements in future 
health state value. Willingness to pay for life expectancy was relatively low and for 
increases smaller than three years respondents were not willing to trade. This finding 
confirms results of a recent Norwegian study, showing that people attach little value to 
small gains in life expectancy.47  
This study also investigated the impact of costs induced by lifestyle behavior change. As 
expected, respondents had a lower preference for situations with higher monetary costs 
than for situations with lower monetary costs. It was striking however, that time 
investment for lifestyle change did not influence consumer choices, since consumers 
reported time investment as an important negative consequence of and barrier to 
lifestyle behavior change during interviews conducted prior to the choice experiment. It 
is possible that although time investment was not relevant on average, latent classes of 
respondents can be distinguished: one consisting of respondents who are willing to 
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invest time for lifestyle change and second one consisting of respondents who are 
averse to do so.  
A number of limitations of this study are worth mentioning. First, we defined health 
outcomes as pertaining to life expectancy and EQ-5D health state dimensions. While this 
definition represents current economic evaluation practice, health outcomes could also 
be defined in a broader fashion. Additionally, we can’t preclude the possibility that there 
is a relation or overlap between the non-health outcomes examined and EQ-5D 
dimensions (e.g. between endurance and the mobility dimension of the EQ-5D). More 
research is required to disentangle relationships between the different outcomes 
produced by HP interventions and to clarify definitions of health, non-health and process 
outcomes.  
Second, the study sample consisted of participants in a lifestyle intervention trial aged 
between 30 and 50 years. Therefore, the study results may not be generalized to regular 
consumers of HP, other HP interventions or other age groups. 
Third, due to the generic context used in the study, preferences towards outcomes of 
lifestyle behavior change were assessed without considering the process by which 
outcomes are produced. Respondents may value outcomes differently depending on 
whether these are produced by for instance physical activity or dietary changes. 
Fourth, by not including an opt-out option in the choice task, we implicitly assumed that 
respondents would always choose to make lifestyle changes. This may not be realistic 
and limits the possibility to use our findings to predict adoption of lifestyle changes and 
participation in HP interventions.22,37  
Fifth, although attributes in the estimated discrete choice model significantly contribute 
to the prediction of consumer choices, the explanatory power of the model was only 
moderate with a Pseudo R2 of 0.17. According to Hensher et al. (2005)23 a decent R2 
would be around 0.3. The moderate explanatory power may be due to the fact that we 
failed to include some key attributes having an impact on consumer choices. It is natural 
that a DCE cannot cover every attribute that is important to every respondent, because 
it generates a model of preferences over a group.45 Additional qualitative data suggest, 
however, that only few respondents considered omitted attributes. The low model fit 
may also be caused in part by scale heterogeneity in the data set (i.e. choice behavior of 
some respondents is more random than that of others).48 In situations, where scale 
heterogeneity is important the RPL model is likely to provide suboptimal approximation 
of discrete choice data. Hence, alternatives have been proposed describing 
heterogeneity either as pure scale effect or using a Generalized MNL model, which can 
accommodate both scale and residual taste heterogeneity.48 The application of such 
models should be tested in future research, as it may yield a more accurate 
representation of the data and a better model fit. Recent research suggests, however, 
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that failure to account for taste heterogeneity has greater consequences for behavioral 
outputs, such as willingness to pay, than failure to account for scale heterogeneity.49  
Finally, we used qualitative levels for two non-health attributes that were difficult to 
quantify (i.e. endurance and experienced control). If not well defined, qualitative levels 
may be interpreted differently by respondents.21 Overall qualitative attributes behaved in 
line with a priori expectations in this study. Further testing is needed, however, to 
optimize description of non-health attributes in the future. Quantifying non-health 
outcomes is a challenging task, which has so far received little attention and needs 
further exploration.15  
Discrete Choice Experiments only provide stated preference data. Therefore it would be 
helpful for cross-validation to collect additional revealed preference data on actual 
lifestyle choices of consumers. Such research is challenging and rare in the health 
sector, but out-of-pocket payments for lifestyle changes make it possible.50 
Conclusion 
The present study used a discrete choice experiment to explore consumer preferences 
for different outcomes of lifestyle behavior change. The findings show that previously 
identified non-health outcomes and spillover effects of lifestyle behavior change were as 
important to participants of a HP intervention trial as health outcomes. This has 
potentially important implications for decision makers, who should respond to consumer 
preferences and consider relevant non-health outcomes and spillover effects when 
deciding about health promotion interventions. Non-health outcomes and spillover 
effects could either be incorporated directly within economic evaluations or considered 
as separate source of evidence during the appraisal phase of the decision-making 
process. Future research needs to provide insights into relevant non-health outcomes 
and spillover effects in other application areas of HP and test methods to account for 
them in decision-making. 
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Abstract 
Objective 
To use contingent valuation (CV) to derive individual consumer values for both health 
and broader benefits of a public health intervention directed at lifestyle behavior change 
(LBC), and to examine feasibility and validity of the method. 
 
Methods 
Participants of a lifestyle intervention trial (n=515) were invited to complete an online 
CV survey. Respondents (n=312) expressed willingness to invest money and time for 
changes in life expectancy, health-related quality of life (HRQOL) and broader quality of 
life aspects. Internal validity was tested for by exploring associations between 
explanatory variables (i.e. income, paid work, experience and risk factors for 
cardiovascular diseases) and willingness to invest, and by examining respondents’ 
sensitivity to ordering and scope of the benefits presented. 
 
Results 
The majority of respondents (94.3%) attached value to benefits of LBC and 87.4% were 
willing to invest both money and time. Respondents were willing to invest more for 
improvements in HRQOL (€42/month; 3 hours/week) and broader quality of life aspects 
(€40/month; 2.6 hours/week) than for improvements in life expectancy (€24/month; 2 
hours/week). Protest answers were limited (3%) and findings regarding internal validity 
were mixed. 
 
Conclusion 
The importance of broader quality of life outcomes to consumers suggests that these 
outcomes are relevant to consider in decision-making. Our research showed that CV is a 
feasible method to value both health and broader outcomes of LBC, but generalizability 
to other areas of public health still needs to be examined. Mixed evidence regarding 
internal validity pleads for caution to use CV as only base for decision-making. 
Consumer willingness to invest money and time for benefits of lifestyle behavior change 
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Introduction 
Economic evaluation studies provide insights into the relative costs and benefits of 
alternative intervention options and can be a useful tool for policy makers.1 They are 
increasingly used to support decisions about funding of clinical health interventions, 
including pharmaceuticals, medical devices and diagnostic or surgical procedures.2,3 For 
decision-making on public health, economic evaluations are hardly used yet, because 
procedures for decision-making in the field of public health are less well established(4) 
and because the available economic evaluation evidence is limited, especially for public 
health interventions addressing wider social or economic determinants of health.3,5 The 
lack of economic evaluation studies can be attributed to both limited funding available to 
conduct these studies3 and the fact that evaluation methods are insufficiently developed 
to deal with the challenges posed by complex modern public health interventions.2,6-9  
The wide range of benefits produced by public health interventions is one of the key 
challenges. Modern public health interventions do not only aim to improve health, but 
seek to impact also on broader aspects of quality of life and wellbeing. They aim for 
instance to empower people and increase their capacity to live a full and productive life 
by improving health literacy, self-awareness, stress management, problem solving skills 
and access to education.10-12 To achieve these broad objectives public health 
interventions address multiple factors on different operational levels.10,13,14 At the 
individual level educational interventions may be implemented to promote healthy 
lifestyle choices and enhance people’s life skills. At the community level interventions 
may be directed at developing systems to strengthen public participation in health 
matters12 and societal level interventions may address social, economic and 
environmental determinants of wellbeing by means of fiscal measures (e.g. alcohol tax), 
legislation (e.g. smoke free work place legislation) or organizational changes (e.g. 
changing food offerings in schools).14-16 The wide range of interventions also results in a 
wide range of benefits both inside and outside the domain of health for the individual, 
the community and society as a whole.17 Outcome measurement in economic evaluation 
however, tends to capture only individual benefits and focuses on health only.  
Cost-effectiveness analyses, which have been most frequently used to evaluate public 
health interventions3, measure outcomes in a single unit of effect relevant for the 
interventions under evaluation, such as infections averted or life years saved. 
Intermediate outcomes (e.g. behavior change or cholesterol reduction) are also often 
used, which may or may not be translated to health outcomes using modeling. This 
approach is limited by the fact that it is not based on public or consumer preferences 
and allows only for comparison of interventions with the same type of (health) 
outcome.18 Therefore, cost-utility analyses are increasingly used, which measure 
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intervention outcomes in Quality Adjusted Life Years (QALYs). QALYs incorporate 
changes in life expectancy and health-related quality of life in a single generic 
preference-based measure, allowing for comparisons across different health 
interventions.18 They are a useful measure when the objective is to maximize health, but 
they do not capture broader benefits for individual consumers or benefits that accrue to 
the wider social environment.2,6,19 
Cost-benefit analysis (CBA) using Contingent Valuation (CV) to value outcomes in 
monetary terms, has been presented in the literature as a potential solution to capture 
intended broader benefits of public health.2,20,21 The CV method is a survey-based 
technique eliciting willingness to pay (WTP) for non-market goods. It is rooted in welfare 
economic theory and has two major advantages: (a) it does not pose restrictions on the 
number and types of outcomes to be valued and (b) it provides a monetary value for 
intervention benefits, which allows for comparison with other societal sectors also using 
CBA frameworks to evaluate for example road safety measures or interventions to 
improve air quality.22-24  
Despite these advantages, CV is not used much to support healthcare decision-making, 
due to uncertainty regarding the feasibility and ability of the method to derive valid WTP 
values.23,25,26 Respondents may have (ethical) objections against expressing monetary 
values for outcomes of health interventions and either refuse to complete the survey or 
give strategic answers, which do not reflect their true WTP (e.g. protest zeros).23 
Another issue of concern is that respondents may not have clear and ready-made 
preferences for non-marketed goods. Hence, elicited WTP values are suggested to be 
both inconsistent and invalid.27,28 
The aim of this study was to apply the CV method to derive individual consumer values 
for both health and broader outcomes of a public health intervention directed at 
improving lifestyle behaviors, and to examine the feasibility and validity of the method. 
Methods 
A contingent valuation (CV) survey was conducted among participants of the Hoorn 
Prevention Study (HPS), a randomized controlled trial evaluating the effectiveness of a 
public health intervention aiming to change physical activity, smoking and dietary 
behaviors in adults with an increased risk for developing type 2 diabetes (T2D) and/or 
cardiovascular disease (CVD).29 Study participants were recruited from the semi-rural 
region of West-Friesland in the Netherlands and selected by means of a two-step 
screening procedure, which is described in more detail elsewhere.29 In February 2008 
participants were randomly allocated to an intervention (n=314) or a control group 
(n=308). The intervention group received a theory-based cognitive behavioral program 
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delivered by trained practice nurses using counseling techniques of motivational 
interviewing and problem solving treatment. The control group received written 
information about their risk of developing T2D and CVD, and existing brochures 
containing guideline recommendations for a healthy diet and physical activity, as well as 
advice on smoking cessation. 
Participants still included in the HPS cohort (n=515) in June 2010, were invited to 
complete the contingent valuation survey. Invitations were sent by mail and if e-mail 
addresses were available (n=499) also by e-mail, including a direct link to the online-
survey. Non-responders received up to six reminders during the 6-week period after 
invitations were received. The VU University Medical Centre Research Ethics Committee 
granted approval for this research (Protocol no: 2007/107).  
The survey instrument 
An online survey format was used, because evidence suggests that survey-based CV 
studies have higher participation rates than personal interviews and are less likely to 
produce socially desirable answers than telephone interviews.30 The survey commenced 
with general background questions and an introduction about potential benefits of 
lifestyle behavior change (LBC). Benefits of LBC presented in the survey were based on 
literature and qualitative research among intervention group members of the Hoorn 
prevention study.19 They included benefits captured within the QALY framework (i.e. life 
expectancy and HRQOL) and broader quality of life aspects (i.e. changes in clothing size, 
relaxation, endurance and experienced control over lifestyle choices). HRQOL was 
defined according to the EQ-5D instrument, which is commonly used in economic 
evaluation studies, and includes the following five HRQOL dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/depression. 
After the introduction, respondents were presented with the CV exercise. As LBC may 
require both monetary (e.g. subscription in a gym) and time investments (e.g. hours 
spend on exercise), the CV exercise was designed to derive both maximum willingness 
to pay (WTP) and maximum willingness to invest time (WTIT) to achieve any or all of 
three types of potential benefits of LBC: life expectancy, HRQOL and broader quality of 
life. 
Each respondent was presented with two scenarios (see Appendix 6.1). Scenario A 
elicited WTP and WTIT for one of the three types of benefits of LBC and Scenario B 
elicited WTP and WTIT for all benefits of LBC together. For Scenario A a split sample 
design was used, dividing respondents at random into the following three groups: 
Respondents valuing life expectancy benefits (Group 1), respondents valuing EQ-5D 
based HRQOL benefits (Group 2) and respondents valuing broader quality of life benefits 
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(Group 3). To neutralize potential ordering effects, the order in which respondents 
received scenario A and B was also randomized.  
WTP values were elicited by means of a payment scale, because this approach is 
regarded most appropriate for the health care context.23,31-33 Respondents were first 
asked to choose the maximum amount they would pay per month on LBC to achieve the 
presented benefits on a scale ranging from €0 to >€250. Between these boundaries, 
there were ten range categories, each increasing with €25. Respondents selecting one of 
the range categories were subsequently asked to indicate a more accurate maximum 
WTP. For example, if they had selected €1-25, they were asked to select the WTP 
amount closest to the amount they would maximally pay from the following options: 
€1-5, €6-10, €11-15, €16-20 and €21-25. Payment scale values were based on market 
prices for gym subscriptions and WTP values for effective lifestyle interventions 
expressed by HPS participants during the previously mentioned qualitative research.19  
Immediately after answering WTP questions, respondents were presented with a scale 
to elicit the maximum amount of time they would spend on LBC per week to achieve the 
same benefits. The scale ranged from 0 to >10 hours per week. Between these 
boundaries, there were ten range categories, each increasing with one hour. These 
categories were based on assumptions of the research team regarding a realistic 
maximum time investment.  
Respondents expressing zero WTP and/or WTIT amounts were asked to indicate reasons 
using eight answer categories: (1) My household income does not allow me to pay 
more; (2) I already spend enough on lifestyle behavior change; (3) I find it more 
important to enjoy my life now than to have a good health in the future; (4) I would not 
succeed in achieving the described consequences anyway; (5) I find that the 
government should pay for this; (6) I find that my health insurance should pay for this; 
(7) I find that my employer should pay for this; (8) Other reason, please indicate. The 
survey instrument was piloted (n=7) to assess understandability and acceptability of the 
questions. This led to minor adaptations of survey layout, wording and instructions. 
Data analyses 
The primary outcome variables in the analyses were WTP and WTIT values for scenarios 
A1, A2, A3 and B. To facilitate statistical data analyses categorical WTP and WTIT 
variables were transformed to continuous variables by recoding WTP and WTIT 
categories to category mean values. The upper boundary value of the WTP scale 
(>€250/month) was recoded to €298/month and the upper boundary value of the WTIT 
scale (>10 hours/week) was recoded to 11.75 hours/week. For lower boundaries of the 
WTP and WTIT scale (i.e. zero values), we assessed reasons provided by respondents, 
to distinguish between real and protest zero answers. Answer categories five to seven 
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(see above) were always regarded as protest zero answers and for answer category 
eight open-ended responses were further examined.  
Descriptive analyses were conducted to examine WTP and WTIT values for each 
scenario, their distributions and correlations with each other.  
Concordance of WTP and WTIT values with economic theory was explored using three 
common tests of internal validity. We examined whether WTP and WTIT values were (1) 
sensitive to the scope of the benefits to be valued, whether they were (2) sensitive to 
the order in which benefits of LBC were presented to respondents and (3) whether 
associations between explanatory variables and WTP/WTIT were in line with theoretical 
expectations.  
Sensitivity to scope was examined by comparing means of scenario A with means of 
scenario B for each split sample group. Wilcoxon Signed-Rank tests were used, because 
all WTP and WTIT values were non-normally distributed (Kolmogorov-Smirnov test: 
P<0.001). Ordering effects were tested for by performing stratified comparisons for 
respondents who received scenario A and respondents who received scenario B first. 
To examine associations between explanatory variables and WTP/WTIT values three 
linear regression models were tested. The first model used basic background 
characteristics as predictors (see Table 6.1). Income was entered into the analyses as 
dichotomous variable with categories high income (high and middle high categories) and 
low income (low and middle low categories). Answers in the ‘do not want to tell’ income 
category were treated as missing values in the regression. It was hypothesized that a 
higher income is associated with a higher WTP. While differences in ability to pay are 
expected to translate into differences in WTP, this is not necessarily the case for WTIT. 
People with a limited ability to pay may for instance compensate a low WTP by means of 
a higher WTIT. As a proxy for availability of time, we used the variable paid work in the 
regression model. It was hypothesized that respondents who have paid work will express 
lower WTIT than respondents without paid work.  
The second model used risk factors for developing T2D and CVD as predictors. These 
included the following variables: smoking status; having a parent with T2D; highly 
increased waist circumference; and elevated blood pressure. These variables were 
obtained from data collected for the baseline assessment of the HPS (performed by 
Lakerveld et al. 200829) and consist of a combination of physical measurements and self-
report data. Cut-off values for waist circumference and blood pressure were based on 
national treatment guidelines of the Dutch College of General Practitioners (NHG).34,35 
Our hypothesis was that WTP and WTIT would increase with presence of each of the 
risk factors in the model.  
The third model used experience factors as predictors. Two of these were measured for 
the whole sample. They included the group into which respondents had been 
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randomized (intervention vs. control group) and whether or not respondents had 
completed all follow up measurements of the HPS. The remaining four predictor-
variables (i.e. respondent satisfaction with the counseling program, the number of face-
to-face counseling sessions received, the number of booster phone counseling sessions 
received, and the extent to which respondents perceived counseling sessions as helpful 
regarding improving their lifestyle behaviors) were only measured for intervention group 
members and therefore entered into the model as interaction effects with the 
intervention group variable. The experience factor variables were obtained from data 
collected during the process evaluation of the HPS (see Lakerveld et al., 2012).36 It was 
hypothesized that WTP and WTIT would be higher for respondents who have positive 
previous experiences with the lifestyle behavior change intervention of the HPS. More 
specifically we expected that WTP and WTIT would increase with increases in 
satisfaction with the intervention and with perceiving the counseling as more helpful. 
The other predictor variables were only included to control for potential confounding. 
To increase statistical power of the regression analyses WTP and WTIT values for the 
three A scenarios were combined in one variable. Two dummy variables were added to 
correct for the different A-scenarios. The outcome variables were transformed, because 
WTP and WTIT were non-normally distributed. Squared-root transformation approached 
the normal distribution better than log transformation and was therefore applied before 
the regression analyses. All data analyses were performed using SPSS 18. 
Results 
Study participants 
Completed surveys were returned by 312 of the participants still enrolled in the HPS 
(60.6%). From these we excluded respondents, who had missing values on the primary 
WTP or WTIT questions (n=1, 0.3%) or gave protest zero answers (n=10, 3.2%). 
Protest zero answers included two of the previously provided closed-ended answers: ‘I 
find that the government should pay for this’ (n=6); ‘I find that my health insurance 
should pay for this’ (n=6) and four additional open-ended answers: ‘I find this a 
nonsensical question’ (n=1); ‘I already pay enough for my health insurance’ (n=1); ‘I 
don’t understand what you want, I find the question indefinable’ (n=1); ‘Yet another 
expenditure, I already pay like crazy for the health insurance premiums and do not get 
back for it since years’ (n=1). Exclusion of these respondents resulted in a final sample 
of 301 respondents for further analyses. Table 6.1 presents background characteristics 
of study participants and shows that the three split-sample groups for scenario A were 
comparable. 
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Respondents included in this study were similar to non-responders with respect to 
background characteristics, risk factors and experience factors (data not shown). It is 
worth noting that even HPS participants who were not satisfied with the counseling 
program or did not complete all follow up measurements of the HPS have participated in 
this research (18.6 % and 2.3% of included respondents respectively).  
 
Table 6.1 Background characteristics of study participants 
 n (%) 
 Group 1 
(n=87) 
Group 2 
(n=106) 
Group 3 
(n=108) 
Total (n=301) 
Trial arm     
 Intervention group 44 (50.6) 47 (44.3) 53 (49.1) 144 (47.8) 
      
Gender     
 Females 56 (64.4) 58 (54.7) 65 (60.2) 179 (59.5) 
     
Age     
 30-39 14 (16.1) 13 (12.3) 13 (12.0)   40 (13.3) 
 40-49 46 (52.9) 59 (55.7) 59 (54.6) 164 (54.5) 
 50-59 27 (31.0) 34 (32.1) 36 (33.3)   97 (32.2) 
      
Education level     
 Primary education 17 (19.5) 19 (17.9) 18 (16.7)   54 (17.9) 
 Secondary education 35 (40.2) 46 (43.4) 55 (50.9) 136 (45.2) 
 Higher education 35 (40.2) 41 (38.7) 34 (31.5) 110 (36.5) 
      
Household income (net/month)     
 Low ( € 1100) 8 (9.2) 3 (2.8) 6 (5.6) 17 (5.6) 
 Middle low ( € 2300) 26 (29.9) 29 (27.4) 29 (26.9)   84 (27.9) 
 Middle high ( €3500) 29 (33.3) 42 (39.6) 34 (31.5) 105 (34.9) 
 High (>3500) 12 (13.8) 16 (15.1) 23 (21.3)   51 (16.9) 
 Do not want to tell 12 (13.8) 16 (15.1) 16 (14.8)   44 (14.6) 
      
Work situation      
 Having paid work 72 (82.8) 93 (87.7) 96 (88.9) 267 (88.7) 
      
Living situation     
 Living with partner  75 (86.2) 96 (90.9) 96 (88.9) 267 (88.7) 
 Living with child(ren)  76 (87.4) 90 (84.9) 80 (74.1) 246 (81.7) 
      
EQ5D health state utility      
 Mean (SD) 0.87 (0.12) 0.89 (0.14) 0.89 (0.14) 0.89 (0.13) 
Notes: Group 1= Respondents valuing life expectancy benefits, group 2= respondents valuing EQ-
5D based HRQOL benefits and group 3= respondents valuing broader quality of life benefits. 
Percentages for education level do not add up to 100% for group 3 and the total, because of 
missing values.  
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WTP and WTIT for benefits of LBC 
The majority of respondents attached at least some value to benefits of LBC: 94.3% of 
respondents (n=284) were willing to pay either money or time and 87.4% of 
respondents (n=263) were willing to pay both money and time for at least one of the 
two scenarios presented. Average WTP and WTIT values for scenario A and B in each 
split sample group are presented in Table 6.2. These show that respondents were willing 
to invest most for HRQOL benefits (€42/month; 3 hours/week) and broader QOL 
benefits (€40/month; 2.6 hours/week). For life expectancy benefits respondents were 
willing to invest considerably less (€24/month; 2 hours/week). Zero answers were less 
frequent for WTIT (8.5-18.4%) than for WTP (12.3-27.6%) and less frequent for HRQOL 
outcomes and broader QOL outcomes than for life expectancy outcomes. Correlations 
between WTP and WTIT in all split sample groups consistently showed significant 
positive associations between WTP and WTIT (Spearman’s  ranged between 0.30 and 
0.62). 
Scope sensitivity and ordering effects 
The results of the Wilcoxon Signed Rank Tests indicate that respondents were overall 
sensitive to differences in scope (see Table 6.2). For instance, respondents were willing 
to invest significantly more money and time for all benefits together (scenario B) than 
for only life expectancy (scenario A1) or broader QOL benefits (scenario A3). Differences 
were however not significant for the comparison of WTP and WTIT values between all 
benefits (scenario B) and HRQOL benefits (scenario A2).  
Stratified analyses comparing subgroups of respondents receiving scenario A first and 
respondents receiving scenario B first (not shown) suggest that WTP and WTIT answers 
were sensitive to the order in which outcomes were presented. When Scenario A was 
presented first, the differences in WTP and WTIT between the A scenarios and scenario 
B became smaller and non-significant. The only exception was the difference in WTIT for 
scenario A2 (HRQOL outcomes) and scenario B, which became significant in this 
subgroup, suggesting a higher WTIT for scenario A2 than for scenario B. When Scenario 
B was presented first, we found the opposite effect. The differences in WTP and WTIT 
between the A scenarios and scenario B became larger for all spilt sample groups. 
Significance of differences did not change in most cases. The difference between 
scenario A2 and scenario B is the only exception. It was non-significant in the analyses 
for the total sample (see Table 6.2) and became significant when Scenario B was 
presented first.  
Given this evidence for ordering effects on a univariate level, we also included an 
ordering variable in the multivariate regression model testing associations of WTP and 
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WTIT with background variables (see Table 6.3 and 6.4). This has the advantage of a 
larger sample size and allows controlling for other variables. 
 
Table 6.2 Average willingness to invest money and time (SD) for outcomes of life style behavior 
change and Wilcoxon Signed-Rank tests comparing the A scenarios with scenario B 
 
 
Life 
expectancy 
(A1) 
HRQOL 
EQ-5D based 
(A2) 
Other QOL 
aspects  
(A3) 
All  
outcomes 
(B) 
Test () 
Group 1 (n=87) 23.90 (27.89) - - 35.03 (43.03)   3.20** 
Group 2 (n=106) - 41.78 (51.93) - 43.56 (54.58) 0.730 
Money per 
month (€) 
Group 3 (n=108) - - 40.08 (45.41) 45.41 (45.98) 2.56* 
 n (%) real zeros 24 (27.59) 13 (12.26) 15 (13.89) 48 (15.95) - 
Group 1 (n=87) 1.98 (1.80) - - 2.57 (2.29)   3.36** 
Group 2 (n=106) - 3.00 (2.45) - 2.69 (2.26) -1.620 
Time per 
week (h) 
Group 3 (n=108) - - 2.63 (2.17) 2.89 (2.26)  1.98* 
 n(%) real zeros 16 (18.39) 9 (8.49) 11 (10.19) 34 (11.30) - 
*significant at the 0.05 level, **significant at the 0.01 level 
 
Results of the regression analyses 
The results of regression analysis using squared-root transformed outcomes were 
comparable to results of the analysis without transformed outcomes. Hence, for ease of 
interpretation we also present results of analyses with untransformed outcomes here. In 
line with our hypotheses, we found that WTP was positively associated with income (see 
Table 6.3). The dummies included to correct for the different Scenario A-groups were 
also significant, confirming that respondents were willing to pay more for outcomes in 
scenario A2 (HRQOL) and A3 (broader QOL) than for A1 (life expectancy). Three 
additional covariates had consistent significant associations with WTP (i.e. gender, age 
and education level) and two had significant associations, which were not consistent 
across all models tested (i.e. paid work and living with children).  
The regression results provided limited support for our hypothesis that having paid work 
is associated with a lower WTIT (see Table 6.4). We found a negative association 
between paid work and WTIT across all models tested, the association was however 
only significant for Scenario A in the model with the untransformed outcome variable. In 
concordance with the findings for WTP the dummies for the different Scenario A-groups 
are also significant for WTIT, suggesting that respondents are willing to invest 
significantly more time for HRQOL and broader QOL than for life expectancy.  
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Table 6.3 Associations between background characteristics and WTP 
 SQRT transformed Untransformed 
 WTP 
Scenario A 
WTP 
Scenario B 
WTP 
Scenario A 
WTP 
Scenario B 
 St. Coef. S.E. St. Coef. S.E. Coef. S.E. Coef. S.E. 
Gender_female -0.22** 0.42 -0.28** 0.44 -17.21** 5.80 -26.73** 6.17 
Age 0.12* 0.04 0.15* 0.04 1.28* 0.55 1.74** 0.58 
Education_secondary 0.12 0.59 0.20* 0.60 9.58 8.07 15.95 8.57 
Education_higher 0.28** 0.62 0.38** 0.64 23.53** 8.53 32.46** 9.06 
Income_high 0.14* 0.47 0.15* 0.49 12.98* 6.50 17.16* 6.91 
Paid work -0.10 0.68 -0.07* 0.70 -22.22* 9.33 -21.70* 9.92 
Living with partner 0.05 0.70 0.10 0.72 7.36 9.55 14.01 10.15 
Living with child(ren) -0.06 0.56 -0.12 0.58 -9.13 7.71 -17.13* 8.20 
EQ5D utility 0.01 1.60 -0.09 1.67 -1.68 21.99 -38.82 23.38 
Intervention -0.04 0.40 -0.07 0.41 -2.19 5.51 -4.43 5.86 
Ordering -0.10 0.41 0.03 0.42 -7.55 5.63 -1.93 5.98 
Group_A2 0.20** 0.50 0.04 0.52 16.50* 6.89 5.41 7.32 
Group_A3 0.19** 0.51 0.12 0.52 14.35* 6.95 9.28 7.39 
Constant (not standardized) 0.62 2.37 1.95 2.45 -17.69 32.64 1.40 34.70 
F 4.07** 4.98** 3.37** 4.67** 
R2 adjusted 0.14 0.17 0.11 0.16 
*significant at the 0.05 level, **significant at the 0.01 level 
 
 
Table 6.4 Associations between background characteristics and WTIT 
 SQRT transformed Untransformed 
 WTIT 
Scenario A 
WTIT 
Scenario B 
WTIT 
Scenario A 
WTIT 
Scenario B 
 St. Coef. S.E. St. Coef. S.E. Coef. S.E. Coef. S.E. 
Gender_female -0.08 0.10 -0.12 0.10 -0.21 0.29 -0.58 0.30 
Age -0.00 0.01 0.05 0.01 0.00 0.03 0.04 0.03 
Education_secondary 0.08 0.13 0.15 0.13 0.31 0.40 0.50 0.41 
Education_higher 0.13 0.14   0.24* 0.14 0.40 0.42 0.77 0.44 
Income_high 0.07 0.11 -0.02 0.11 0.32 0.32 0.02 0.33 
Paid work -0.10 0.15 -0.05 0.15 -0.92* 0.46 -0.79 0.48 
Living with partner -0.01 0.16 0.02 0.16 0.03 0.47 -0.13 0.49 
Living with child(ren) -0.01 0.13 0.01 0.13 -0.28 0.39 -0.03 0.40 
EQ5D utility -0.05 0.36 -0.09 0.36 -0.24 1.08 -1.33 1.13 
Intervention -0.10 0.09 -0.05 0.09 -0.48 0.27 -0.15 0.28 
Ordering -0.17** 0.09 0.05 0.09 -0.75* 0.28 0.03 0.29 
Group_A2 0.26** 0.11 0.04 0.11 1.13** 0.34 0.14 0.35 
Group_A3 0.20** 0.11 0.13 0.12 0.76* 0.34 0.54 0.36 
Constant (not standardized) 1.73* 0.53 1.45** 0.54 3.28* 1.60 2.42 1.68 
F 2.36** 1.09 2.14* 0.97 
R2 adjusted 0.06 0.00 0.06 -0.00 
*significant at the 0.05 level, **significant at the 0.01 level 
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Multivariate regression analyses provided weaker evidence for ordering effects than 
univariate analyses. Ordering did not have a significant impact on WTP and for WTIT the 
impact of ordering was only significant for scenario A, suggesting that respondents’ 
WTIT was lower for scenario A, when scenario B was presented first.  
In contrast to the regression model with background variables, which contributed 
significantly to the explained variance in WTP and WTIT (for Scenario A), the models 
with experience and risk factors had poor explanatory power and did not reach statistical 
significance. Therefore these results are not presented here.  
Discussion 
The present paper reports on a study using CV to value benefits of a LBC intervention 
from an individual consumers perspective. Benefits included benefits incorporated within 
the QALY framework (i.e. life expectancy and HRQOL) and impacts on broader quality of 
life aspects (i.e. clothing size, relaxation, endurance and experienced control over 
lifestyle choices). Our results indicate that the majority of respondents (94.3%) attach 
value to benefits achieved by LBC. In concordance with previous CV studies,37-39 we 
found consistent positive associations between monetary and time investments, 
indicating that respondents, who are willing to invest time to achieve benefits of LBC are 
generally also willing to invest money. However, zero willingness to invest was 
somewhat more frequent for WTP than for WTIT questions suggesting that some 
respondents only want to invest time for LBC, but no money. Respondents were willing 
to invest more for improvements in HRQOL and other QOL benefits than for life 
expectancy benefits. This finding is consistent with results of a discrete choice 
experiment conducted among a smaller sample of HPS participants,40 providing some 
evidence for external validity of our findings.  
Our findings regarding the internal validity of the CV method were mixed. Respondents 
were overall sensitive to the qualitatively different scope of benefits presented to them. 
They were willing to invest significantly more money and time for all types of benefits 
together than for improvements in only life expectancy or broader QOL aspects. 
However, this was not the case for HRQOL outcomes. Our findings regarding scope 
sensitivity contrast earlier research by Olsen et al. (2004),41 who reported that 
respondents were insensitive to both the size of health programs as well as the size of 
the benefits. Our findings are concordant however with findings by Smith (2001)42 and 
Yeung et al. (2003),43 showing that sensitivity to scale decreases with increasing utility 
of the benefit being valued. In both studies diminishing sensitivity to scale was ascribed 
to a budget constraint, which becomes increasingly relevant as the benefit increases. 
The budget constraint could either be an actual budget constraint, referring to inability 
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to pay more,44 or a psychological budget constraint, referring to the possibility that 
respondents construct their own purpose-specific budgets.45  
The environmental economics literature has shown that CV applications comprising 
multiple valuation questions are vulnerable to question ordering effects.46 Kartman et al. 
(1996)47, who tested for ordering effects within the healthcare setting, did not find 
evidence for ordering effects. In our study we found ordering effects, but these became 
weaker after controlling for other explanatory variables. Ordering effects are 
problematic, because they suggest that preferences of respondents are unstable and not 
clearly defined. Several techniques have been suggested to minimize ordering effects, 
such as giving respondents the opportunity to revise their answers after all questions 
have been completed.25 However, there is evidence that ordering bias cannot be fully 
eliminated. It is not a problem inherent to CV, but rather a fundamental property of 
human decision-making, which raises questions about which benchmarks to use when 
examining the validity of CV in future research.48  
Associations between exploratory variables and WTP/WTIT outcomes also provided 
mixed evidence for internal validity. In line with theoretical assumptions and previous 
research, we found that respondents’ income was consistently positively associated with 
WTP.49 Having paid work, which was used as a proxy for availability of time, only 
showed a weak negative association with WTIT in one of the four models presented. 
This could have several reasons. The proxy measure used for availability of time could 
have been suboptimal, availability of time may not determine WTIT, or the weak 
association between paid work and WTIT is due to bias related to the CV method. Only 
two other studies have to our knowledge examined potential predictors of WTIT so 
far,38,39 while predictors of WTP have received considerable attention in previous 
research. This highlights the need for more research to identify and test relevant 
predictors for WTIT.  
Against our hypotheses, associations between WTP/WTIT and respondent’s health risk 
factors, as well as intervention experiences were not significant. This may be explained 
by a number of reasons. First, the time difference of 2.5 years between measuring risk 
factors and conducting the CV study could have been too long for risk factors to have 
any impact. Second, although respondents had different types of health risk factors, 
they all had an increased risk for T2D, CVD or both. Hence, it is possible that there was 
not sufficient variation in perceived importance of risk between respondents. Third, the 
fact that we did not find a significant impact of experience factors may be due to limited 
power in the analyses, since experience factors were only measured among half of the 
study participants.  
A number of limitations of this research need mentioning. The study sample consisted of 
participants in a trial evaluating a LBC intervention. Hence, results may not be 
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generalized to other populations, such as consumers of regular LBC interventions and 
consumers in other application areas of public health.  
Another limitation is related to the definition of life expectancy gains used in our 
research (i.e. 2.6 years). This definition was based on results of a study quantifying life 
expectancy gains that may be achieved by changing physical activity levels.50 Recent 
Canadian research quantifying life expectancy gains for multiple lifestyle factors, 
suggests however that LBC may achieve considerably larger gains (of up to 7.5 years).51 
Although the Canadian estimate represents life expectancy gains that may be achieved 
when all lifestyle factors are improved at the same time and participants of the HPS 
often only worked on improving one of these factors, we cannot preclude that we may 
have underestimated possible life expectancy gains and hence their perceived 
importance to respondents.  
Our research also had several strengths. It adds to the limited number of CV studies 
applied to broader public health programs.20,52-54 Applications of CV to public health are 
increasing, but the majority has concentrated on clinical public health programs, such as 
screening,55 vaccinations,56,57 preventive dental care38,58 or drugs for smoking 
cessation.27,59 Additionally, we are aware of only two studies valuing both health and 
broader benefits of a public health program.20,53 An important limitation of these studies 
was that broader benefits were not well defined or quantified and that health outcomes 
were not described in terms of their impact on HRQOL. Our research addresses this 
limitation by providing detailed definitions of three types of public health outcomes to be 
valued.  
Another advantage of our study was the simultaneous use of WTP and WTIT to value 
consequences of LBC. Given that LBC may require both time and monetary investments, 
this approach seems more realistic in the context of behavior change interventions than 
only using WTP. Experience with deriving preferences using WTIT questions is to date 
very limited. Few studies have measured WTIT so far37-39,60 and none of these addressed 
the question how both measures could be used simultaneously within a CBA framework. 
Van Helvoort – Postulart et al. (2009)37 and Johanneson (1992)60 suggested converting 
WTIT values into monetary units using opportunity costs of leisure time, but it is still 
unclear which method to use for this purpose and whether monetary values of WTP and 
WTIT can simply be added up for CBA.  
The importance of broader quality of life benefits of LBC to consumers has implications 
for decision-makers, who wish to respond to consumer preferences. To support this 
process, research needs to develop methods for considering such broader benefits in 
decision-making. The CV method has been suggested as a possible way to capture 
broader benefits of public health within an economic evaluation framework. It has 
proven to be a feasible method in our study, which appears from a limited number of 
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protest zeros (3%), as well as from the 61% response rate achieved, which is regarded 
reasonable for survey-based research.61 Feasibility of the CV method also needs to be 
tested in other application areas of public health and among general population samples, 
for which lifestyle changes are less urgent.  
Conclusion 
The results of this study have shown that consumers are willing to invest both time and 
money to achieve benefits of lifestyle change. In addition to benefits incorporated within 
the QALY framework, they are also willing to invest for broader individual-level benefits. 
This highlights the need to develop methods to consider such benefits in decision-
making about LBC. The CV method has shown to be a feasible approach to value both 
health and broader benefits of a public health intervention, but generalizability to other 
areas of public health still needs to be examined. Given mixed evidence for internal 
validity, we recommend using CV not as the sole method to support decision-making, 
but rather it in conjunction with other methods, such as discrete choice experiments, 
ranking exercises and qualitative research.  
 
Consumer willingness to invest money and time for benefits of lifestyle behavior change 
 
Ch
ap
te
r 
6 
 
129
References 
1. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic 
Evaluation of Health Care Programmes New York: Oxford University Press; 2005. 
2. Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, et al. Methods for 
assessing the cost-effectiveness of public health interventions: Key challenges and 
recommendations. Health Policy 2009;93:85-92. 
3. McDaid D, Needle J. What use has been made of economic evaluation in public health? A 
systematic review of the literature. In: Dawson S, Morris ZS, editors. Future Public Health: 
Burdens, Challenges and Opportunities. Basingstone: Palgrave Macmillan; 2009:248-64. 
4. Allin S, Mossialos E, McKee M, Holland W. Making decisions on public health: a review of eight 
countries. Copenhagen: World Health Organization; 2004. 
5. Rush B, Shiell A, Hawe P. A census of economic evaluations in health promotion. Health 
Education Research 2004;19:707-19. 
6. Lorgelly PK, Lawson KD, Fenwick EAL, Briggs AH. Outcome measurement in economic 
evaluations of public health interventions: a role for the capability approach?.International 
Journal of Environmental Research and Public Health 2010;7:2274-89. 
7. Kelly M, Morgan A, Ellis S, Younger T, Huntley J, Swann C. Evidence based public health: A 
review of the experience of the National Institute of Health and Clinical Excellence (NICE) of 
developing public health guidance in England. Social Science & Medicine 2010;71:1056-62. 
8. Chalkidou K, Culyer A, Naidoo B, Littlejohns P. Cost-effective Public Health Guidance: Asking 
questions from the Decision-Maker's viewpoint. Health Economics 2008;17:441-8. 
9. Shiell A. In search of social value. International Journal of Public Health 2007;52:333-4. 
10. Fielding JE, Teutsch S, Breslow L. A Framework for Public Health in the United States. Public 
Health Reviews 2010;32:174-89. 
11. WHO. Health Promotion Glossary. Geneva: World Health Organization; 1998. 
12. WHO. Milestones in Health Promotion: Statements from Global Conferences. Geneva: World 
Health Organization; 2009. 
13. Awofeso N. What's New About the ''New Public Health''? American Journal of Public Health 
2004;94:705-9. 
14. McLeroy KR, Bibeau D, Steckler A, Glanz K. An Ecological Perspective on Health Promotion 
Programs. Health Education Quarterly 1988;15:351-77. 
15. Allwright S, Paul G, Greiner B, Mullally BJ, Pursell L, Kelly A, et al. Legislation for smoke-fee 
workplaces and health of bar workers in Ireland: before and after study. British Medical 
Journal 2005;331:1117-20. 
16. Wagenaar AC, Tobler AL, Komro KA. Effects of Alcohol Tax and Price Policies on Morbidity and 
Mortality: A Systematic Review. American Journal of Public Health 2010;100:2270-8. 
17. Smith RD, Petticrew M. Public health evaluation in the twenty-first century: time to see the 
wood as well as the trees. Journal of Public Health 2010;32:2-7. 
18. Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and Valuing Health Benefits for 
Economic Evaluation. New York: Oxford University Press; 2007. 
19. Goebbels AFG, Lakerveld J, Ament AJHA, Bot SDM, Severens JL. Exploring non-health 
outcomes of health promotion: The perspective of participants in a lifestyle behaviour change 
intervention. Health Policy 2012;106:177-86. 
20. Borghi J, Jan S. Measuring benefits of health promotion programmes: Application of the 
contingent valuation method. Health Policy 2008;87:235-48. 
21. Hale J. What contribution can health economics make to health promotion? Health Promotion 
International 2000;15:341-8. 
22. O'Brien B, Gafni A. When Do the ''Dollars'' Make Sense? Toward a Conceptual Framework for 
Contingent Valuation Studies in Health Care. Medical Decision Making 1996;16:288-99. 
23. Hanley N, Ryan M, Wright R. Estimating the monetary value of health care: lessons from 
environmental economics. Health Economics 2003;12:3-16. 
  
Ch
ap
te
r 
6 
 
130 
24. Olsen JA. Aiding priority setting in health care: Is there a role for the contingent valuation 
method? Health Economics 1997;6:603-12. 
25. Venkatachalam L. The contingent valuation method: a review. Environmental Impact 
Assessment Review 2004;24:89-124. 
26. de Meijer C, Brouwer W, Koopmanschap M, van den Berg B, van Exel J. The value of informal 
care - a further investigation of the feasibility of contingent valuation in informal caregivers. 
Health Economics 2010;19:755-71. 
27. Olsen JA, RØgeberg OJ, Stavem K. What explains willingness to pay for smoking-cessation 
treatments - addiction level, quit-rate effectiveness or the opening bid?. Applied Health 
Economics and Health Policy 2012;10:1-9. 
28. van Exel NJA, Brouwer WBF, van den Berg B, Koopmanschap MA. With a little help from an 
anchor: Evidence of starting point bias in contingent valuation of informal caregiver time 
inputs. Journal of Socio-Economics 2006;35:836-53  
29. Lakerveld J, Bot DM, Chinapaw MJ, van Tulder MW, van Oppen P, Dekker JM, et al. Primary 
prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive behavior 
program aimed at lifstyle changes in people at risk: Design of a randomized controlled trial. 
BMC Endocrine Disorders 2008;8:1-11. 
30. Maguire KB. Does mode matter? A comparison of telephone, mail, and in-person treatments in 
contingent valuation surveys. Journal of Environmental Management 2009;90:3528-33. 
31. Donaldson C, Thomas R, Torgerson DJ. Validity of open-ended and payment scale approaches 
to willingness to pay. Applied Economics 1997;29:79-84. 
32. Frew EJ, Whynes DK, Wolstenholme JL. Eliciting Willingness to Pay: Comparing Closed-Ended 
and Payment Scale Approaches. Medical Decision Making 2003;23:150-9. 
33. Bobinac A, van Exel NJA, Rutten FFH. Willingness to pay for a QALY: the individual 
perspective. Value in Health 2010;13:1046-55. 
34. van Binsbergen JJ, Langens FNM, Dapper ALM, Van Halteren MM, Glijsteen R, Cleyndert GA, 
et al. NHG-Standaard Obesitas. Huisarts Wet 2010;53:609-25. 
35. NHG. NHG-Standaard Cardiovasculair risicomanagment (eerste herziening). Huisarts Wet 
2012;55:14-28. 
36. Lakerveld J, Bot S, Chinapaw M, van Tulder M, Kingo L, Nijpels G. Process Evaluation of a 
Lifestyle Intervention to Prevent Diabetes and Cardiovascular Diseases in Primary Care. Health 
Promotion Practice 2012;13:696-706. 
37. van Helvoort-Postulart D, Dirksen CD, Kessels AGH, van Engelshoven JMA, Hunink MGM. A 
comparison between willingness to pay and willingness to give up time. European Journal of 
Health Economics 2009;10:81-91. 
38. Vermaire JH, van Exel NJA, Van Loveren C, Brouwer WBF. Putting your money where your 
mouth is: Parents' valuation of good oral health of their children. Social Science & Medicine 
2012;75:2200-6. 
39. Barner JC, Mason HL, Murray MD. Assessment of Asthma Patients' Willingness to Pay for and 
Give Time to an Asthma Self-Managment Program. Clinical Therapeutics 1999;21:878-94. 
40. Alayli-Goebbels AFG, Dellaert BGC, Knox SA, Ament AJHA, Lakerveld J, Bot SDM, et al. 
Consumer preferences for health and non-health outcomes of health promotion: results from 
a discrete choice experiment. Value in Health 2013;16:114-23. 
41. Olsen JA, Donaldson C, Pereira J. The insensitivity of 'willingness-to-pay' to the size of the 
good: New evidence for health care. Journal of Economic Psychology 2004;25:445-60. 
42. Smith RD. The relative sensitivity of willingness-to-pay and time-trade-off to changes in health 
status: an empirical investigation. Health Economics 2001;10:487-97. 
43. Yeung RYT, Smith RD, McGhee SM. Willingness to pay and size of health benefit: an 
integrated model to test for 'sensitivity to scale'. Health Economics 2003;12:791-6. 
44. Smith RD. Sensitivity to scale in contingent valuation: the importance of the budget 
constraint. Journal of Health Economics 2005;24:515-29. 
45. Thaler R. Mental Accounting Matters. Journal of Behavioural Decision Making 1999;12:183-
206. 
Consumer willingness to invest money and time for benefits of lifestyle behavior change 
 
Ch
ap
te
r 
6 
 
131
46. Powe NA, Bateman IJ. Ordering effects in nested 'top-down' and 'bottom-up' contingent 
valuation designs. Ecological Economics 2003;45:255-70. 
47. Kartman B, Stålhammar NO, Johanneson M. Valuation of health changes with the contingent 
valuation method: A test of scope and question order effects. Health Economics 1996;5:531-
41. 
48. Clark J, Friesen L. The causes of order effects in contingent valuation surveys: An 
experimental investigation. Journal of Environmental Economics and Management 
2008;56:195-206. 
49. Kling CL, Phaneuf DJ, Zhao J. From Exxon to BP: Has some number become better than no 
number? Journal of Economic Perspectives 2012;26:3-26. 
50. Franco OH, de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of Physical 
Activity on Life Expectancy with Cardiovascular Disease. Archives of Internal Medicine 
2005;165:2355-60. 
51. Manuel D, Perez R, Bennett C, Rosella L, Taljaard M, Roberts M, et al. Seven more years: The 
impact of smoking, alcohol, diet, physical activity and stress on health and life expectancy in 
Ontario. Toronto: Institute for Clinical Evaluative Sciences and Public Health Ontario; 2012. 
52. Cawley J. Contingent valuation analysis of willingness to pay to reduce childhood obesity. 
Economics and Human Biology 2008;6:281-91. 
53. Haines TP, McPhail S. Patient preference for falls prevention in hospitals revealed through 
willingness-to-pay, contingent valuation survey. Journal of Evaluation in Clinical Practice 
2011;17:304-10. 
54. Sorenson SB. Funding Public Health: The Public's Willingness to Pay for Domestic Violence 
Prevention Programming. American Journal of Public Health 2003;93:1934. 
55. Yasunaga H. Willingness to pay for mass screening for prostate cancer: A contingent valuation 
survey. International Journal of Urology 2008;15:102-5. 
56. Heinzen RR, Bridges JFP. Comparison of four contingent valuation methods to estimate the 
economic value of a pneumococcal vaccine in Bangladesh. International Journal of Technology 
Assessment in Health Care 2008;24:481-87. 
57. Palanca-Tan R. The demand for a dengue vaccine: A contingent valuation survey in Metro 
Manila. Vaccine 2008;26:914-23. 
58. Oscarson N, Lindholm L, Källestål. The value of caries preventive care among 19-year olds 
using the contingent valuation method within a cost-benefit approach. Community Dentristry 
and Oral Epidemiology 2007;35:109-17. 
59. Weimer DL, Vining AR, Thomas RK. Cost-benefit analysis involving addictive goods: 
Contingent valuation to estimate willingness-to-pay for smoking cessation. Health Economics 
2009;18:181-202. 
60. Johanneson M. Economic evaluation of lipid lowering - A feasibility test of the contingent 
valuation approach. Health Policy 1992;20:309-20. 
61. Baruch Y. Response rate in academic studies - A comparative analysis. Human Reations 
1999;52:421-38. 
 
  
Ch
ap
te
r 
6 
 
132 
 
A
pp
en
di
x 
6.
1
 
Co
nt
in
ge
nt
 v
al
ua
tio
n 
sc
en
ar
io
s
G
en
er
al
 in
tr
od
uc
tio
n 
Im
ag
in
e 
yo
u 
ca
n 
pa
rt
ic
ip
at
e 
in
 a
 p
ro
gr
am
 t
ha
t 
he
lp
s 
yo
u 
ch
an
ge
 y
ou
r 
lif
es
ty
le
 b
eh
av
io
r.
 T
hi
s 
pr
og
ra
m
 c
on
si
st
s 
of
 t
en
 c
ou
ns
el
in
g 
se
ss
io
ns
. T
og
et
he
r 
w
ith
 a
 c
ou
ns
el
or
 y
ou
 d
ev
el
op
 
a 
pl
an
 fo
r 
lif
es
ty
le
 c
ha
ng
e 
th
at
 is
 t
ai
lo
re
d 
to
 y
ou
r 
ne
ed
s.
 Y
ou
r 
pa
rt
ic
ip
at
io
n 
in
 t
he
se
 c
ou
ns
el
in
g 
se
ss
io
ns
 is
 f
re
e 
of
 c
ha
rg
e.
 B
ut
 e
ac
h 
se
ss
io
n 
w
ill
 c
os
t 
yo
u 
on
e 
ho
ur
 o
f 
yo
ur
 t
im
e.
 
  Th
e 
pl
an
 t
ha
t 
is
 d
ev
el
op
ed
 d
ur
in
g 
co
un
se
lin
g 
se
ss
io
ns
 m
ay
 a
ls
o 
as
k 
fo
r 
an
 a
dd
iti
on
al
 in
ve
st
m
en
t 
fr
om
 y
ou
. F
or
 e
xa
m
pl
e 
it 
m
ay
 c
os
t 
tim
e 
to
 b
ec
om
e 
m
or
e 
ph
ys
ic
al
ly
 a
ct
iv
e 
or
 t
o 
co
ok
 h
ea
lth
ie
r 
m
ea
ls
. L
ife
st
yl
e 
be
ha
vi
or
 c
ha
ng
es
 m
ay
 a
ls
o 
co
st
 m
on
ey
, f
or
 e
xa
m
pl
e 
w
he
n 
yo
u 
ta
ke
 o
ut
 a
 s
ub
sc
rip
tio
n 
in
 a
 g
ym
 o
r 
w
he
n 
yo
u 
bu
y 
ot
he
r 
fo
od
 p
ro
du
ct
s.
 
 Th
e 
co
ns
eq
ue
nc
es
 y
ou
 w
ill
 e
xp
er
ie
nc
e 
fr
om
 li
fe
st
yl
e 
be
ha
vi
or
 c
ha
ng
e 
w
ill
 d
ep
en
d 
on
 y
ou
r 
in
ve
st
m
en
t 
an
d 
on
 t
he
 a
ct
iv
iti
es
 t
ha
t 
yo
u 
un
de
rt
ak
e.
 Y
ou
 w
ill
 n
ow
 s
ee
 t
w
o 
si
tu
at
io
ns
 
w
ith
 d
iff
er
en
t 
po
ss
ib
le
 c
on
se
qu
en
ce
s.
  
 H
ow
 m
uc
h 
m
on
ey
 a
nd
 t
im
e 
w
ou
ld
 y
ou
 m
ax
im
al
ly
 in
ve
st
 if
 y
ou
 k
ne
w
 f
or
 s
ur
e 
th
at
 y
ou
 w
ou
ld
 e
xp
er
ie
nc
e 
th
es
e 
co
ns
eq
ue
nc
es
? 
 
Sc
en
ar
io
 A
1 
Sc
en
ar
io
 B
 
M
y 
lif
e 
ex
pe
ct
an
cy
 is
 8
3 
ye
ar
s.
 T
ha
t 
m
ea
ns
 t
ha
t 
I 
w
ill
 b
ec
om
e 
2.
6 
ye
ar
s 
ol
de
r 
th
an
 t
he
 
av
er
ag
e 
pe
rs
on
 in
 t
he
 N
et
he
rla
nd
s,
 w
ho
 w
ill
 d
ie
 a
t 
an
 a
ge
 o
f 
80
.4
 y
ea
rs
.  
 Sc
en
ar
io
 A
2 
M
y 
fu
tu
re
 h
ea
lth
 s
ta
te
 h
as
 a
 v
al
ue
 o
f 
1.
 T
hi
s 
m
ea
ns
 t
ha
t 
I 
ha
ve
 n
o 
pr
ob
le
m
s 
in
 w
al
ki
ng
 
ab
ou
t,
 w
ith
 s
el
f-
ca
re
 o
r 
to
 p
er
fo
rm
 m
y 
us
ua
l a
ct
iv
iti
es
. I
 h
av
e 
no
 p
ai
n 
or
 d
is
co
m
fo
rt
 a
nd
 
I 
am
 n
ot
 a
nx
io
us
 o
r 
de
pr
es
se
d.
 T
hi
s 
he
al
th
 s
ta
te
 s
ta
rt
s 
in
 t
w
o 
ye
ar
s 
an
d 
re
m
ai
ns
 f
or
 t
he
 
re
st
 o
f 
m
y 
lif
e.
 I
n 
th
e 
ne
xt
 t
w
o 
ye
ar
s 
be
fo
re
 t
he
 f
ut
ur
e 
he
al
th
 s
ta
te
 s
ta
rt
s,
 I
 w
ill
 k
ee
p 
m
y 
cu
rr
en
t 
he
al
th
 s
ta
te
. 
 Sc
en
ar
io
 A
3 
I 
ha
ve
 m
y 
id
ea
l c
lo
th
in
g 
si
ze
, w
ith
 w
hi
ch
 I
 f
ee
l c
om
fo
rt
ab
le
 in
 m
y 
bo
dy
. 
 I 
ha
ve
 6
-7
 d
ay
s 
pe
r 
w
ee
k 
w
ith
 s
uf
fic
ie
nt
 r
el
ax
at
io
n.
 O
n 
a 
da
y 
w
ith
 s
uf
fic
ie
nt
 r
el
ax
at
io
n 
I 
ha
ve
 a
t 
le
as
t 
1 
ho
ur
 d
ur
in
g 
w
hi
ch
 I
 c
an
 r
ea
lly
 c
al
m
 d
ow
n 
an
d 
cl
ea
r 
m
y 
he
ad
. I
 a
m
 n
ot
 
te
ns
e 
an
d 
ex
pe
rie
nc
e 
no
 s
tr
es
s 
du
rin
g 
th
at
 t
im
e.
  
 Co
m
pa
re
d 
to
 p
eo
pl
e 
of
 m
y 
ag
e,
 I
 h
av
e 
a 
ve
ry
 g
oo
d 
en
du
ra
nc
e .
 T
ha
t 
m
ea
ns
 t
ha
t 
I 
ha
ve
 
go
od
 m
us
cu
la
r 
st
re
ng
th
 a
nd
 c
an
 s
us
ta
in
 in
te
ns
e 
ph
ys
ic
al
 s
tr
ai
ns
 e
as
ily
. I
 d
on
’t 
ge
t 
ou
t 
of
 b
re
at
h 
ea
si
ly
 a
nd
 c
an
 r
ec
ov
er
 q
ui
ck
ly
 f
ro
m
 s
tr
en
uo
us
 a
ct
iv
iti
es
.  
 I 
ex
pe
rie
nc
e 
a 
lo
t 
of
 c
on
tr
ol
 o
ve
r 
lif
es
ty
le
 c
ho
ic
es
. T
ha
t 
m
ea
ns
 t
ha
t 
I 
ha
ve
 s
tr
on
g 
co
nf
id
en
ce
 t
ha
t 
I 
ca
n 
m
ak
er
 p
er
so
na
lly
 d
es
ira
bl
e 
lif
es
ty
le
 c
ho
ic
es
.  
M
y 
lif
e 
ex
pe
ct
an
cy
 is
 8
3 
ye
ar
s.
 T
ha
t 
m
ea
ns
 t
ha
t 
I 
w
ill
 b
ec
om
e 
2.
6 
ye
ar
s 
ol
de
r 
th
an
 t
he
 
av
er
ag
e 
pe
rs
on
 in
 t
he
 N
et
he
rla
nd
s,
 w
ho
 w
ill
 d
ie
 a
t 
an
 a
ge
 o
f 
80
.4
 y
ea
rs
.  
 M
y 
fu
tu
re
 h
ea
lth
 s
ta
te
 h
as
 a
 v
al
ue
 o
f 
1.
 T
hi
s 
m
ea
ns
 t
ha
t 
I 
ha
ve
 n
o 
pr
ob
le
m
s 
in
 w
al
ki
ng
 
ab
ou
t,
 w
ith
 s
el
f-
ca
re
 o
r 
to
 p
er
fo
rm
 m
y 
us
ua
l a
ct
iv
iti
es
. I
 h
av
e 
no
 p
ai
n 
or
 d
is
co
m
fo
rt
 a
nd
 
I 
am
 n
ot
 a
nx
io
us
 o
r 
de
pr
es
se
d.
 T
hi
s 
he
al
th
 s
ta
te
 s
ta
rt
s 
in
 t
w
o 
ye
ar
s 
an
d 
re
m
ai
ns
 f
or
 t
he
 
re
st
 o
f 
m
y 
lif
e.
 I
n 
th
e 
ne
xt
 t
w
o 
ye
ar
s 
be
fo
re
 t
he
 f
ut
ur
e 
he
al
th
 s
ta
te
 s
ta
rt
s,
 I
 w
ill
 k
ee
p 
m
y 
cu
rr
en
t 
he
al
th
 s
ta
te
. 
 I 
ha
ve
 m
y 
id
ea
l c
lo
th
in
g 
si
ze
, w
ith
 w
hi
ch
 I
 f
ee
l c
om
fo
rt
ab
le
 in
 m
y 
bo
dy
. 
 I 
ha
ve
 6
-7
 d
ay
s 
pe
r 
w
ee
k 
w
ith
 s
uf
fic
ie
nt
 r
el
ax
at
io
n.
 O
n 
a 
da
y 
w
ith
 s
uf
fic
ie
nt
 r
el
ax
at
io
n  
I 
ha
ve
 a
t 
le
as
t 
1 
ho
ur
 d
ur
in
g 
w
hi
ch
 I
 c
an
 r
ea
lly
 c
al
m
 d
ow
n 
an
d 
cl
ea
r 
m
y 
he
ad
. I
 a
m
 n
ot
 
te
ns
e 
an
d 
ex
pe
rie
nc
e 
no
 s
tr
es
s 
du
rin
g 
th
at
 t
im
e.
  
 Co
m
pa
re
d 
to
 p
eo
pl
e 
of
 m
y 
ag
e,
 I
 h
av
e 
a 
ve
ry
 g
oo
d 
en
du
ra
nc
e .
 T
ha
t 
m
ea
ns
 t
ha
t 
I 
ha
ve
 
go
od
 m
us
cu
la
r 
st
re
ng
th
 a
nd
 c
an
 s
us
ta
in
 in
te
ns
e 
ph
ys
ic
al
 s
tr
ai
ns
 e
as
ily
. I
 d
on
’t 
ge
t 
ou
t 
of
 b
re
at
h 
ea
si
ly
 a
nd
 c
an
 r
ec
ov
er
 q
ui
ck
ly
 f
ro
m
 s
tr
en
uo
us
 a
ct
iv
iti
es
.  
 I 
ex
pe
rie
nc
e 
a 
lo
t 
of
 c
on
tr
ol
 o
ve
r 
lif
es
ty
le
 c
ho
ic
es
. T
ha
t 
m
ea
ns
 t
ha
t 
I 
ha
ve
 s
tr
on
g 
co
nf
id
en
ce
 t
ha
t 
I 
ca
n 
m
ak
er
 p
er
so
na
lly
 d
es
ira
bl
e 
lif
es
ty
le
 c
ho
ic
es
. 
*b
as
e 
le
ve
l o
f 
ef
fe
ct
 c
od
ed
 v
ar
ia
bl
es
 
  
 
 
 
CHAPTER 7 
 
 
 
General discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Ch
ap
te
r 
7 
 
134 
  
  General discussion 
 
Ch
ap
te
r 
7 
 
135
Introduction 
Economic evaluation studies are a useful tool to support decisions on allocation of 
limited health care resources. They integrate information about both costs and 
effectiveness of alternative technologies and are a key source of evidence to consider in 
the health technology assessment process. Economic evaluation evidence is increasingly 
used in decision-making about funding of health technologies, such as pharmaceuticals, 
medical devices, diagnostic and surgical procedures. For public health programs 
economic evaluation evidence is still relatively scarce. One key reason for the lack of 
economic evaluation studies is that public health programs pose methodological 
challenges to economic evaluation. The research in this dissertation contributes to 
improving the evidence-base for decision-making in public health by addressing 
methodological challenges and questions that have been raised regarding the 
methodological quality of existing studies. This chapter provides an overview of the main 
findings of the studies described in this thesis. Based on a systematic literature review 
assessing the methodological quality and progress of economic evaluations of behavior 
change programs remaining challenges for evaluation were identified. As a next step, we 
discuss the findings of four empirical studies exploring potential solutions to overcome 
challenges associated with a) comparing efficiency across multiple societal sectors and 
b) considering impacts of public health interventions on broader domains of wellbeing 
not captured within the QALY framework. Based on the overall research findings, we 
conclude with a description of the state of scientific progress in applying economic 
evaluation methods to public health and the resulting implications for practice, decision-
making and future research.  
State of the art and what this research adds 
The systematic literature review reported in Chapter 2 identified 142 economic 
evaluations of public health programs directed at behavior change. These studies 
provide evidence to support funding decisions. Methodological quality of the studies 
showed several weaknesses, however, which limits their usefulness for decision-making. 
These weaknesses included for instance insufficient reporting of essential study details 
and lack of compliance with methodological standards, such as performing an 
incremental analysis, sensitivity analyses and the use of discounting.  
Based on an analysis of economic evaluation studies published before April 2009, the 
progress with addressing methodological challenges for evaluation was overall limited. 
Mathematical modeling techniques to extrapolate intermediate outcomes to long-term 
health outcomes have the potential to overcome the challenge caused by the long time 
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horizon of public health programs. More than half of the economic evaluations included 
in our systematic review made use of modeling techniques. The time horizon of many of 
these studies was however insufficiently long to capture all health outcomes and costs 
relevant to the decision problem. Another finding was that lacking data often hampered 
modeling of underlying causal relationships.  
Our review also shows that it remains challenging to consider impacts on broader 
domains of wellbeing not captured by the QALY. Very few economic evaluations 
identified or measured such broader outcomes, and validated methods or instruments 
for their consideration have not yet been developed (see Chapter 2). The qualitative 
research described in Chapter 4 contributed to the limited evidence about broader 
impacts of public health interventions in the context of lifestyle change. The discrete 
choice experiment described in Chapter 5 provides evidence that the identified broader 
outcomes of lifestyle behavior change are equally important to consumers as health 
outcomes captured by QALYs. This finding underlines the importance to develop 
methods to consider broader outcomes in decision-making. Contingent valuation (CV) 
has been suggested as a potential method for capturing both health and broader 
outcomes of public health programs. In the present research CV has been a feasible 
method for monetary valuation of health and broader benefits of a public health 
intervention from an individual consumer perspective (see Chapter 6). Evidence 
regarding the internal validity of the method was inconclusive, however.  
Several studies included in our systematic review incorporated consequences for 
individuals not directly targeted by the program under evaluation. The progress in this 
area was mainly limited to studies evaluating programs directed at sexual behaviors, 
which considered health outcomes (e.g. HIV or other infections averted), life years or 
QALYs gained among sexual partners of targeted individuals. Hardly any efforts have 
been made to consider consequences on a community or societal level and suitable 
measures for capturing community-level changes (e.g. increased sense of community) 
are not yet available.  
Despite the fact that reducing health inequities is an important public health objective, 
not a single study examined the impact of behavior change programs on equity 
outcomes. 
The majority of economic evaluations examined in our review used effectiveness 
evidence from RCTs. Only few studies used evidence from alternative designs, such as 
quasi-experiments or comparisons with historical data. It is currently unclear which study 
design to use in situations in which RCT designs are not feasible and in which evidence 
from RCTs insufficient to inform decision-making. 
Non-health sector costs (e.g. costs of violent crimes and law enforcement) were 
considered in several economic evaluations in our review (see Chapter 2), but methods 
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used to identify, measure and value these were not described in much detail. Hence, 
there still is no clear guidance regarding the types of non-heath sector costs public 
health programs produce and how to incorporate them within an economic evaluation 
framework.  
Using a common parameter of efficiency may be a potential solution to overcome the 
challenge associated with comparing investments in public health with investments in 
other societal sectors. Chapter 3 describes a study exploring the possibility of using the 
Value of Statistical Life (VSL) for this purpose. Study findings show that, when 
determined by means of a retrospective investment analysis, the VSL is not an adequate 
method for multi-sector comparison. Even when determined empirically using an ex-ante 
stated preference approach, it would not be an ideal parameter of efficiency, as 
reduction in risk of premature death is the only outcome it captures. Our findings 
suggest that other outcomes are also relevant to consider within an economic evaluation 
framework. This is not only the case for public health programs, but also for 
interventions in other societal sectors. For instance, transport interventions may lead to 
a reduction of non-lethal road accidents, and hence to improved health and quality of 
life outcomes for people who would otherwise have been injured. On the contrary, the 
CV method does not pose restrictions on the number of types of outcomes to be valued. 
It is commonly used to determine efficiency of interventions in other societal sectors 
(e.g. transport and environment), and hence may be an alternative approach to multi-
sector comparisons given that the validity issues surrounding the method can be 
resolved.  
Implications for economic evaluation practice 
Our research identified a number of steps that evaluators may take to improve future 
economic evaluation evidence for decision-making in public health. Compliance with 
methodological standards could be improved through more use of good practice 
guidelines (e.g. Ramsey et al.1 and Caro et al.2) when planning and designing new 
economic evaluation studies.  
Reporting of studies could be improved by using quality assessment checklists, which 
identify methodological aspects that are essential to report in economic evaluation (e.g. 
Drummond et al.3, Evers et al.4 or Philips et al.5). Davidson et al.6 could be used to 
identify program characteristics essential to report, and Abraham and Michie7 for 
describing conceptually distinct behavior change techniques that are used in the 
program. 
Long-term costs and outcomes should be considered more often in economic evaluation 
studies to provide insights into all relevant costs and outcomes of interest to decision-
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makers. This requires more use of mathematical modeling to extrapolate costs and 
translate short-term intermediate outcomes to long-term outcomes. Given that 
performing an intervention trial and a subsequent model-based study to extrapolate the 
trial findings can be both time consuming and costly, we suggest that evaluators engage 
more in joint modeling projects where a basic model structure is developed for use 
across a wide range of research projects that require modeling of the same processes. 
The chronic disease model of the Dutch National Institute for Public Health and the 
Environment (RIVM) is a good example.8 It describes the relationship between several 
risk factors (e.g. smoking, body mass index and blood pressure) and the development of 
chronic diseases (e.g. lung cancer, coronary heart disease and diabetes mellitus) and 
has been applied to a wide range of public health programs, including obesity 
prevention, smoking prevention and cessation and interventions against alcohol 
abuse.9-11 
In situations where specific data for populating model parameters are not available, we 
recommend using scenario analyses to examine impacts of these parameters and to use 
sensitivity analyses in case values exist but are uncertain.12 In situations where too 
many parameters are lacking to build a model, we recommend to conduct cost-
effectiveness analysis using a measurable intermediate outcome or a more descriptive 
cost-consequence analysis approach, in which both quantifiable and non-quantifiable 
outcomes can be presented simultaneously. Together with the results of this analysis, 
evaluators could present a logic model of the program under evaluation to provide 
insights to decision-makers about processes and outcomes that are expected to occur 
based on theoretical models used for program development.13 
Modeling requires skills, which are often not part of the standard toolbox of evaluators. 
Hence, providing more training in model building is another measure likely to contribute 
to more use of modeling.  
Our research also highlighted the need to consider a wider range of outcomes of public 
health programs, including impacts on broader domains of wellbeing for targeted 
individuals, outcomes for individuals not directly targeted and the wider community or 
society. Given that methods to incorporate such broader outcomes directly within 
economic evaluation are currently not well developed, we suggest that evaluators 
identify, describe, and where possible measure relevant broader outcomes that cannot 
be directly incorporated in summary measures of cost-effectiveness. Presenting program 
outcomes in a disaggregated manner does not provide decision-makers with a clear 
decision rule. However, it gives them a more complete picture of the programs under 
evaluation and the possibility to define and apply their own decision criteria. It also 
creates the opportunity to adopt a multi-criteria decision-analysis approach to priority 
setting, which applies weights to different decision criteria.14  
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Methods for incorporating non-health sector costs are also uncertain. Hence, the same 
recommendations apply as for broader outcomes. Evaluators could present both 
identified costs and outcomes that were not incorporated in the economic analysis in a 
table, which describes their expected impact on cost-effectiveness (i.e. direction and 
size). It would also be helpful to indicate the analytical levels on which these costs and 
outcomes are produced as well as the analytical perspective from which they would be 
relevant to consider. This might help decision-makers to determine which of the costs 
and outcomes that have not been incorporated are relevant for them to consider or 
require further research.  
Based on previous literature, our research has identified several systematic methods 
evaluators could use to consider equity within economic evaluation. These include 
reviewing background information on equity, presenting cost-effectiveness for equity-
relevant subgroups, and systematic assessment of expected distributional effects of 
implementing interventions under evaluation.15,16 Results of these methods provide 
useful information to decision-makers who want to consider the impact of public health 
programs on equity outcomes. The need to consider equity outcomes is likely to be the 
highest for public health programs that target disadvantaged populations and lifestyle 
behavior change programs, which may be less effective among ‘hard-to-reach 
disadvantaged groups.15  
To facilitate improvements of future economic evaluation evidence using the steps 
outlined above it is important that health economists and public health experts 
collaborate. Public health experts need to help health economists understand the 
programs being evaluated, while health economists need to communicate the 
possibilities and impossibilities of economic evaluation to public health experts and assist 
them in designing, conducting and reporting economic evaluations.  
Implications for decision-making 
The findings of this research have implications for two aspects of decision-making: a) 
the scope of scientific evidence considered and b) the infrastructure to support decision-
making in public health.  
Scope of evidence considered 
Our research highlighted that economic evaluation studies of public health programs are 
generally based on evidence from a limited number of sources. The majority of economic 
evaluations use RCTs as only source of evidence on effectiveness (see Chapter 2). RCTs 
are an important source of information on effectiveness of a program under ideal 
circumstances, but they cannot provide insights into other determinants of effectiveness 
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of public health programs in the real world, such as the intervention process, local 
context circumstances, participant experiences and stakeholder views.13,17 Economic 
evaluation studies also tend to focus on health outcomes and do not consider broader 
impacts on quality of life and wellbeing (see Chapter 2). However, our research shows 
that participants of a public health program aimed at changing lifestyle behavior also 
experience broader non-health outcomes (see Chapter 3) and attach value to them (see 
Chapter 4 and 5). This finding suggests that decision-makers who wish to respond to 
consumer preferences should consider such broader outcomes of public health 
programs. 
In practice technology assessments supporting healthcare decision-making tend to 
consider only a limited scope of scientific evidence.14,18 The scientific evidence most 
commonly considered is evidence regarding effectiveness, safety, costs and cost-
effectiveness.19 This evidence tells decision-makers whether a program works in general, 
but it does not provide insights into how a program works and whether it could be 
implemented in a particular local context.20 The latter insights are essential for decision-
making in public health because public health programs often need to be tailored to 
specific local and organizational circumstances. So far, however, information regarding 
the specific local circumstances in which a program is implemented is usually considered 
only in the appraisal phase of the technology assessment process and not based on 
scientific methods. To provide better information to decision makers regarding local 
implementability of public health programs, we recommend broadening the scope of the 
scientific evidence produced and examined during technology assessments.  
Lomas et al.20 have identified two forms of scientific evidence relevant to decision-
makers: context-free and context-sensitive evidence. Context-free evidence pertains to 
evidence that reveals universal truths about what might be achieved under ideal 
circumstances. This type of evidence is closely linked to the evidence-based medicine 
concept and is based on a clear hierarchy of evidence, with meta-analyses and 
systematic reviews representing the highest level of evidence. Context-free evidence is 
derived using clinical research methods such as epidemiology and biostatistics. Context-
sensitive evidence relates to evidence about the context relevant to a particular decision. 
It is embedded more strongly in the social sciences and includes evidence about 
attitudes, implementation, organizational capacity, forecasting, economics/finance and 
ethics. Given the potentially diverse context elements, the methods to derive context-
sensitive evidence are diverse as well. They may include experimental evidence, quasi-
experimental evidence, qualitative research, survey-based research, regression analyses, 
time series, econometric methods, economic evaluation, public consultation and 
distributional analyses. The appropriate methods for obtaining evidence on context 
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factors are not the same as those for obtaining evidence on efficacy of a program under 
ideal circumstances, but both methods are equally scientific.20  
Figure 7.1 depicts how context-free and context sensitive evidence can complement 
each other in the technology assessment process. This figure is a simplified version of a 
figure developed by Davies21 and adapted by Lomas et al.20 Given the importance of 
reducing health inequities in the field of public health and the availability of scientific 
methods to examine equity impacts of public health programs in specific local settings, 
we added ‘equity evidence’ as form of context-sensitive evidence to this figure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Technology assessment: context-sensitive evidence complements context-free 
evidence (adapted from Davies21 and Lomas et al.20) 
 
 
Health technology assessments to date predominantly produce context-free scientific 
evidence (i.e. efficacy and safety evidence) and some context-sensitive evidence (i.e. 
economic evaluation evidence using context–free efficacy data and context-sensitive cost 
data). 
Based on the findings of this research, we recommend broadening the scope of context-
sensitive scientific evidence examined and produced in technology assessments that 
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inform decisions about funding and implementation of public health programs. The type 
of context-sensitive evidence relevant to incorporate in a technology assessment will 
depend on both the public health program in question and the specific decision-making 
context.  
Scientific evidence derived by systematic and replicable methods is not the only factor 
determining decision-making in public health. Funding decisions are inherently political 
and involve the appraisal of other types of information such as values and judgments 
from a range of stakeholders.22 Lomas et al.20 refer to this information as colloquial 
evidence. They define it as “anything that establishes a fact or gives reason for believing 
something”, and divide it into evidence about available resources, expert and 
professional opinion, political judgment, values, habits and traditions, lobbyists and 
pressure groups, and the particular pragmatics and contingencies of the situation. To 
develop appropriate, feasible and realistic public health policies, both scientific and 
colloquial evidence need to be considered by decision-makers. Figure 7.2 shows how 
colloquial evidence can complement scientific evidence in the deliberative technology 
appraisal process. It may also act as substitute for scientific evidence in situations where 
scientific evidence on context is missing.20  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Technology appraisal: colloquial evidence complements scientific evidence 
 (based on Davies21 and Lomas et al.20)  
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The National Institute for Health and Care Excellence in the UK has adopted such a 
pluralistic perspective to scientific evidence in their new methods guide for developing 
public health guidance.23 How diverse forms of evidence will actually be integrated into 
decision-making in practice still remains to be seen. There is currently little insight into 
best practices of deliberative processes for appropriately combining and weighting 
diverse forms of evidence for decision-making20. A recent study by Marsh et al.14 
successfully applied multi-criteria decision analysis to combine and weight both different 
types of scientific evidence and stakeholder values for priority setting in public health. 
This method provides a possible way forward, but still requires further development and 
testing. Hence, at this point, we recommend that decision-makers document in a 
transparent manner how they combined diverse forms of evidence in arriving at a 
decision.  
Infrastructure to support decision‐making 
The systematic use of evidence to inform decisions on public health in the Netherlands 
and many other countries is currently hampered by a lack of formal structures to support 
decision-making.24 To encourage more use of economic evaluation evidence and thereby 
efficient allocation of public resources, clearer decision-making structures need to be 
developed.  
England was one of the first countries worldwide to introduce formal organizational 
structures for systematic and transparent consideration of evidence in decision-making 
about public health programs.25 Since 2006 the Centre for Public Health Excellence and 
Public Health Guidance, which is located at the National Institute for Health and Care 
Excellence (NICE), provides recommendations on a wide range of public health 
programs focusing on smoking cessation, family planning, creation of safe open spaces 
for physical activity, controlling the number of fast food restaurants and alcohol outlets 
in inner city zones, as well as programs addressing health inequalities.25 
Recommendations are made at the population, community, organizational, group, family 
and individual level, recognizing the wide spectrum of determinants of population and 
individual health. Independent advisory committees develop guidance according to clear 
processes and methods using the best available evidence.23 Throughout the 
development of the guidance views of different stakeholders are considered, including 
professionals, academic institutions, industry and interest groups from the general 
public. Topics for guidance development are identified by the Department of Health.25,26 
The guidance applies in England and may selectively be applied in Northern Ireland, 
Scotland and Wales.27 It is developed for a wide range of audiences, including the 
National Health Service (NHS), local government, a range of central government 
departments responsible for taxation, transport, housing and criminal justice, and the 
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voluntary and private sectors.23,25 Once a guidance is finalized, it is made publicly 
available on the NICE website together with the evidence on which it was based.25 
This approach is innovative and could provide direction to other countries wishing to 
develop more formal structures to support evidence informed decision-making in public 
health.  
When developing new decision-making structures, it is important to consider that 
decisions about funding and implementation of public health programs tend to take 
place on multiple levels, including the international, national, regional and local level. 
Decisions at an international level are required, because determinants of disease and 
behavior do not obey national boundaries (e.g. food contamination, availability of 
condoms and hand washing behaviors in one country can impact on global transmission 
of infectious diseases). Hence, prevention strategies need to be coordinated between 
countries. Decisions at the national level are required for the development of national 
public health policies, such as legislation to promote population health. Regional level-
decisions are needed, because public health priorities may differ across regions. Finally, 
decisions need to be taken at the local level, to coordinate implementation of policies 
locally, where there is direct access to populations.24  
The method of funding of a health care system plays an important role in defining 
decision-making authority on each of these levels. In tax-funded systems, such as the 
UK, there is generally more authority and infrastructure for public health on a central 
level,24 which makes it easier to establish systematic procedures to support decision-
making on a national level. In health care systems, which are predominantly social 
health insurance-based, such as the Netherlands or Germany, authority tends to be 
more decentralized and national level infrastructure for public health is less developed.24 
In the Netherlands there is considerable autonomy on the local (municipal) level for 
funding, priority setting and implementing of public health activities.24 Hence, it may 
require more time and effort to create structures to support evidence-informed decision-
making. These might require a more complex multi-level structure consisting of an 
overarching national-level organization which determines general methodological 
guidelines for evidence informed decision-making, as well as a regional- and/or local-
level structure being closely connected to the national level. The national-level structure 
could focus on producing recommendations for national-level programs (e.g. the national 
immunization program in the Netherlands) and consider context-free scientific evidence 
for public health programs requiring regional or local decision-making. The evidence 
assessed at the national level could be integrated at the regional/local level with context-
sensitive scientific evidence, as well as colloquial evidence relevant for the specific 
application context of the program.  
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Implications for research 
Our research provides insights into how economic evaluations of behavior change 
interventions have tackled methodological challenges for evaluation so far. It also gives 
several directions on how to overcome the challenges associated with comparing 
efficiency across multiple societal sectors and considering impacts of public health 
programs on broader domains of quality of life and wellbeing. Given that this research is 
one of the first studies exploring potential solutions to overcome these challenges, there 
is still more work required. Based on our findings, we have outlined a number of priority 
areas for future research.  
Impacts on broader domains of quality of life and wellbeing 
Measures to examine health outcomes achieved by public health programs are plentiful 
and relatively straightforward. They include measures of mortality, life expectancy, 
disease incidence or prevalence and health-related quality of life. By combining changes 
in life expectancy and health-related quality of life (HRQOL) in a single measure, QALYs 
provide a useful summary measure of health outcome for use in economic evaluation. 
However, they do not capture impacts public health programs may have on broader 
domains of an individual’s quality of life or wellbeing (e.g. improvements in knowledge, 
skills, and opportunities for personal development or access to services and resources). 
Impacts on broader domains of quality of life and wellbeing are not well understood and 
theoretically underpinned measures to capture them in economic evaluation lacking.  
This research has contributed to the identification of broader outcomes experienced by 
participants of a lifestyle behaviour change intervention implemented in a primary care 
setting (see Chapter 3). Future research should continue to identify and define broader 
outcomes of public health programs in other settings and among other populations, and 
examine how these are related to existing measures of HRQOL. An overview and 
categorisation of broader outcomes and their relevance for different areas of public 
health would help evaluators identify outcomes to consider in a specific (economic) 
evaluation study.  
Developing validated instruments for considering impacts on broader domains of 
wellbeing within economic evaluation is also a priority for future research. Lorgelly et 
al.28 explored the possibility to develop an instrument based on Sen’s capability 
approach.29 According to this approach wellbeing is determined by what people can do 
(i.e. their capabilities), rather than by what they actually do (i.e. their functioning), 
which forms the basis of generic preference-based measures currently used to calculate 
QALYs. Al-Janabi et al.30 took this work further and developed a first brief self-report 
measure of capability wellbeing for the general adult population. This instrument is 
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referred to as ICECAP-A and consists of the following five domains: stability, attachment, 
achievement, autonomy and enjoyment. Acceptability and validity of the instrument still 
needs to be assessed and index values generated to allow for expressing a participant’s 
capability score in a single number for use within economic evaluation.  
A quality of life (QOL) model developed by a research group at the Centre for Health 
Promotion at the University of Toronto may provide a useful alternative to the capability 
approach and also requires further exploration and validation.31,32 The model is 
consistent with modern public health in two ways: it regards health as a resource for 
daily living rather than the objective of living and takes a holistic approach to 
conceptualizing QOL, stressing the importance of personal control and opportunities to 
improve QOL by changing the environment.31 It defines QOL as degree to which a 
person enjoys possibilities in three major domains of life: (1) being, (2) belonging, (3) 
becoming. Being refers to who a person is, belonging refers to how a person fits with 
environments and becoming refers to self-expressing, achievement of personal goals 
and aspirations. A number of validated instruments have been developed to measure 
QOL using these domains among different target groups,33-35 but so far no algorithms 
are available that allow transforming responses into a utility score (i.e. quality weight) 
for use within a QALY framework or single-index score for use within cost-effectiveness 
analysis. Until such algorithms are available QOL outcomes can only be presented in a 
disaggregated manner. Consequently, there is no clear decision-rule and decision-
makers need to apply their own weighting to each outcome. 
Finally, instead of using generic instruments capturing broader domains of wellbeing that 
could be used across a variety of public health programs, it is also possible to develop 
program-specific utility measures using a discrete choice experiment (DCE). In an 
application to a social care intervention for older people Ryan et al.36 have shown how 
DCEs can be used to derive utility (or: quality) weights for individuals based on 
previously identified intervention outcomes. Based on results of a DCE asking 
respondents to trade between the different intervention outcomes, they estimated an 
algorithm from which they could obtain quality weights for use in QALY calculations. 
Their exploratory study suggests that the DCE approach can produce both valid and 
reliable quality weights. However, several methodological issues remain to be solved, 
including which anchor to use when creating a utility scale and how to account for 
different scales of attributes.  
The DCE study reported in Chapter 5 suggests that it is feasible to apply a DCE approach 
to a lifestyle behaviour change intervention. More applications are needed across a 
broader range of public health interventions and testing of the method for the purpose 
of economic evaluation. The DCE-based approach has the advantage that it is flexible 
and allows for comparison with investments in other areas of healthcare, where QALYs 
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have become the standard approach. However, a potential disadvantage of developing a 
program-specific utility measure may be that it is costly and time consuming.  
Impacts on the wider community  
Impacts public health programs have on the wider community fall into two broad 
categories: those that occur at an individual level and those that occur at a system or 
community level. Individual-level outcomes can be summed up to determine a total for 
an entire population or community (e.g. the total number of infections averted or QALYs 
gained). Economic evaluation studies in the area of sexually transmitted disease 
prevention have used such aggregate values for example to capture the number of HIV 
infections averted among sexual partners of program participants (see Chapter 2). This 
approach is not so much used yet in other areas of public health (e.g. smoking cessation 
or physical activity), partly because data on social diffusion effects are not available, but 
in principle this is possible.  
It is methodologically more challenging to capture outcomes that occur at a community 
or system level, such as changes in structures, policies, decision-making or 
organizational processes, community capacity or the build environment. These cannot be 
measured or integrated in a single parameter and added up across individuals.37 Health 
economists need to develop novel methods to allow for their consideration in economic 
evaluation. These could build on the health promotion literature, which has already 
developed approaches to measure community or system-level changes.38 These include 
qualitative and quantitative research methods as well as the use of system-level 
population indicators38,39. Evaluators use qualitative research to understand for example 
policy changes or subjective perceptions of changes by vulnerable populations,38 and 
quantitative methods, such as household surveys, to measure community social 
dynamics (e.g. sense of community and community participation).40 Population 
indicators of system-level wellbeing and social functioning used in evaluation research 
include for instance unemployment rates, women rates in offices, income distributions, 
family life measures (e.g. divorce and birth rates), immigration rates and government 
spending on education.38,41 Indicators used to describe a neighborhood’s physical 
environment include for example walkability, accessibility, connectivity, transportation 
network characteristics, traffic safety, presence of sidewalks and aesthetics (e.g. 
cleanliness and the availability of natural or commercial sights).42 
Given the large variety of potential methods and measures to examine community or 
system-level changes, it would be quite challenging to apply all of them at once. This 
raises the question of how to find the right mix. Based on experiences with the WHO 
Healthy Cities Initiative, which represents a typical example of a complex modern public 
health program, de Leeuw39 suggests using ‘Realist Evaluation’ as a framework to guide 
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the composition of the methods toolbox. The key assumption of Realist Evaluation is that 
each program has its own unique program theory that can be tested. Evaluation should 
address the unique specifics and underlying causal mechanisms pertaining to the 
program under evaluation. Consequently, the choice of evaluation methods should be 
driven by the purpose of a program in its local context.39 If this is the new direction for 
measuring system-level changes in public health, health economists need to respond to 
this with tools that allow for sufficient flexibility in the sort of outcome measures these 
can consider. Available tools health economists could use for this purpose are cost 
consequence analysis (CCA) and contingent valuation (CV). In CCA different types of 
costs and outcomes are again presented in a disaggregated manner, while CV could in 
principle value different outcomes in a single monetary measure. Both approaches need 
to be further tested and future research needs to explore ways to overcome challenges 
associated with them (i.e. a lack of a clear decision rule in CCA and validity issues 
associated with CV).  
Using cost‐benefit analysis 
Cost-benefit analysis (CBA) has the potential to capture a broad number of benefits and 
enable comparisons of cost-effectiveness across multiple sectors. Our research suggests 
that the VSL is not an adequate parameter to use in CBA of public health programs. 
However, the use of CBA in public health could be facilitated through solving 
methodological issues surrounding CV. Our research showed that CV was a feasible 
method to elicit monetary values for individual benefits of lifestyle behavior change (see 
Chapter 6). Feasibility of CV should also be examined for valuing other benefits of public 
health programs, including those occurring at a community of system level. In the 
environmental economics literature CV is commonly used to value system level benefits, 
such as expansion of open access woodlands.43,44 Similar approaches should also be 
tested in public health applications. Future research should also explore how to value 
both individual and system-level outcomes within a single study.  
The application of CV described in Chapter 6 highlights the need to further investigate 
the validity of the method. Two questions need to be answered in this context: a) what 
are the reasons that CV results are inconsistent with neo-classical economic theory?; and 
b) what is the size of the problem? Underlying reasons for results that are inconsistent 
with neo-classical economic theory (e.g. scope insensitivity and ordering effects) could 
be assessed using qualitative interviews, focus groups and think aloud approaches 
conducted simultaneously to the CV task. These can help understand how respondents 
arrive at WTP values.45 Such studies may also provide further evidence regarding the 
correctness of the ‘neo-classical paradigm of rational agents’. This paradigm has been 
challenged by behavioral economics research, which provides alternative theories and 
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hypotheses to explain departures from neoclassical assumptions.46 Given that evidence 
regarding internal validity tests is mixed,47 it would also be helpful to gain better 
knowledge of the size of the problem through systematic reviews of recent literature.48 
Other areas for future research 
The systematic literature review reported in Chapter 2 identified several other knowledge 
gaps that need to be addressed in future research. These relate to input data and 
methods for modelling, consideration of non-health sector costs and equity outcomes, as 
well as study designs used to determine effectiveness.  
Many economic evaluation studies in public health currently focus only on intermediate 
outcomes of individual program participants. Mathematical models can translate 
intermediate outcomes into long-term outcomes. This requires a good understanding of 
the processes, by which intermediate outcomes lead to long-term outcomes. Some of 
the processes involved in public health interventions are well understood and can be 
modeled well, such as the relationship between smoking and cardiovascular disease, 
COPD or lung-cancer.49,50 For other relationships empirical data are missing and it is 
currently impossible to build an appropriate model structure and populate model 
parameters.51 Our findings suggests that there is a lack of data for modeling regarding 
program outcomes that go beyond the unidirectional effect on targeted individuals (e.g. 
interactions of the program with the wider social and structural environment) and for 
intermediate outcomes other than behavior changes (e.g. unwanted pregnancies 
prevented or increased knowledge and skills). Future research needs to address these 
knowledge gaps and provide further insights into complex processes involved in modern 
public health programs. 
Modeling complex processes may also require departing from Markov models, which are 
commonly used in economic evaluation. These models represent changes in terms of 
(health) state transitions and may not provide an adequate reflection of change 
processes involved in public health programs, for example interactions between 
individuals and interactions between individuals and the environment. Hence, alternative 
model types, such as discrete-event simulation or system dynamics need to be 
tested.52,53 A recent application of system dynamics simulation modeling to assess cost-
effectiveness of alternative policy options in the US healthcare system, suggests that 
these types of models could be a way forward.54 
It is important that researchers make models available to other researchers,55 who can 
adapt them to fit circumstances in other settings or countries. Orme and colleagues56 
developed a model that calculates health and economic consequences of smoking 
related disease and made this widely accessible through an interactive software tool. 
This is an innovative approach, which should be taken up by other researchers.  
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Future research should also give attention to non-health sector costs. Given that we lack 
insights into the type of costs public health programs pose on non-health sector 
budgets, it would be helpful to compile an overview of relevant non-health sector costs 
for different areas of behavior change and for other public health programs. At the same 
time there is a need for more methodological guidance regarding how to identify, 
measure and value these costs. Clear methodological guidance may contribute to more 
consistency in the methods used by economic evaluation studies and thus to better 
comparability. Gold et al.57 have conducted one of the first studies to systematically 
identify costs of a community-based health promotion program. They used a system-
level approach to identifying costs and tracked a wide range of resource inputs from 
around the community. This work may give directions to other researchers, who seek to 
identify costs of complex modern public health programs or want to develop 
methodological guidance.  
To better reflect the objectives of public health programs, economic evaluation studies 
should consider equity outcomes. Our research has identified several methods, which 
evaluators can use to provide information to decision-makers regarding actual or 
anticipated equity outcomes (i.e. reviewing background information on equity, 
presenting cost-effectiveness for equity-relevant subgroups and systematic assessment 
of expected distributional effects of implementing interventions under evaluation).15,16 
These methods can be readily applied using standard methods of health technology 
assessment, when suitable data are available.15 Equity weighting analysis is another 
method that could be used to consider equity within economic evaluation. This method 
is still in development and has not been used to support decision-making in practice, yet. 
It explicitly attaches a value to reducing inequalities. Program benefits (e.g. QALYs 
gains) are weighted based on characteristics of the people who experience the benefits. 
Appropriate weights can be determined from relevant stakeholders, such as the general 
public or policy-makers.15 Different methods have been suggested to derive equity 
weights, including discrete choice experiments. Two recent studies using a DCE to 
determine equity weights in the UK58 and Australia59 produced contradictory findings 
regarding equity weights based on population preferences. More research is needed to 
further test these methods and address open methodological questions, for instance 
regarding the number and types of equity dimensions to be considered.58 Related to this 
is the need for a clear definition of ‘equity’. There are different philosophical 
underpinnings of the equity concept, which determine how to operationalize equity 
outcomes.60 
The clear hierarchy of evidence adopted for biomedical and clinical health interventions, 
does not apply in the same way to public health programs.61,62 This has two main 
reasons: a) RCTs are not always a feasible and appropriate design option in public 
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health and b) RCTs cannot provide all information relevant to decision-making. Our 
research highlighted for example the importance of context-sensitive evidence in public 
health. Currently, clear guidance is lacking regarding best practices for producing 
context-sensitive evidence. Future research needs to develop evaluation standards and 
methods for answering ‘why’ and ‘how’ public health programs work.63 At the same time 
research must continue to explore how RCTs can be used most optimally in public 
health.63 Hawe et al.64 suggest for instance to adapt RCT designs when applying them to 
complex public health programs by changing how these define standardization. 
Standardization usually means that all program components are the same. For complex 
programs it would make more sense to standardize only the function and process of the 
program, while the program form or components are tailored to local circumstances. The 
feasibility and validity of this approach needs to be tested. Usually a single study design 
will not provide sufficient evidence for public health decision-making.63 Hence, a variety 
of evidence sources may need to be used. Methods to synthesize diverse sources of 
evidence for the purpose of decision-making need to further developed.  
Finally, in order to develop innovative solutions to overcome challenges in the economic 
evaluation of public health programs, it is essential to increase dialogue and 
collaboration between health economics and public health researchers. To date relatively 
few public health specialist are trained in economic evaluation methods and relatively 
few health economists are familiar with the specific characteristics of modern public 
health programs that create challenges for economic evaluation. Additional training is 
needed to increase understanding of each other’s language and make this dialogue more 
fruitful. Given that all innovations ultimately aim to assist decision-makers, it is important 
to engage decision-makers in the process of their development. A key task that lies 
ahead for a collaborative working group is the development and regular update of good 
practice guidelines for the economic evaluation of public health programs.  
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Summary 
Economic evaluation studies of health programs provide insights into the costs and 
benefits of decision alternatives. They are increasingly used to support decisions about 
health technologies, such as pharmaceuticals, medical devices, diagnostic and surgical 
procedures. Economic evaluation methods have not yet been much applied to modern 
public health programs. These programs are challenging for evaluation, because they 
tend to address multiple determinants of health and behavior, consist of multiple 
strategies and produce multiple outcomes on the individual and societal or system level. 
This research provides insights into the state of the art of applying economic evaluation 
to public health programs in the area of behavior change and presents potential 
solutions to overcome key methodological challenges. Seven methodological challenges 
are addressed in this research: 1) the long time horizon needed to achieve all benefits of 
public health programs; 2) the impacts public health programs may have on broader 
domains of individual quality of life or wellbeing that are not captured by the QALY; 3) 
the outcomes public health programs may produce on a community or societal level; 4) 
the objective of many public health programs to achieve more health equity; 5) the fact 
that evidence in public health does not always fit into the hierarchy of evidence adopted 
for biomedical and clinical health interventions; 6) the non-health sector costs public 
health programs may produce; and 7) the need for comparing public health programs 
with interventions in other societal sectors, due to multi-sector collaboration. 
 
Chapter 2 presents a systematic review of existing economic evaluations of lifestyle 
behavior change programs. It demonstrates that the number of economic evaluations 
has considerably increased over the past decade. However, methodological quality of the 
studies shows several weaknesses, including insufficient reporting of essential study 
details and limited adherence to good practice guidelines. Progress with addressing 
methodological challenges has also been limited. These shortcomings in the existing 
evidence impede efficient resource allocation to public health programs.  
 
Chapter 3 reports a study exploring the possibility to use the Value of Statistical Life 
(VSL) as efficiency parameter in multi-sector comparisons. Our study determined and 
compared implicit VSL estimates for life saving interventions implemented by the Dutch 
government in the health, water control, consumer safety and transport sector. The 
study findings suggest that the VSL is not an ideal parameter to compare public health 
programs with interventions in other societal sectors, because reduction in risk of 
premature death is the only outcome it captures. Nevertheless, the cost-benefit 
framework, on which the VSL is based, may still be a useful approach to encourage 
multi-sector comparisons. 
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Chapter 4 provides further insights into outcomes that may be relevant to consider in 
addition to reductions in risk of premature death. Based on a qualitative study using a 
combination of focus groups and individual interviews, we identified outcomes 
experienced by participants of a randomized controlled trial evaluating the effectiveness 
of a theory-based lifestyle intervention in adults at risk for diabetes mellitus and/or 
cardiovascular disease. By means of a thematic analysis approach identified outcomes 
were coded into outcomes that are captured by EQ-5D based QALYs (i.e. changes in life 
expectancy and health-related quality of life dimensions measured by the EQ-5D 
instrument) and other outcomes usually not considered in economic evaluations. Other 
outcomes included direct consequences of the lifestyle intervention (e.g. increased 
awareness and motivation for behavior change) and consequences of lifestyle behavior 
change (e.g. increased feeling of control and body satisfaction). The study findings also 
indicate that lifestyle behavior change may have social spillover effects to other people 
in participants’ direct social environment.  
 
Chapter 5 describes a discrete choice experiment (DCE), which explores the relative 
importance health outcomes have to consumers compared to broader outcomes of 
lifestyle behavior change. Respondents were asked to make a series of binary choices 
between situations that can be experienced after lifestyle behavior change. The 
situations were described in terms of ten attributes. Three of these represented health 
outcomes measured within the QALY framework (i.e. life expectancy, future health state 
and timing of future health state). Five attributes were based on broader outcomes 
identified in the qualitative research reported in Chapter 4 (i.e. clothing size above or 
conform ideal, days with sufficient relaxation, endurance, experienced control over 
lifestyle choices and lifestyle improvement of partner and/or children). Finally, two 
attributes were included to reflect the monetary and time costs associated with lifestyle 
behavior change (i.e. monetary cost per month and time cost per week). With the 
exception of time cost per week and timing of future health state, all attributes 
significantly determined consumer choices. Marginal rates of substitution between the 
monetary cost attribute and the other attributes suggest that respondents attached most 
value to improvements in endurance, days with sufficient relaxation and future health 
state value. These findings suggest, that decision-makers, who wish to respond to 
consumer preferences, should consider both health and non-health outcomes when 
deciding about lifestyle behavior change interventions.  
 
Chapter 6 presents an application of the contingent valuation (CV) method to support 
decision-making that requires consideration of both health and non-health outcomes. 
The CV task asked participants of a lifestyle intervention trial to express their willingness 
to invest money and time for changes in three benefits of lifestyle change: improved life 
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expectancy, health-related quality of life and broader quality of life aspects. Our findings 
indicate that the majority of respondents attached value to all three benefits and that 
most were willing to invest both money and time. The CV method is controversial, 
because there is uncertainty regarding the feasibility and ability of the method to derive 
valid WTP values. In the present research CV has proven to be a feasible approach for 
monetary valuation of a range of benefits from an individual consumer perspective. 
Three tests of internal validity produced mixed results, however. Thus, at present CV 
cannot be recommended as sole base for decision-making.  
 
The overall findings of this research lead to a number of recommendations for economic 
evaluation practice, decision-making and future research, which are described in the 
general discussion (see Chapter 7). Recommendations for economic evaluation practice 
focus on improvement of reporting of studies, increasing adherence with good practice 
guidelines and existing methods that can be used to deal with challenges caused by the 
long-time horizon of public health programs, non-health sector costs, and broader 
benefits or equity outcomes they may produce. For decision-making two 
recommendations are made: a) broadening the scope of scientific evidence produced 
and examined during technology assessments in the field of public health, and b) 
establishing better infrastructure to support systematic use of evidence. This research 
also highlights several areas for future research, including: the identification and 
definition of broader outcomes in different application areas of public health; developing 
validated instruments or measures that allow for consideration of impacts on wider 
domains of wellbeing; development of methods to capture community or system-level 
changes; further testing of the feasibility and validity of the CV method; producing input 
data for modeling, testing new approaches for modeling of complex processes; 
developing methodological guidance regarding how to deal with non-health sector costs; 
further testing of methods for equity weighting analysis; defining equity outcomes for 
economic evaluation; establishing best practices for producing context-sensitive 
evidence; and developing methods to synthesize diverse forms of quantitative and 
qualitative evidence for use in technology assessment and economic evaluation. Finally, 
in order to develop innovative solutions to overcome remaining challenges in the 
economic evaluation of public health programs, it is essential to increase dialogue and 
collaboration between health economics, public health researchers and decision-makers. 
The development and regular update of good practice guidelines for the economic 
evaluation of public health programs is a key task ahead, which requires collaborative 
action. 
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